Interferon gamma variants and antigen binding molecules comprising these variants

By combining the IFNG variant with the tumor-associated antigen fibroblast activation protein, efficient T cell activation in the tumor environment is achieved, solving the problem of poor effectiveness of existing IFNG therapy in immune desert-type tumors, and significantly improving the anti-epidemic The intensity of the tumor immune response.

CN119095880APending Publication Date: 2024-12-06F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030362.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-28
Filing Date
2023-03-27
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing interferon gamma (IFNG) therapy is difficult to effectively activate T cells in the tumor environment due to dose limitation, toxicity and flood effects, especially in immune desert tumors.

Method used

A tumor-targeting IFNG variant was developed to directly deliver to the tumor environment by conjugating it to the tumor-associated antigen fibroblast activation protein (FAP), to activate T cells, and terminate using the C-terminal amino acid sequence KRKRP IFNG variant polypeptide ensures that the tumor site remains active and avoids the effects of healthy tissue.

Benefits of technology

It has achieved efficient activation of T cells in the tumor site, enhanced anti-tumor immune response, and improved the effect of immunotherapy, especially in immune desert-type tumors, which significantly improved the chance of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005059518160000281
    Figure BDA0005059518160000281
  • Figure BDA0005059518160000291
    Figure BDA0005059518160000291
  • Figure BDA0005059518160000681
    Figure BDA0005059518160000681
Patent Text Reader

Abstract

The present invention relates to novel antigen-binding molecules comprising (i) an antibody that specifically binds to a tumor-associated antigen and (ii) an interferon gamma (IFNG) variant polypeptide terminated with the C-terminal amino acid sequence KRKRP (SEQ ID NO: 1); to novel IFNG variant polypeptides included therein; to methods of producing these molecules; and to methods of use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a new antigen binding molecule comprising (i) an antibody that specifically binds to a tumor-associated antigen and (ii) a new interferon gamma (IFNG) variant polypeptide terminated with a C-terminal amino acid sequence KRKRP (SEQ ID NO: 1); specifically, it relates to an antigen binding molecule comprising an antibody that specifically binds to a fibroblast activation protein (FAP) and a new IFNG variant polypeptide. In addition, the present invention relates to a new IFNG variant polypeptide included therein, and to a polynucleotide molecule encoding an antigen binding molecule or an IFNG variant polypeptide, and a vector and a host cell comprising such a polynucleotide molecule. Other aspects of the present invention are methods for producing these molecules and methods of using them. Background Art

[0002] In recent years, the use of immunotherapy to treat cancer has grown dramatically, and cancer immunotherapy has become an important strategy in the fight against cancer. Immune checkpoint modulators, including anti-PD-1, have been established as the standard of care for many cancer types. However, despite all the progress that has been made in cancer immunotherapy over the past few years, some patients still do not respond to available immunotherapies due to intrinsic or adaptive resistance mechanisms. In particular, it is becoming increasingly clear that patients who do not respond to cancer immunotherapy are often characterized by a non-inflammatory immune phenotype. In fact, a correlation has been shown between immune cell infiltration in tumors and the ability of patients to respond to immunotherapy treatment. Overall, there is a clear medical need for the development of new therapies designed to enhance immunogenicity and increase immune cell infiltration in tumors.

[0003] In parallel with the above developments, interest in cytokines as potential cancer treatments has increased dramatically. Interferon gamma (IFNG or IFN-γ) is a cytokine produced primarily by activated lymphocytes (such as CD4 + and CD8 + T cells) and natural killer (NK) cells in response to inflammation or immune stimulation and produce and secrete cytokines. IFNG is a homodimer, and its receptors (IFNGR1 and IFNGR2) are expressed in hematopoietic and non-hematopoietic cells. IFNGR1 is stably expressed on the cell surface, while IFNGR2 is differentially expressed and used to regulate IFNG signals. The binding of IFNG to its receptor induces the recruitment and activation of Janus kinases JAK1 and JAK2, which phosphorylate and activate STAT1. After phosphorylation, STAT1 translocates to the nucleus, where it binds to specific promoters and regulates the transcription of genes regulated by IFNG.

[0004] Contrary to many cancer therapies on the market and under development, IFNG has the ability to act on both tumor cells and multiple immune cells (including T cells and dendritic cells). IFNG has several benefits to the effect of different cell types, including 1) enhancing the expression of MHC-I molecules on the surface of both tumor cells and antigen presenting cells, 2) recruiting immune cells to tumor sites and 3) increasing the ability of tumor antigen cross presentation by inducing the production of CXCL9, CXCL10 and CXCL11, and subsequently enhancing anti-tumor immune response. In addition to all these effects, IFNG plays a role in the generation of Th1 environment, monocyte differentiation, macrophage polarization and angiogenesis. Based on the cell inhibition, pro-apoptosis and anti-proliferation functions of IFNG, IFNG is considered to be potentially useful in cancer therapy.

[0005] However, the receptors for IFNG are expressed on many different cell types, and therefore its activity may be weakened by the sink effect. IFNG may also show undesirable side effects. In addition, problems of administration, bioavailability and short half-life may occur. Therefore, new IFNG molecules that can selectively activate T cells in the tumor environment are needed. WO 2017 / 139468A1 discloses a fusion protein comprising a scFv that binds Her2 and an interferon gamma monomer terminated with the amino acid sequence AKTGKRKRSQ (SEQ ID NO: 127). However, there is still a need to provide a molecule with high stability to maintain IFNG activity and more suitable for administration to human patients. Summary of the invention

[0006] To overcome current challenges, mainly associated with dose-limiting toxicities and sink effects, we developed a tumor-targeted, masked IFNG that is inactivated in the circulation and healthy tissues and active only at the tumor site, thus eliciting the above-mentioned benefits. Direct delivery of active IFNG to the tumor environment would overcome the potential dose limitations of IFNG produced after T-cell and NK-cell activation, and in particular, would provide the opportunity to be effective also in immune-desert tumors, which are currently in greater need of new cancer immunotherapies.

[0007] Therefore, the present invention provides a novel method, that is, by conjugating IFNG variants with antibodies that bind to tumor-associated antigens, particularly fibroblast activation protein (FAP), IFNG variants with favorable properties for immunotherapy are directly targeted to immune effector cells (such as cytotoxic T lymphocytes) rather than tumor cells. This leads to the activation of T cells in the tumor microenvironment. Fibroblast activation protein (FAP) is a serine protease that is highly expressed on the cell surface of cancer-associated stromal cells and on fibroblast reticular cells of secondary lymphoid organs, but its expression in normal tissues is very limited. FAP is very common in various cancer indications, making it useful as a targeting moiety for drugs that should accumulate in the tumor stroma.

[0008] The molecules of the present invention comprise homodimers of interferon gamma (IFNG) variant polypeptides terminated with the C-terminal amino acid sequence KRKRP (SEQ ID NO: 1). It has been shown herein that the presence of the KRKR patch, i.e., the amino acid sequence of KRKR (SEQ ID NO: 78), is important for the activity of IFNG. The inventors have found that in order to avoid proteolysis, the C-terminus of wild-type IFNG must be stabilized with a proline cap, such that the sequence of the IFNG variant polypeptide terminates with the amino acid sequence KRKRP (SEQ ID NO: 1).

[0009] Thus, provided herein are antigen binding molecules comprising

[0010] (i) an antibody that specifically binds to a tumor-associated antigen, and

[0011] (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized by a C-terminal amino acid sequence KRKRP (SEQ ID NO: 1), meaning that it ends at the C-terminus with the amino acid sequence KRKRP (SEQ ID NO: 1).

[0012] Therefore, these antigen binding molecules comprise antibodies fused to two identical interferon gamma (IFNG) variant polypeptides, which are different from wild-type IFNG and terminate with the amino acid sequence KRKRP (SEQ ID NO: 1). In one aspect, the interferon gamma (IFNG) variant polypeptide comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3. In one aspect, the interferon gamma (IFNG) variant polypeptide consists of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3. In a specific aspect, the IFNG variant polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 2.

[0013] In one aspect, an antigen binding molecule is provided, comprising (i) an antibody that specifically binds to a tumor-associated antigen and (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized in that it terminates at the C-terminus with the amino acid sequence KRKRP (SEQ ID NO: 1), and wherein the first IFNG variant polypeptide is fused at its N-terminus to the C-terminus of the first heavy chain, and the second IFNG variant polypeptide is fused at its N-terminus to the C-terminus of the second heavy chain, optionally via a linker.

[0014] In one aspect, the antibody that specifically binds to a tumor-associated antigen is an antibody that specifically binds to fibroblast activation protein (FAP). In one aspect, an antigen binding molecule is provided, wherein the antibody that specifically binds to FAP comprises: (a) a heavy chain variable region (V H FAP), the heavy chain variable region comprises: a heavy chain complementarity determining region (CDR-H1), which comprises the amino acid sequence of SEQ ID NO: 4; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 5; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 6; and a light chain variable region (V L FAP), the light chain variable region comprises: a light chain complementary determining region (iv) CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 7; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 8; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 9; or (b) a heavy chain variable region (V H FAP), the heavy chain variable region comprises: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 12; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 13; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 14; and a light chain variable region (V L FAP), the light chain variable region comprises: CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 15; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 16; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 17. In one aspect, an antigen binding molecule is provided, wherein the antibody that specifically binds to FAP comprises: a heavy chain variable region (V H FAP), which comprises the amino acid sequence of SEQ ID NO: 10; and a light chain variable region (V L FAP), which comprises the amino acid sequence of SEQ ID NO: 11; or the antibody comprises: a heavy chain variable region (V H FAP), which comprises the amino acid sequence of SEQ ID NO: 18; and a light chain variable region (V LFAP), which comprises the amino acid sequence of SEQ ID NO: 19. In a specific aspect, an antigen binding molecule is provided, wherein the antibody that specifically binds to FAP comprises: a heavy chain variable region (V H FAP), which comprises the amino acid sequence of SEQ ID NO: 10; and a light chain variable region (V L FAP), which comprises the amino acid sequence of SEQ ID NO:11.

[0015] In one aspect, the antigen binding molecules include Fc domains, particularly IgG1 Fc domains or IgG4 Fc domains. In one aspect, the Fc domains include one or more amino acid substitutions that reduce the binding affinity of antibodies to Fc receptors and / or effector functions. In one aspect, the Fc domains belong to human IgG1 subclasses, and they have amino acid mutations L234A, L235A and P329G (EU numbering according to Kabat EU indexes). On the other hand, the Fc domains are murine Fc domains, and include amino acid mutations D265A and P329G (EU numbering according to Kabat EU indexes).

[0016] In one aspect, the antigen binding molecule is protease activatable and comprises a protease recognition site and a masking portion. Thus, the antigen binding molecule comprises (i) an antibody that specifically binds to a tumor-associated antigen, (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized in that it terminates at the C-terminus with an amino acid sequence KRKRP (SEQ ID NO: 1), (iii) a protease recognition site and (iv) a masking portion.

[0017] In one aspect, the protease recognition site is a substrate for matriptase. In one aspect, the protease recognition site comprises or consists of the amino acid sequence PQARK (SEQ ID NO: 20) or HQARK (SEQ ID NO: 21). In a specific aspect, the protease recognition site comprises or consists of the amino acid sequence PQARK (SEQ ID NO: 20). In one aspect, the protease recognition site is part of a cleavable peptide linker that connects the masking moiety to the IFNG variant polypeptide.

[0018] In one aspect, an antigen binding molecule is provided wherein the masking moiety is fused at its N-terminus to the C-terminus of the IFNG variant polypeptide via a cleavable peptide linker (mask-released form). In one aspect, the IFNG variant polypeptide is fused at its N-terminus to the C-terminus of the antibody via a stable linker.

[0019] In another aspect, an antigen binding molecule is provided wherein the masking moiety is fused at its N-terminus to the C-terminus of the Fc domain via a stable linker and at its C-terminus to the N-terminus of the IFNG variant polypeptide via a cleavable peptide linker (cytokine releasing form).

[0020] In one aspect, the masking moiety is an antibody fragment that specifically binds to IFNG. In a specific aspect, the masking moiety is a scFv that specifically binds to IFNG.

[0021] In one aspect, a masking moiety that specifically binds to IFNG, particularly a scFv, comprises

[0022] (a) Heavy chain variable region (V H IFNG), the heavy chain variable region comprising: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 22; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 23; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 24; and a light chain variable region (V L IFNG), the light chain variable region comprising: a light chain complementary determining region (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 25; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 26; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 27; or

[0023] (b) Heavy chain variable region (V H IFNG), the heavy chain variable region comprising: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 30; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 31; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 32; and a light chain variable region (V L IFNG), the light chain variable region comprising: CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 33; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 34; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 35.

[0024] In one aspect, the masking moiety that specifically binds to IFNG, particularly scFv, comprises: (a) a heavy chain variable region (V H IFNG), which comprises the amino acid sequence of SEQ ID NO: 28; and a light chain variable region (V L IFNG), which comprises the amino acid sequence of SEQ ID NO: 29; or (b) a heavy chain variable region (V HIFNG), which comprises the amino acid sequence of SEQ ID NO: 36; and a light chain variable region (V L IFNG), which comprises the amino acid sequence of SEQ ID NO: 37. In a specific aspect, the masking portion that specifically binds to IFNG, especially scFv, comprises: (a) a heavy chain variable region (V H IFNG), which comprises the amino acid sequence of SEQ ID NO: 28; and a light chain variable region (V L IFNG), which comprises the amino acid sequence of SEQ ID NO:29.

[0025] In a specific aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0026] (i) two heavy chains comprising the amino acid sequence of SEQ ID NO: 40, and two light chains comprising the amino acid sequence of SEQ ID NO: 41; or

[0027] (ii) two heavy chains comprising the amino acid sequence of SEQ ID NO:42, and two light chains comprising the amino acid sequence of SEQ ID NO:41; or

[0028] (iii) two heavy chains comprising the amino acid sequence of SEQ ID NO: 43, and two light chains comprising the amino acid sequence of SEQ ID NO: 44; or

[0029] (iv) two heavy chains comprising the amino acid sequence of SEQ ID NO:45, and two light chains comprising the amino acid sequence of SEQ ID NO:44.

[0030] In addition, interferon gamma (IFNG) variant polypeptides are provided herein, wherein the IFNG variant polypeptide is characterized by a C-terminal amino acid sequence KRKRP (SEQ ID NO: 1). In one aspect, the IFNG variant polypeptide is a human IFNG variant polypeptide and comprises or consists of the amino acid sequence of SEQ ID NO: 2. In another aspect, the IFNG variant polypeptide is a mouse IFNG variant polypeptide and comprises or consists of the amino acid sequence of SEQ ID NO: 3.

[0031] According to another aspect of the present invention, one or more isolated polynucleotides encoding antigen binding molecules as described herein before are provided. Also provided are isolated polynucleotides encoding IFNG variant polypeptides as described herein before. The present invention further provides a vector, particularly an expression vector, comprising an isolated polynucleotide of the present invention; and a host cell is provided, comprising an isolated nucleic acid or expression vector of the present invention. In some aspects, the host cell is a eukaryotic cell, particularly a mammalian cell. In some aspects, the host cell is a prokaryotic cell. On the other hand, a method for producing an antigen binding molecule or an IFNG variant polypeptide as described herein before is provided, comprising culturing a host cell as described above under conditions suitable for expressing an antigen binding molecule or an IFNG variant polypeptide, and separating an antigen binding molecule or an IFNG variant polypeptide. The present invention also encompasses an antigen binding molecule comprising an IFNG variant polypeptide or an IFNG variant polypeptide produced by the methods described herein.

[0032] The present invention also provides a pharmaceutical composition comprising an antigen binding molecule as described herein before or an IFNG variant polypeptide as described herein before and a pharmaceutically acceptable carrier. In one aspect, the pharmaceutical composition comprises an additional therapeutic agent. In one aspect, the pharmaceutical composition is used for the treatment of a disease. In a specific aspect, the disease is cancer.

[0033] The present invention also encompasses an antigen binding molecule or IFNG variant polypeptide as described herein before, or a pharmaceutical composition comprising the antigen binding molecule or IFNG variant polypeptide, for use as a medicament.

[0034] In one aspect, an antigen binding molecule as described herein before or an IFNG variant polypeptide as described herein before or a pharmaceutical composition of the present invention is provided for use in treating cancer. In another specific aspect, the invention provides an antigen binding molecule as described herein before or an IFNG variant polypeptide for use in treating cancer, wherein the antigen binding molecule or IFNG variant polypeptide is administered in combination with a chemotherapeutic agent, radiation and / or other agents for use in cancer immunotherapy.

[0035] In a further aspect, the present invention provides a method of inhibiting the growth of tumor cells in an individual, comprising administering to the individual an effective amount of an antigen binding molecule as described herein before or an IFNG variant polypeptide or a pharmaceutical composition of the present invention to inhibit the growth of tumor cells. On the other hand, the present invention provides a method of treating a disease in an individual, comprising administering to the individual a therapeutically effective amount of an antigen binding molecule as described herein before or an IFNG variant polypeptide or a pharmaceutical composition of the present invention. In a specific aspect, the disease is cancer.

[0036] Also provided is the use of an antigen binding molecule as described herein before in the manufacture of a medicament for treating a disease in an individual in need thereof, particularly in the manufacture of a medicament for treating cancer. In a specific aspect, the disease is cancer. In any of the above aspects, the individual is a mammal, particularly a human. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figures 1A to 1C An overview of the engineering of the IFNG C-terminal sequence is provided. Figure 1A In, a schematic scheme of the format of the IFNG molecule prepared in Example 1 is shown. IFNG is fused to the C-terminus of the heavy chain of a targeting IgG antibody. The IgG-fused IFNG wild-type C-terminus is susceptible to proteolytic degradation, resulting in the truncated variant being inactive in signaling. Figure 1B In Figure 1, the IFNG C-terminal sequence is shown with certain C-terminal amino acids missing. For the deletion series, the C-terminal residue is gradually removed and then replaced with other amino acids to provide a cap. The KRKR sequence is important for activity and must be conserved. Figure 1C An overview of the amino acid mutations introduced into the KRKR sequence in the mutation series as described in Example 1 is given. Figure 1D A schematic scheme of the masked release format is shown. IFNG is fused to the C-terminus of the heavy chain of the targeting IgG via a stable linker (Linker 1). To generate the masked format, the IFNG specific scFv domain is fused to the C-terminus of IFNG via a cleavable linker (Linker 2 with a PQARK cleavage site). Figure 1E A schematic scheme of the cytokine release format is shown.IFNG is fused to the C-terminus of an IFNG-specific scFv domain via a cleavable linker (Linker 2 with a PQARK cleavage site), which is fused to the heavy chain of a targeting IgG via a stable linker (Linker 1).

[0038] Figures 2A to 2C Shown are the signaling activities of human IFNG deletion series variants measured on HEK-blue IFNG reporter cells. Figure 2A In the present study, the signaling activities of wild-type IFNG (P1AF3568), an inactivated variant (P1AF3569) and a molecule with IFNG variants described in the literature (Slodowski et al.) were compared. Figure 2B A wild-type IFNG molecule (P1AF3568) was compared to a molecule containing a proline-terminated IFNG variant. Figure 2C The wild-type IFNG molecule (P1AF3568) was compared to a molecule containing a serine-proline terminated IFNG variant.

[0039] Figures 3A to 3CShown are the signaling activities of a series of human IFNG mutant variants measured on HEK-blue IFNG reporter cells. Figure 3A In the present study, the signaling activity of an IFNG variant with a C-terminal KRKRP (P1AF3574) was compared with IFNG variant molecules in which one or two amino acids in the KRKR patch had been replaced with glutamic acid. Figure 3B The signaling activity of an IFNG variant with a C-terminal KRKRP (P1AF3574) was compared with IFNG variant molecules in which one or two amino acids in the KRKR patch had been replaced with proline. Figure 3C The signaling activity of an IFNG variant with a C-terminal KRKRP (P1AF3574) was compared with IFNG variant molecules in which one or two amino acids in the KRKR patch had been replaced with serine.

[0040] Figure 4A Multiple sequence alignments of human and murine wild-type IFNG and engineered IFNG variants are shown. The sequences shown are consensus sequence (SEQ ID NO: 125), human IFNG KRKRP 1-132 (SEQ ID NO: 2), murine IFNG KRKRP 22-153 (SEQ ID NO: 3), human wild-type IFNG (SEQ ID NO: 60) and mouse wild-type IFNG (SEQ ID NO: 61). Figure 4B Shown is the induction of MHC-I on the murine MC38-huCEA tumor cell line in response to two days of treatment with FAP-targeted, anti-murine IFNG-scFv masked IFNG compounds containing a cleavable PQARK linker, with and without Matriptase, compared to the activity of FAP-targeted, unmasked IFNG. Figure 4C Shown is the induction of PD-L1 on the murine MC38-huCEA tumor cell line in response to two days of treatment with FAP-targeted, anti-murine IFNG-scFv masked IFNG compounds containing a cleavable PQARK linker, with and without Matriptase, compared to the activity of FAP-targeted, unmasked IFNG.

[0041] Figure 5 The study layout is shown, which highlights the key events of the in vivo studies conducted to test the activity of P1AG3755 in vivo. The KPC4662-huCEA tumor model is an excluded tumor model, meaning that CD8 T cells are only present in the periphery of the tumor. MHC-I and PD-L1 expression are low at baseline. P1AG3755 was administered once at two different doses to observe changes in MHC-I, PD-L1 expression, and CD8 infiltration.

[0042] Fig. 6A and Figure 6B Shows the cancer cells at different time points in the study ( Fig. 6A ) and fibroblasts ( Figure 6B ) MHC-I expression on cancer cells and fibroblasts was statistically significantly increased by flow cytometry only at the higher doses, both early and late (days 3 and 7) after therapy administration. Figure 6C and Fig.6D Shows the cancer cells at different time points in the study ( Figure 6C ) and fibroblasts ( Fig.6D PD-L1 expression on both cell types was also statistically significantly increased at the higher dose, but only at 3 days post-treatment instead of 7 days post-treatment.

[0043] Figure 7 Results of histological analysis by immunofluorescence (3DIP) are shown and illustrate CD8 T cell infiltration and MHCI expression in tumor sections. MHCI expression increased in a dose-dependent manner 3 and 7 days after P1AG3755 administration, confirming the flow cytometry results. The increase in MHCI expression was local and not the same for the entire tumor. The MHCI expression pattern was associated with the presence of CD8 T cells in the tumor core.

[0044] exist Figure 8 In the 3D images, it was shown that CD8 infiltration into the tumors, as measured by flow cytometry, was not statistically significantly different from the vehicle group. This was expected because CD8 T cell infiltration followed the highly localized MHCI expression. By immunofluorescence imaging, it became clear that CD8 T cells were more strongly present in MHC-I positive areas at day 3 post therapy compared to day 7 post therapy.

[0045] Fig. 9 Cytokine analysis was involved and showed that the T cell attracting chemokine CXCL9 was statistically significantly increased in serum only 7 days after therapy injection (at 10 mg / kg), but not before therapy injection, not at lower doses, and not in tumor tissue.

[0046] Fig. 10A Shown is a schematic diagram of sterically masked IFNG (P1AG8692) as described in Example 6. The IFNG variant was inserted between the upper and lower hinge regions of an IgG1 antibody. Fig. 10B A schematic diagram of an unmasked control compound (P1AG8697) is shown in which the IFNG variant is fused to the Fab via a linker (Linker 4). Fig. 10CGraph showing the activity of spatially masked IFNG variants measured on HEK-blue IFNG reporter cells as relative absorbance. DETAILED DESCRIPTION

[0047] definition

[0048] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly used in the field to which the invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural, and vice versa.

[0049] As used herein, the term "antigen binding molecule" in its broadest sense refers to a molecule that specifically binds to an antigenic determinant. Examples of antigen binding molecules are antibodies, bispecific antibodies or multispecific antibodies, immunoconjugates, antibody fragments, and scaffold antigen binding proteins.

[0050] As used herein, the term "antibody that specifically binds to a tumor-associated antigen" or "part that specifically binds to a tumor-associated antigen" refers to a polypeptide molecule that specifically binds to an antigenic determinant. In one aspect, the antigen binding domain is capable of activating signal transduction through its target cell antigen. In a specific aspect, the antigen binding domain is capable of guiding an entity connected thereto (e.g., an IFNG variant polypeptide) to a target site, such as a specific type of tumor cell or tumor matrix carrying an antigenic determinant. Antigen binding domains that can specifically bind to tumor-associated antigens include antibodies and fragments thereof as further defined herein. In addition, antibodies that can specifically bind to tumor-associated antigens include scaffold antigen binding proteins as further defined herein, such as binding domains based on designed repeat sequence proteins or designed repeat sequence domains (see, e.g., WO 2002 / 020565). In particular, antibodies that can specifically bind to tumor-associated antigens are antibodies that can specifically bind to fibroblast activation protein (FAP). With respect to antibodies or fragments thereof, the term "antibody that specifically binds to a tumor-associated antigen" refers to a portion of a molecule that contains a region that specifically binds to part or all of an antigen and is complementary thereto. An antigen binding domain capable of specific antigen binding can be provided, for example, by one or more antibody variable domains (also referred to as antibody variable regions). Specifically, an antigen binding domain capable of specific antigen binding includes an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH). On the other hand, an "antigen binding domain capable of specific binding to a tumor-associated antigen" can also be a Fab fragment or a cross Fab fragment.

[0051] The term "antibody" herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific and multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.

[0052] The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous antibody population, i.e., except for possible variant antibodies (e.g., containing naturally occurring mutations or produced during the production of monoclonal antibody preparations, such variants are usually present in small amounts), the individual antibodies comprising the population are identical and / or bind to the same epitope. Contrary to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is directed against a single determinant on the antigen.

[0053] As used herein, the term "monospecific" antibody refers to an antibody having one or more binding sites, each binding site binding to the same epitope of the same antigen. The term "bispecific" means that the antigen binding molecule can specifically bind to at least two unique antigenic determinants. Typically, a bispecific antigen binding molecule comprises two antigen binding sites, each of which has specificity for different antigenic determinants. In certain embodiments, a bispecific antigen binding molecule can simultaneously bind to two antigenic determinants, particularly two antigenic determinants expressed on two unique cells. Bispecific antigen binding molecules as described herein can also form a part of a multispecific antibody.

[0054] The term "valence" used in the present application means that there is a specific number of binding sites with specificity to a unique antigenic determinant in an antigen binding molecule that is specific to a unique antigenic determinant. Therefore, the terms "divalent", "tetravalent" and "hexavalent" respectively represent that there are two binding sites, four binding sites and six binding sites with specificity to a specific antigenic determinant in an antigen binding molecule. In a particular aspect of the present invention, the bispecific antigen binding molecules according to the present invention can be monovalent to a specific antigenic determinant, meaning that they only have one binding site to the antigenic determinant, or can be divalent or tetravalent to a specific antigenic determinant, meaning that they have two binding sites or four binding sites to the antigenic determinant, respectively.

[0055] The terms "full-length antibody" and "complete antibody" are used interchangeably herein to refer to antibodies with structures substantially similar to natural antibody structures. "Native antibodies" refer to naturally occurring immunoglobulin molecules with different structures. For example, natural IgG class antibodies are heterotetrameric glycoproteins of about 150,000 daltons, which are composed of two light chains and two heavy chains bonded by disulfide bonds. From N-terminal to C-terminal, each heavy chain has a variable region (VH) (also referred to as variable heavy chain domain or heavy chain variable domain), followed by three constant domains (CH1, CH2 and CH3) (also referred to as heavy chain constant region). Similarly, from N-terminal to C-terminal, each light chain has a variable region (VL) (also referred to as variable light chain domain or light chain variable domain), followed by a light chain constant domain (CL) (also referred to as light chain constant region). The heavy chains of antibodies can be assigned to one of five types, called α (IgA), δ (IgD), ε (IgE), γ (IgG), or μ (IgM), some of which can be further divided into subtypes, such as γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1), and α2 (IgA2). The light chains of antibodies can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of their constant domains.

[0056] "Antibody fragment" refers to a molecule other than an intact antibody, which comprises a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies, triabodies, tetrabodies, cross-Fab fragments; linear antibodies; single-chain antibody molecules (e.g., scFv); and single-domain antibodies. For a review of certain antibody fragments, see Hudson et al., Nat Med 9, 129-134 (2003). For a review of scFv fragments, see, for example, Plückthun, in The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore, eds., Springer-Verlag, New York, pp. 269 to 315 (1994); see also WO 93 / 16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For a discussion of Fab and F(ab')2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Pat. No. 5,869,046. Diabodies are antibody fragments having two antigen binding sites that can be bivalent or bispecific, see, e.g., EP 404,097; WO 1993 / 01161; Hudson et al., Nat Med 9, 129-134 (2003); and Hollinger et al., Proc Natl Acad Sci USA 90, 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat Med 9, 129-134 (2003). Single domain antibodies are antibody fragments comprising all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. In certain embodiments, the single domain antibody is a human single domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Pat. No. 6,248,516B1). Antibody fragments can be prepared by various techniques, including but not limited to proteolytic digestion of intact antibodies, and production by recombinant host cells (e.g., E. coli or phage), as described herein.

[0057] Papain digestion of whole antibodies produces two identical antigen-binding fragments called "Fab" fragments, each of which contains a heavy chain variable domain and a light chain variable domain, as well as a constant domain of a light chain and a first constant domain (CH1) of a heavy chain. Therefore, as used herein, the term "Fab fragment" refers to an antibody fragment comprising a light chain fragment and a VH domain and a first constant domain (CH1) of a heavy chain, the light chain fragment comprising a VL domain and a light chain constant domain (CL). The difference between a Fab' fragment and a Fab fragment is that the Fab' fragment has some residues added to the carboxyl terminus of the heavy chain CH1 domain, which residues include one or more cysteines from the hinge region of the antibody. Fab'-SH is a Fab' fragment in which the cysteine ​​residues of the constant domain have free sulfhydryl groups. Pepsin treatment produces a F(ab')2 fragment having two antigen-binding sites (two Fab fragments) and a portion of the Fc region. According to the present invention, the term "Fab fragment" also includes a "cross Fab fragment" or "exchange Fab fragment" as defined below.

[0058] The term "crossover Fab fragment" or "xFab fragment" or "exchange Fab fragment" refers to a Fab fragment in which the variable regions or constant regions of the heavy and light chains are exchanged. Two different chain compositions of exchange Fab molecules are possible and are included in the bispecific antibodies of the present invention: in one aspect, the variable regions of the Fab heavy and light chains are exchanged, i.e., the exchange Fab molecule comprises a peptide chain consisting of a light chain variable region (VL) and a heavy chain constant region (CH1), and a peptide chain consisting of a heavy chain variable region (VH) and a light chain constant region (CL). This exchange Fab molecule is also called CrossFab (VLVH) On the other hand, when the constant regions of the Fab heavy chain and light chain are exchanged, the exchange Fab molecule comprises a peptide chain consisting of a heavy chain variable region (VH) and a light chain constant region (CL), and a peptide chain consisting of a light chain variable region (VL) and a heavy chain constant region (CH1). This exchange Fab molecule is also called CrossFab. (CLCH1) .

[0059] "Single-chain Fab fragments" or "scFab" are polypeptides consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL), and a linker, wherein the antibody domains and the linker have one of the following orders in the N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1, or d) VL-CH1-linker-VH-CL; and wherein the linker is a polypeptide of at least 30 amino acids, preferably 32 to 50 amino acids. The single-chain Fab fragments are stabilized via natural disulfide bonds between the CL domain and the CH1 domain. In addition, these single-chain Fab molecules can be further stabilized by generating interchain disulfide bonds via the insertion of cysteine ​​residues (e.g., position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).

[0060] "Exchange single-chain Fab fragments" or "x-scFab" are polypeptides consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL), and a linker, wherein the antibody domains and the linker have one of the following orders in the N-terminal to C-terminal direction: a) VH-CL-linker-VL-CH1 and b) VL-CH1-linker-VH-CL; wherein VH and VL together form an antigen binding site that specifically binds to an antigen, and wherein the linker is a polypeptide of at least 30 amino acids. In addition, these x-scFab molecules can be further stabilized by generating interchain disulfide bonds via the insertion of cysteine ​​residues (e.g., position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).

[0061] A "single-chain variable fragment (scFv)" is a fragment of the heavy chain variable region (V H ) and light chain variable region (V L ) fusion protein, connected to a short linker peptide of ten to about 25 amino acids. The linker is usually rich in glycine for flexibility, and rich in serine or threonine for solubility, and V H The N-terminus of LThe antibody fragment is a fragment of a single-chain polypeptide, which is characterized by having a VH domain, i.e., being able to be assembled into a functional antigen binding site together with a VL domain; or having the characteristics of a VL domain, i.e., being able to be assembled into a functional antigen binding site together with a VH domain, thereby providing the antigen binding properties of a full-length antibody.

[0062] "Scaffold antigen binding proteins" are known in the art, for example, fibronectin and designed ankyrin repeat proteins (DARPins) have been used as alternative scaffolds for antigen binding domains, see, for example, Gebauer and Skerra, Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13:245-255 (2009) and Stumpp et al., Darpins: A new generation of protein therapeutics. Drug Discovery Today 13:695-701 (2008). In one aspect of the invention, the scaffold antigen binding protein is selected from the group consisting of: CTLA-4 (Evibody), lipocalin (Anticalin), protein A derived molecules (such as the Z domain of protein A (affimer)), A domain (Avimer / giant antibody), serum transferrin (transbody); designed ankyrin repeat protein (DARPin), variable domain of antibody light or heavy chain (single domain antibody, sdAb), variable domain of antibody heavy chain (nanobody, aVH), V NAR fragments, fibronectin (AdNectin), C-type lectin domain (tetranectin); variable domain of neoantigen receptor β-lactamase (V NAR fragments), human γ-crystallin or ubiquitin protein (Affilin molecule); Kunitz-type domains of human protease inhibitors, minibodies (such as proteins from the knottin family), peptide aptamers and fibronectin (adnectin). CTLA-4 (cytotoxic T lymphocyte-associated antigen 4) is mainly expressed in CD4 +CD28 family receptor expressed on T cells. Its extracellular domain has a variable domain-like Ig fold. The loops corresponding to the antibody CDR can be replaced with heterologous sequences to confer different binding properties. CTLA-4 molecules engineered to have different binding specificities are also called Evibodies (e.g., US7166697B1). Evibody is roughly the same size as the isolated variable region of an antibody (e.g., a domain antibody). For further details, see Journal of Immunological Methods 248 (1-2), 31-45 (2001). Lipocalins are a family of extracellular proteins that transport small hydrophobic molecules such as steroids, bile, retinoids, and lipids. They have a rigid β-sheet secondary structure with many loops at the open end of the cone structure, which can be engineered to bind to different target antigens. Anticalins are between 160-180 amino acids in size and are derived from lipocalins. For further details, see Biochim Biophys Acta 1482: 337-350 (2000), US7250297B1 and US20070224633. Affimers are scaffolds of protein A derived from Staphylococcus aureus that can be engineered to bind antigens. The domain consists of a three-helix bundle of about 58 amino acids. Libraries have been formed by randomization of surface residues. For further details, see Protein Eng. Des. Sel. 2004, 17, 455-462 and EP 1641818A1. Avimers are multi-domain proteins derived from the A domain scaffold family. The natural domain of about 35 amino acids adopts a determined disulfide bonded structure. Diversity is formed by the natural variation exhibited by the recombinant A domain family. For further details, see Nature Biotechnology 23 (12), 1556-1561 (2005) and Expert Opinion on Investigational Drugs 16 (6), 909-917 (June 2007). Transferrin is a monomeric serum transport glycoprotein. Transferrin can be engineered by inserting peptide sequences in the surface loops allowed to bind different target antigens. Examples of engineered transferrin scaffolds include trans-isomers. For further details, see J.Biol.Chem 274, 24066-24073 (1999). Designed ankyrin repeat proteins (DARPins) are derived from ankyrin, which is a protein family that mediates the attachment of integral membrane proteins to cell scaffolds. A single ankyrin repeat is a 33-residue motif consisting of two α-helices and a β-turn.They can be designed to bind different target antigens by randomizing the residues in the first α-helix and β-turn in each repeat sequence. Their binding interface can be increased by increasing the number of modules (affinity maturation method). For further details, see J.Mol.Biol.332,489-503 (2003), PNAS 100 (4), 1700-1705 (2003) and J.Mol.Biol.369,1015-1028 (2007) and US20040132028A1. Single domain antibodies are antibody fragments consisting of a single monomer variable antibody domain. The first single domain is derived from the variable domain of the antibody heavy chain of camelids (nanoantibodies or V. H H fragment). In addition, the term single domain antibody includes autologous human heavy chain variable domain (aVH) or VH derived from shark. NAR Fragment. Fibronectin can be engineered to bind to the scaffold of the antigen. Adnectin consists of the backbone of the natural amino acid sequence of the 10th domain of 15 repeating units of type III human fibronectin (FN3). The three loops at one end of the β-sandwich can be engineered to enable Adnectin to specifically recognize the target therapeutic target. For further details, see Protein Eng. Des. Sel. 18, 435-444 (2005), US20080139791, WO2005056764 and US6818418B1. Peptide aptamers are combined recognition molecules that consist of a constant scaffold protein, usually thioredoxin (TrxA), which contains a constrained variable peptide loop inserted at the active site. For further details, see Expert Opin. Biol. Ther. 5, 783-797 (2005). Minibodies are derived from naturally occurring microproteins containing 3 to 4 cysteine ​​bridges and 25 to 50 amino acids in length, examples of which include KalataBI and conotoxins and knottins. Microproteins have loops that can be engineered to include up to 25 amino acids without affecting the overall folding of the microprotein. For further details on engineered knottin domains, see WO2008098796.

[0063] An "antibody that binds to the same epitope" as a reference molecule refers to an antigen-binding molecule that blocks the binding of a reference molecule to its antigen by 50% or more in a competition assay, and conversely, the reference molecule blocks the binding of an antigen-binding molecule to its antigen by 50% or more in a competition assay. An "antibody that does not bind to the same epitope" as a reference molecule refers to an antigen-binding molecule that does not block the binding of a reference molecule to its antigen by 50% or more in a competition assay, and conversely, the reference molecule does not block the binding of an antigen-binding molecule to its antigen by 50% or more in a competition assay.

[0064] The term "antigen binding domain" or "antigen binding site" refers to a portion of an antigen binding molecule that includes a region that specifically binds to and is complementary to a portion or all of an antigen. In the case of a larger antigen, an antigen binding molecule may bind only to a specific portion of the antigen, which is called an epitope. The antigen binding domain may be provided by, for example, one or more variable domains (also referred to as variable regions). Preferably, the antigen binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).

[0065] As used herein, the term "antigenic determinant" is synonymous with "antigen" and "epitope", and refers to a site on a polypeptide macromolecule (e.g., a continuous amino acid or a conformational configuration consisting of different regions of non-continuous amino acids), to which an antigen-binding portion binds, thereby forming an antigen-binding portion-antigen complex. Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, on the surface of immune cells, in free matter in serum and / or in the extracellular matrix (ECM). Unless otherwise indicated, the protein used as an antigen herein can be any natural form of protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). In a specific embodiment, the antigen is a human protein. When referring to a specific protein herein, the term encompasses "full length", unprocessed protein, and any form of protein produced by intracellular processing. The term also encompasses naturally occurring protein variants, such as splice variants or allelic variants.

[0066] "Specific binding" refers to binding that is selective for an antigen and can be distinguished from unwanted or nonspecific interactions. The ability of an antigen-binding molecule to bind to a specific antigen can be measured by enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art (e.g., surface plasmon resonance (SPR) technology (analyzed on a BIAcore instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)) and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). In one embodiment, for example, as measured by SPR, the degree of binding of an antigen-binding molecule to an unrelated protein is less than about 10% of the degree of binding of the antigen-binding molecule to the antigen. In certain embodiments, the molecule that binds to the antigen has a specific binding affinity of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -8 M or lower, e.g. 10 -8 M to 10 -13 M, for example 10 -9 M to 10 -13 The dissociation constant (Kd) of the

[0067] "Affinity" or "binding affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be represented by a dissociation constant (Kd), which is the ratio of the dissociation rate constant to the association rate constant (koff and kon, respectively). Therefore, equivalent affinities can include different rate constants as long as the ratio of the rate constants remains the same. Affinity can be measured by conventional methods known in the art, including those described herein. A particular method for measuring affinity is surface plasmon resonance (SPR).

[0068] An "affinity matured" antibody is one with one or more alterations in one or more hypervariable regions (HVRs) which result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody which does not possess such alterations.

[0069] As used herein, "tumor-associated antigen" or TAA refers to an antigenic determinant present on the surface of a target cell, such as a cell in a tumor (such as a cancer cell or a cell of a tumor stroma). In certain embodiments, the target cell antigen is an antigen on the surface of a tumor cell. In one embodiment, TAA is selected from the group consisting of: fibroblast activation protein (FAP), carcinoembryonic antigen (CEA), folate receptor alpha (FolR1), melanoma-associated chondroitin sulfate proteoglycan (MCSP), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and p95HER2. In particular, the tumor-associated antigen is fibroblast activation protein (FAP).

[0070] The term "fibroblast activation protein (FAP)" is also referred to as prolyl endopeptidase FAP or Seprase (EC3.4.21), and unless otherwise indicated, the term refers to any natural FAP of any vertebrate origin, such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys) and rodents (e.g., mice and rats). The term encompasses "full-length" unprocessed FAP, as well as any form of FAP produced by processing in cells. The term also encompasses naturally occurring variants of FAP, such as splice variants or allelic variants. In one embodiment, the antigen binding molecules of the present invention can specifically bind to human, mouse and / or cynomolgus monkey FAP. The amino acid sequence of human FAP is shown in UniProt (www.uniprot.org) Accession No. Q12884 (version 149, SEQ ID NO: 46) or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_004451.2. The extracellular domain (ECD) of human FAP extends from amino acid position 26 to position 760. The amino acid sequence of mouse FAP is shown in UniProt accession number P97321 (version 126, SEQ ID NO: 47) or NCBI RefSeq NP_032012.1. The extracellular domain (ECD) of mouse FAP extends from amino acid position 26 to amino acid position 761. Preferably, the anti-FAP binding molecules of the present invention bind to the extracellular domain of FAP.

[0071] The term "variable region" or "variable domain" refers to the domain of the antibody heavy chain or light chain that participates in the binding of an antigen-binding molecule to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, wherein each domain comprises four conserved framework regions (FR) and three hypervariable regions (HVR). See, e.g., Kindt et al., Kuby Immunology, 6th edition, WH Freeman and Co., p. 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity.

[0072] As used herein, the term "hypervariable region" or "HVR" refers to individual regions of an antibody variable domain that are hypervariable in sequence and determine antigen binding specificity, such as the "complementarity determining region" ("CDR").

[0073] Typically, antibodies contain six CDRs; three in VH (CDR-H1, CDR-H2, CDR-H3), and three in VL (CDR-L1, CDR-L2, CDR-L3). Exemplary CDRs herein include:

[0074] (a) hypervariable loops occurring at the following amino acid residues: 26 to 32 (L1), 50 to 52 (L2), 91 to 96 (L3), 26 to 32 (H1), 53 to 55 (H2), and 96 to 101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987));

[0075] (b) CDRs occurring at amino acid residues 24 to 34 (L1), 50 to 56 (L2), 89 to 97 (L3), 31 to 35b (H1), 50 to 65 (H2), and 95 to 102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and

[0076] (c) Antigenic contact points occur at the following amino acid residues: 27c to 36 (L1), 46 to 55 (L2), 89 to 96 (L3), 30 to 35b (H1), 47 to 58 (H2), and 93 to 101 (H3) (MacCallum et al., J. Mol. Biol. 262:732-745 (1996)).

[0077] Unless otherwise indicated, CDRs are determined according to the method described in Kabat et al., supra. One skilled in the art will appreciate that CDR names may also be determined according to the method described in Chothia, supra, the method described in McCallum, supra, or any other scientifically accepted naming system.

[0078] "Framework" or "FR" refers to the variable domain residues excluding the complementarity determining regions (CDRs). The FR of a variable domain is usually composed of the following four FR domains: FR1, FR2, FR3, and FR4. Therefore, CDR and FR sequences usually appear in the following sequence in VH (or VL): FR1-CDR-H1 (CDR-L1)-FR2-CDR-H2 (CDR-L2)-FR3-CDR-H3 (CDR-L3)-FR4.

[0079] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0080] The "class" of an antibody refers to the type of constant domain or constant region possessed by the heavy chain of the antibody. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and some of them can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0081] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, typically two, variable domains, wherein all or substantially all of the HVRs (e.g., CDRs) correspond to the HVRs of a non-human antibody, and all or substantially all of the FRs correspond to the FRs of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. An antibody in "humanized form," such as a non-human antibody, refers to an antibody that has undergone humanization. Other forms of "humanized antibodies" encompassed by the present invention are antibodies in which the constant region has been additionally modified or altered relative to the original antibody to produce the properties according to the present invention, particularly with respect to C1q binding and / or Fc receptor (FcR) binding.

[0082] The term "CH1 domain" refers to the portion of an antibody heavy chain polypeptide that extends approximately from EU position 118 to EU position 215 (EU numbering system according to Kabat). In one aspect, the CH1 domain has an amino acid sequence of ASTKGPSVFP LAPSSKSTSGGTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPSNTKVDKKV (SEQ ID NO: 48). Typically, a fragment having an amino acid sequence of EPKSC (SEQ ID NO: 49) is then connected to the CH1 domain and the hinge region.

[0083] The term "hinge region" refers to the portion of an antibody heavy chain polypeptide that connects the CH1 domain and the CH2 domain in a wild-type antibody heavy chain, for example from about position 216 to about position 230 according to the EU numbering system of Kabat, or from about position 226 to about position 230 according to the EU numbering system of Kabat. The hinge region of other IgG subclasses can be determined by comparing the hinge region cysteine ​​residues with the IgG1 subclass sequence. The hinge region is generally a dimer molecule composed of two polypeptides with the same amino acid sequence. The hinge region generally contains up to 25 amino acid residues and is flexible, allowing the associated target binding site to move independently. The hinge region can be subdivided into three domains: an upper hinge region, a middle hinge region, and a lower hinge region (see, for example, Roux et al., J. Immunol. 161 (1998) 4083). In one aspect, the hinge region has the amino acid sequence DKTHTCPXCP (SEQ ID NO: 50), wherein X is S or P. In one aspect, the hinge region has the amino acid sequence HTCPXCP (SEQ ID NO: 51), wherein X is S or P. In one aspect, the hinge region has the amino acid sequence CPXCP (SEQ ID NO: 52), wherein X is S or P.

[0084] The term "Fc domain" or "Fc region" herein is used to define the C-terminal region of an antibody heavy chain containing at least a portion of a constant region. The term includes native sequence Fc regions and variant Fc regions. The IgG Fc region comprises an IgG CH2 domain and an IgG CH3 domain. The "CH2 domain" of a human IgG Fc region generally extends from an amino acid residue at about position 231 to an amino acid residue at about position 340. (According to the EU numbering system of Kabat). In one aspect, the CH2 domain has an amino acid sequence of APELLGGPSVFLFPPKPKDT LMISRTPEVT CVWDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQESTYRW SVLTVLHQDWLNGKEYKCKV SNKALPAPIE KTISKAK (SEQ ID NO: 53). The uniqueness of the CH2 domain is that it is not tightly paired with another domain. In contrast, two N-connected branched carbohydrate chains are between the two CH2 domains of a complete native Fc region. It is speculated that carbohydrates may provide alternatives for domain-domain pairing and help stabilize the CH2 domain. Burton, Mol. Immunol. 22 (1985) 161-206. In one embodiment, a carbohydrate chain is connected to the CH2 domain. The CH2 domain herein can be a native sequence CH2 domain or a variant CH2 domain. A "CH3 domain" comprises a stretch of residues from the C-terminus to the CH2 domain in the Fc region (i.e., from an amino acid residue at about position 341 to an amino acid residue at about position 447 according to the EU numbering system (according to Kabat of IgG). In one aspect, the CH3 domain has an amino acid sequence of GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 54). The CH3 region herein may be a native sequence CH3 domain or a variant CH3 domain (e.g., a CH3 domain having an introduced "protrusion" ("knob") in one of its chains and a corresponding introduced "cavity" ("hole") in the other of its chains; see U.S. Pat. No. 5,821,333, which is expressly incorporated herein by reference). Such variant CH3 domains may be used to promote heterodimerization of two non-identical antibody heavy chains as described herein. In one embodiment, the human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present.Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0085] The term "wild-type Fc domain" refers to an amino acid sequence identical to the amino acid sequence of an Fc domain found in nature. Wild-type human Fc domains include native human IgG1 Fc regions (non-A and A allotypes), native human IgG2 Fc regions, native human IgG3 Fc regions, and native human IgG4 Fc regions, as well as naturally occurring variants thereof. Wild-type Fc regions are represented in SEQ ID NO: 55 (IgG1, Caucasian allotype), SEQ ID NO: 56 (IgG1, African American allotype), SEQ ID NO: 57 (IgG2), SEQ ID NO: 58 (IgG3), and SEQ ID NO: 59 (IgG4). The term "variant (human) Fc domain" refers to an amino acid sequence that differs from the amino acid sequence of a "wild-type" (human) Fc domain amino acid sequence by at least one "amino acid mutation". In one aspect, the variant Fc region has at least one amino acid mutation compared to the native Fc region, such as from about one to about ten amino acid mutations in the native Fc region, and in one aspect, from about one to about five amino acid mutations. In one aspect, the (variant) Fc region has at least about 95% homology to the wild-type Fc region.

[0086] The "knob-into-hole" technique is described in, for example, US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Typically, the method involves introducing a protrusion ("knob") at the interface of a first polypeptide and introducing a corresponding cavity ("hole") in the interface of a second polypeptide so that the protrusion can be positioned in the cavity to promote the formation of heterodimers and hinder the formation of homodimers. The protrusion is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). A compensatory cavity having the same or similar size as the protrusion is created in the interface of the second polypeptide by replacing a large amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine). The projections and cavities can be prepared by altering the nucleic acid encoding the polypeptide, for example by site-specific mutagenesis or by peptide synthesis. In a specific embodiment, the knob is modified to include the amino acid substitution T366W in one of the two subunits of the Fc domain, while the hole is modified to include the amino acid substitutions T366S, L368A and Y407V in the other of the two subunits of the Fc domain. In another specific embodiment, the subunit comprising the knob-modified Fc domain additionally includes the amino acid substitution S354C, while the subunit comprising the hole-modified Fc domain additionally includes the amino acid substitution Y349C. The introduction of these two cysteine ​​residues results in the formation of a disulfide bond between the two subunits of the Fc region, thereby further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).

[0087] "Regions equivalent to the Fc region of an immunoglobulin" are intended to include naturally occurring allelic variants of the Fc region of an immunoglobulin, as well as variants with modifications that produce substitutions, additions or deletions but do not substantially reduce the ability of the immunoglobulin to mediate effector functions (such as antibody-dependent cellular toxicity). For example, one or more amino acids can be deleted from the N-terminus or C-terminus of the Fc region of an immunoglobulin without substantially losing biological function. Such variants can be selected according to general rules known in the art so as to have minimal effect on activity (see, e.g., Bowie, JU et al., Science 247: 1306-10 (1990)).

[0088] The term "effector function" refers to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex-mediated antigen uptake by antigen-presenting cells, downregulation of cell surface receptors (e.g., B cell receptor), and B cell activation.

[0089] Fc receptor binding-dependent effector functions can be mediated by the interaction of the Fc region of an antibody with an Fc receptor (FcR), which is a specific cell surface receptor on hematopoietic cells. Fc receptors belong to the immunoglobulin superfamily and have been shown to mediate the removal of antibody-coated pathogens by engulfing immune complexes, and to lyse red blood cells and other various cell targets (e.g., tumor cells) coated with the corresponding antibodies by antibody-dependent cell-mediated cytotoxicity (ADCC) (see, e.g., Van de Winkel, JG and Anderson, CL, J. Leukoc. Biol. 49 (1991) 511-524). FcRs are defined by their specificity for immunoglobulin isotypes: the Fc receptors of IgG antibodies are called FcγRs. Fc receptor binding is described, for example, in: Ravetch, JV and Kinet, JP, Annu. Rev. Immunol. 9 (1991) 457-492; Capel, PJ, et al., Immunomethods 4 (1994) 25-34; de Haas, M., et al., J. Lab. Clin. Med. 126 (1995) 330-341 and Gessner, JE, et al., Ann. Hematol. 76 (1998) 231-248.

[0090] Cross-linking of the Fc region receptors of IgG antibodies (FcγRs) triggers a variety of effector functions, including phagocytosis, antibody-dependent cellular cytotoxicity, release of inflammatory mediators, and regulation of immune complex clearance and antibody production. Three classes of FcγRs have been identified in humans, including:

[0091] -FcγRI (CD64) binds monomeric IgG with high affinity and is expressed on macrophages, monocytes, neutrophils and eosinophils. Modification of at least one of the amino acid residues E233-G236, P238, D265, N297, A327 and P329 (numbered according to the EU index of Kabat) in the Fc region of IgG reduces binding to FcγRI. Substitution of IgG2 residues at positions 233-236 by IgG1 and IgG4 reduces binding to FcγRI by 10 3 times, and abolished the response of human monocytes to antibody-sensitized erythrocytes (Armour, KL et al., Eur. J. Immunol. 29 (1999) 2613-2624).

[0092] -FcγRII (CD32) binds complexed IgG with moderate to low affinity and is widely expressed. This receptor can be divided into two subtypes, namely FcγRIIA and FcγRIIB. FcγRIIA is present in many cells involved in killing (such as macrophages, monocytes, neutrophils) and seems to be able to activate the killing process. FcγRIIB seems to play a role in the inhibition process and is present in B cells, macrophages, mast cells and eosinophils. On B cells, it seems to play a role in inhibiting further production of immunoglobulins and isotype conversion to, for example, the IgE class. On macrophages, FcγRIIB serves to inhibit phagocytosis mediated by FcγRIIA. On eosinophils and mast cells, the B type may help inhibit the activation of these cells through the binding of IgE to its individual receptors. For example, antibodies comprising an IgG Fc region comprising mutations in at least one of amino acid residues E233-G236, P238, D265, N297, A327, P329, D270, Q295, A327, R292, and K414 (numbering according to the EU index of Kabat) were found to have reduced binding to FcγRIIA.

[0093] -FcγRIII (CD16) binds IgG with medium to low affinity, and includes two types. FcγRIIIA is present on NK cells, macrophages, eosinophils, and some monocytes and T cells, and mediates ADCC. The expression level of FcγRIIIB on neutrophils is high. It is found that for example antibodies (including IgG Fc regions with mutations of at least one amino acid residue E233-G236, P238, D265, N297, A327, P329, D270, Q295, A327, S239, E269, E293, Y296, V303, A327, K338 and D376 (according to the EU index numbering of Kabat)) have reduced binding to FcγRIIIA.

[0094] Shields, RL et al. J. Biol. Chem. 276 (2001) 6591-6604 describe the location of the binding site on human IgG1 for Fc receptors, the mutation sites mentioned above, and methods for measuring binding to FcγRI and FcγRIIA.

[0095] The term "ADCC" or "antibody-dependent cellular toxicity" is a function mediated by Fc receptor binding, and refers to the lysis of target cells by the antibodies reported herein in the presence of effector cells. The ability of antibodies to induce the initial steps of mediating ADCC is studied by measuring the binding of antibodies to cells expressing Fcγ receptors, such as cells recombinantly expressing FcγRI and / or FcγRIIA or NK cells (expressing FcγRIIIA in nature). In particular, the binding to FcγR on NK cells is measured.

[0096] An "activating Fc receptor" is an Fc receptor that, upon engagement by the Fc region of an antibody, causes a signaling event that stimulates cells bearing the receptor to perform effector functions. Activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89). A specific activating Fc receptor is human FcγRIIIa (see UniProt Accession No. P08637, version 141).

[0097] As used herein, the term "IFNG" refers to any interferon gamma polypeptide, including recombinantly produced polypeptides, synthetically produced polypeptides, and IFNG isolated from cells or tissues (such as from T-lymphocytes and NK cells) and other sources. As isolated from any source or as produced, IFNG polypeptides can be heterogeneous in length and typically range from 124 to 146 amino acids in length. Heterogeneity is typically observed at both ends, at the N-terminus due to post-translational removal of Cys-Tyr-Cys amino acids, and at the C-terminus due to variable proteolytic processing. Heterogeneity may also result from N-glycosylation of the polypeptide. The heterogeneity of IFNG polypeptides can vary depending on the source of the IFNG polypeptide. Therefore, reference to IFNG polypeptides refers to heterogeneous populations produced or isolated.

[0098] IFNG is a cytokine secreted in response to viral infection or cancer growth. IFNG regulates T cell class I and class II MHC antigen expression, Fc receptors and macrophages. IFNG is signaled by a multimeric receptor complex consisting of two different chains: IFNG receptor binding subunits (IFNGR, IFNGR1) and transmembrane cofactors (IFNGR2). The IFNG signaling complex is formed when the IFNG receptor dimerizes driven by the ligand. If appropriate, as used herein, the term "IFNG polypeptide" may include its monomer or dimer form. As used herein, the term "human IFNG" (huIFNG) includes IFNG, allelic variant isoforms, synthetic molecules, proteins isolated from human tissues and cells, and modified forms thereof, and exemplary human wild-type IFNG polypeptides are shown in SEQ ID NO: 60. As used herein, the term "mouse IFNG" (muIFNG) includes IFNG, allelic variant isoforms, synthetic molecules, proteins isolated from murine tissues and cells, and modified forms thereof. An exemplary mouse wild-type IFNG polypeptide is shown in SEQ ID NO:61.

[0099] As used herein, the term "IFNG variant polypeptide" refers to a monomeric IFNG polypeptide in which one or more amino acids are truncated and / or in which there are amino acid substitutions, deletions or insertions compared to the amino acid sequence of a wild-type IFNG polypeptide.

[0100] The terms "anti-IFNG antibody", "anti-IFNG", "IFNG antibody" and "antibody that specifically binds to IFNG" refer to an antibody or antibody fragment that can specifically bind to IFNG with sufficient affinity so that the antibody or antibody fragment can be used as a diagnostic and / or therapeutic agent in targeting IFNG. When associated with a molecule comprising IFNG, the anti-IFNG antibody can act as a masking portion of the molecule. Specifically disclosed herein are scFvs specific for IFNG that can block the activity of cytokines. In one aspect, the degree of binding of the anti-IFNG antibody to unrelated, non-IFNG proteins is less than about 10% of the degree of binding of the antibody to IFNG, for example, as measured by radioimmunoassay (RIA) or flow cytometry (FACS). In certain embodiments, the antibody that binds to IFNG has a specific affinity of ≤1 μM, ≤100nM, ≤10nM, ≤1nM, ≤0.1nM, ≤0.01nM or ≤0.001nM (e.g., 10 - 6 M or smaller, e.g. 10 -68 M to 10 -13 M, for example 10 -8 M to 10 -10 The dissociation constant (K D). In one aspect, the anti-IFNG antibody is an antibody fragment, in particular a scFv.

[0101] The term "linker" or "peptide linker" refers to a peptide comprising one or more amino acids, typically about 2 to 30 amino acids. Peptide linkers are known in the art or described herein. Suitable non-immunogenic linker peptides are, for example, (G4S) n 、(SG4) n or G4(SG4) n A peptide linker wherein "n" is generally a number between 1 and 10, typically between 2 and 5, and in particular 3, i.e. a peptide selected from the group consisting of GGGGS (SEQ ID NO: 62), GGGGSGGGGS (SEQ ID NO: 63), SGGGGSGGGG (SEQ ID NO: 64), GGGGSGGGGSGGGG (SEQ ID NO: 65), (G4S)3 (SEQ ID NO: 66), (G4S)4 (SEQ ID NO: 67) and (G4S)5 (SEQ ID NO: 68), GGGGSGGGGSGGGGSGGGGSGGGGSGGGG (SEQ ID NO: 69), and GGGGSGGG (SEQ ID NO: 72), but also including peptides such as LEVLFQG (SEQ ID NO: 73). NO:73) or GGGGSGGGGSGGGGSGGGGSGLEVLFQGPGGGGGSGGGGG (SEQ ID NO:74). Peptide linkers of particular interest are protease cleavable linkers ("cleavable linkers") GGGGSGGGGSGGGPQARKGGGGGGSGGGG (SEQ ID NO:70) or GGGGSGGGGSGGGHQARKGGGGGGSGGGG (SEQ ID NO:71). "Non-cleavable linkers" are peptide linkers that are not recognized by proteases and are stable to proteolysis.

[0102] The term "amino acid" as used in this application refers to the group of naturally occurring carboxy α-amino acids including: alanine (three letter code: ala, single letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine ​​(cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y) and valine (val, V).

[0103] By "fused" or "linked" is meant that the components (eg, the heavy chains of an antibody and a Fab fragment) are linked by peptide bonds, either directly or via one or more peptide linkers.

[0104] "Amino acid sequence identity percentage (%)" relative to a reference polypeptide (protein) sequence is defined as the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence after aligning the candidate sequence with the reference polypeptide sequence and introducing spaces (if necessary) to achieve maximum sequence identity percentage, and without considering any conservative substitutions as components of sequence identity for the purpose of alignment and without considering any conservative substitutions as components of sequence identity. Alignment for determining amino acid sequence identity percentage can be achieved in various ways within the technical scope of the art, for example, using publicly available computer software, such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software or FASTA program package. Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithm required for achieving maximum alignment over the full length of the compared sequence. Alternatively, the sequence comparison computer program ALIGN-2 can be used to generate identity percentage values. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc., and the source code has been filed with user documentation in the US Copyright Office, Washington DC, 20559, where it is registered under US Copyright Registration No. TXU510087, and is described in WO 2001 / 007611. Unless otherwise indicated, for purposes herein, amino acid sequence identity percentage values ​​are generated using the BLOSUM50 comparison matrix using the ggsearch program of the FASTA package version 36.3.8c or higher. The FASTA program package was created by WR Pearson and DJ Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448; WR Pearson (1996) "Effective protein sequence comparison" Meth. Enzymol. 266:227-258; and Pearson et al. (1997), Genomics 46:24-36 and is publicly available at www.fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml or www.ebi.ac.uk / Tools / sss / fasta.Alternatively, sequences can be compared using a public server accessible at fasta.bioch.virginia.edu / fasta_www2 / index.cgi, using the ggsearch (global protein:protein) program and default options (BLOSUM50; open: -10; ext: -2; Ktup = 2) to ensure that a global rather than a local alignment is performed. The amino acid identity percentage is given in the output alignment header.

[0105] In certain embodiments, the amino acid sequence variants of the bispecific antigen binding molecules provided herein are contemplated. For example, it may be necessary to improve the binding affinity and / or other biological properties of the antigen binding molecules containing TNF ligand trimers. The amino acid sequence variants of the antigen binding molecules containing TNF ligand trimers can be prepared by introducing appropriate modifications into the nucleotide sequence of the coding molecule or by peptide synthesis. Such modifications include, for example, the deletion of residues in the antibody amino acid sequence, and / or insertion and / or substitution. Any combination of deletion, insertion and substitution can be performed to achieve the final construct, provided that the final construct has the desired characteristics, such as antigen binding. The site of interest for substitution mutagenesis includes HVR and framework (FR). Conservative substitutions are provided under the header "preferred substitutions" in Table B, and are further described below with reference to amino acid side chain categories (1) to (6). Amino acid substitutions can be introduced into the target molecule, and the product is screened for desired activity (e.g., retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC).

[0106] Table A

[0107]

[0108]

[0109] Amino acids can be grouped according to common side chain properties:

[0110] (1) Hydrophobicity: norleucine, Met, Ala, Val, Leu, Ile;

[0111] (2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln;

[0112] (3) Acidic: Asp, Glu;

[0113] (4) Basic: His, Lys, Arg;

[0114] (5) Residues that affect chain orientation: Gly, Pro;

[0115] (6) Aromatic: Trp, Tyr, Phe.

[0116] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

[0117] The term "amino acid sequence variant" includes substantial variants, wherein there is an amino acid substitution in one or more hypervariable region residues of a parent antigen binding molecule (e.g., humanized or human antibody). Typically, relative to the parent antigen binding molecule, one or more resulting variants selected for further study will have changes (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) and / or will substantially retain certain biological properties of the parent antigen binding molecule. Exemplary substitution variants are affinity matured antibodies, which can be conveniently generated, for example, using affinity maturation techniques based on phage display such as those described herein. In short, one or more CDR residues are mutated and variant antigen binding molecules are displayed on phage and screened for specific biological activity (e.g., binding affinity). In certain embodiments, substitution, insertion or deletion may occur in one or more HVRs, as long as such changes do not substantially reduce the antigen binding ability of the antigen binding molecule. For example, conservative changes (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity can be made in CDR. The method that can be used to identify antibody residues or regions that can be targeted for mutagenesis is called "alanine scanning mutagenesis", as described in Cunningham and Wells (1989) Science, 244: 1081-1085. In this method, a residue or a group of target residues (e.g., charged residues, such as Arg, Asp, His, Lys and Glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with the antigen is affected. Other substitutions can be introduced at amino acid positions that exhibit functional sensitivity to the initial substitution. Alternatively or additionally, the crystal structure of the antigen-antigen binding molecule complex is used to identify the contact points between the antibody and the antigen. Such contact residues and adjacent residues that are candidates for substitution can be targeted or eliminated. Variants can be screened to determine whether they have the desired properties.

[0118] The amino acid sequence insertion includes amino and / or carboxyl terminal fusions ranging in length from one residue to a polypeptide containing one hundred or more residues, and intrasequence insertions of one or more amino acid residues. Examples of terminal insertions include bispecific antigen binding molecules of the present invention with an N-terminal methionyl residue. Other insertion variants of the molecule include fusions to the N-terminal or C-terminal end of a polypeptide that increases the serum half-life of the bispecific antigen binding molecule.

[0119] In certain aspects, the bispecific antigen binding molecules provided herein are changed to increase or reduce the degree of antibody glycosylation. One or more glycosylation sites can be produced or removed by changing the amino acid sequence, so as to conveniently obtain the glycosylation variant of the molecule. When the antigen binding molecules containing the TNF ligand trimer include the Fc region, the carbohydrate attached thereto can be changed. The natural antibodies produced by mammalian cells typically include the biantennary oligosaccharides of the side chains, which are usually connected to the Asn297 of the CH2 domain of the Fc region by N bonds. See, for example, Wright et al. TIBTECH 15:26-32 (1997). Oligosaccharides may include various carbohydrates, for example, mannose, N-acetylglucosamine (GlcNAc), galactose and sialic acid, and the fucose of the GlcNAc in the "trunk" of the biantennary oligosaccharide structure. In certain embodiments, the oligosaccharides in the antigen binding molecules containing the TNF family ligand trimer can be modified to produce variants with some improved properties. In one aspect, a variant of a bispecific antigen binding molecule or antibody of the present invention is provided, which has a carbohydrate structure lacking fucose attached (directly or indirectly) to the Fc region. Such fucosylated variants may have improved ADCC function, see, for example, U.S. Patent Publication No. US2003 / 0157108 (Presta, L.) or US2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd). On the other hand, the bispecific antigen binding molecule or antibody of the present invention is provided with a variant of a bisected oligosaccharide, for example, wherein the biantennary oligosaccharide attached to the Fc region is bisected by GlcNAc. Such variants may have reduced fucosylation and / or improved ADCC function, see, for example, WO 2003 / 011878 (Jean-Mairet et al.); U.S. Patent No. 6,602,684 (Umana et al.); and US2005 / 0123546 (Umana et al.). Variants having at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function and are described, for example, in WO 1997 / 30087 (Patel et al.); WO 1998 / 58964 (Raju, S.); and WO 1999 / 22764 (Raju, S.).

[0120] In some aspects, it is desirable to produce a cysteine ​​engineered variant of the bispecific antigen binding molecule of the present invention, such as a "thioMAb", in which one or more residues of the molecule are replaced by cysteine ​​residues. In particular aspects, the substituted residue is present in an accessible site of the molecule. By replacing those residues with cysteine, the reactive thiol group is thus located at an accessible site of the antibody, and can be used to conjugate the antibody with other moieties, such as a drug moiety or a linker-drug moiety, to produce an immunoconjugate. In some aspects, any one or more of the following residues can be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) in the heavy chain Fc region. Cysteine ​​engineered antigen binding molecules can be formed as described in, for example, U.S. Patent No. 7,521,541.

[0121] As used herein, "protease-activatable", with respect to an antigen binding molecule comprising an interferon gamma (IFNG) variant, refers to a molecule comprising an IFNG variant whose ability to bind to an IFNG receptor is reduced or eliminated due to a masking moiety that reduces or eliminates the ability of the IFNG variant to bind to the IFNG receptor. When the masking moiety is dissociated by proteolytic cleavage (e.g., by proteolytic cleavage of a linker that connects the masking moiety to the molecule comprising the IFNG variant), binding to the IFNG receptor is restored, and the IFNG variant is thereby able to be activated.

[0122] As used herein, "reversibly hiding" refers to the binding of a masking moiety to an IFNG variant polypeptide, such as to prevent the IFNG variant polypeptide from binding to its receptor. This hiding is reversible because the masking moiety can be released from the IFNG variant polypeptide, for example by protease cleavage, and thereby free the IFNG variant polypeptide to bind to its receptor.

[0123] As used herein, "protease" or "proteolytic enzyme" refers to any proteolytic enzyme that cleaves a linker at a recognition site and is expressed by a target cell. Such proteases may be secreted by the target cell or remain associated with the target cell, for example, on the surface of the target cell. Examples of proteases include, but are not limited to, metalloproteinases, such as matrix metalloproteinases 1-28 and disintegrin and metalloproteinases (ADAM) 2, 7-12, 15, 17-23, 28-30, and 33; serine proteases, such as urokinase-type plasminogen activator and Matriptase; cysteine ​​proteases (e.g., cathepsin S) and matrix metalloproteinases (e.g., MMP-2 and MMP-9). Matriptase matrix metalloproteinase 2 (MMP-2, gelatinase A) and matrix metalloproteinase 9 (MMP-9, gelatinase B) are, for example, overexpressed in breast cancer and ovarian cancer. MMP-2 and MMP-9 activity was detected in the ascites of patients with cervical cancer, breast cancer, ovarian cancer, and epithelial ovarian cancer (EOC), but not in the serum of these patients (Demeter, A. et al., Anticancer Res. 2005, 25, 2885-2889). Although matriptase can be detected in normal epithelial cells, matriptase activity is mainly detected in cancer (LeBeau, AM et al., Proc. Natl. Acad. Sci. USA 2013, 110, 93-98).

[0124] The term "nucleic acid" or "polynucleotide" includes any compound and / or substance comprising a nucleotide polymer. Each nucleotide is composed of a base, particularly a purine or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i.e., deoxyribose or ribose) and a phosphate group. Typically, nucleic acid molecules are described by base sequences, wherein the bases represent the primary structure (linear structure) of the nucleic acid molecule. The base sequence is generally expressed as from 5' to 3'. In this article, the term nucleic acid molecule encompasses synthetic forms of deoxyribonucleic acid (DNA) (including, for example, complementary DNA (cDNA) and genomic DNA), ribonucleic acid (RNA) (particularly messenger RNA (mRNA)), DNA or RNA, and mixed polymers comprising two or more of these molecules. Nucleic acid molecules can be linear or cyclic. In addition, the term nucleic acid molecule includes sense strands and antisense strands, as well as single-stranded and double-stranded forms. In addition, the nucleic acid molecules described herein may contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases with derivatized sugar or phosphate backbone bonds or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules suitable as carriers for direct expression in vitro and / or in vivo (e.g., in a host or patient) of the antibodies of the present invention. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) carriers may be unmodified or modified. For example, mRNA may be chemically modified to enhance the stability of the RNA carrier and / or the expression of the encoding molecule, so that mRNA may be injected into a subject to produce antibodies in vivo (see, e.g., Stadler et al., Nature Medicine 2017, published online on June 12, 2017, doi: 10.1038 / nm.4356 or EP 2 101 823 B1).

[0125] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that normally contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0126] "Isolated nucleic acid encoding a bispecific antigen-binding molecule or antibody" refers to one or more nucleic acid molecules encoding the heavy and light chains (or fragments thereof) of a bispecific antigen-binding molecule or antibody, including such nucleic acid molecules in a single vector or separate vectors, and such nucleic acid molecules present at one or more locations in a host cell.

[0127] With respect to a nucleic acid or polynucleotide having a nucleotide sequence that is at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is meant that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence that is at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with additional nucleotides, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These changes in the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, or may be interspersed individually among the residues of the reference sequence, or may be interspersed in one or more consecutive groups within the reference sequence. As a practical matter, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the invention can be routinely determined using known computer programs, such as those discussed above for polypeptides (e.g., ALIGN-2).

[0128] The term "expression cassette" refers to a polynucleotide generated by recombination or synthesis, which has a series of specific nucleic acid elements that allow a specific nucleic acid to be transcribed in a target cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus or nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes, in addition to other sequences, a nucleic acid sequence to be transcribed and a promoter. In certain embodiments, the expression cassette of the present invention comprises a polynucleotide sequence encoding a bispecific antigen binding molecule of the present invention or a fragment thereof.

[0129] The term "vector" or "expression vector" is synonymous with "expression construct" and refers to a DNA molecule used to introduce a specific gene into a target cell operably associated therewith and to direct the expression of the gene. The term includes vectors that are self-replicating nucleic acid structures, as well as vectors that are incorporated into the genome of a host cell into which it has been introduced. The expression vector of the present invention comprises an expression cassette. The expression vector allows transcription of a large amount of stable mRNA. Once the expression vector is inside the target cell, a ribonucleic acid molecule or protein encoded by the gene is produced by cellular transcription and / or translation mechanisms. In one embodiment, the expression vector of the present invention comprises an expression cassette comprising a polynucleotide sequence encoding a bispecific antigen binding molecule of the present invention or a fragment thereof.

[0130] The terms "host cell", "host cell line" and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acids have been introduced, including progeny of such cells. Host cells include "transformants" and "transformed cells", which include primary transformed cells and progeny derived from the primary transformed cells, regardless of the number of passages. Progeny may not be completely consistent with the nucleic acid content of the parent cell, but may contain mutations. This article includes mutant progeny with the same function or biological activity as screened or selected in the original transformed cells. Host cells are any type of cell system that can be used to generate the bispecific antigen binding molecules of the present invention. Host cells include cultured cells, for example, cultured mammalian cells, such as CHO cells, BHK cells, NS0 cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells and plant cells, as well as cells included in transgenic animals, transgenic plants or cultured plants or animal tissues.

[0131] An "effective amount" of an agent is that amount required to produce a physiological change in the cell or tissue to which it is administered.

[0132] A "therapeutically effective amount" of an agent (e.g., a pharmaceutical composition) refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or preventive result. A therapeutically effective amount of an agent, for example, eliminates, reduces, delays, minimizes, or prevents an adverse effect of a disease.

[0133] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In particular, the individual or subject is a human.

[0134] The term "pharmaceutical composition" or "pharmaceutical formulation" refers to a preparation that is in effective form permitting the biological activity of the active ingredient contained therein, and that contains no additional components that are unacceptably toxic to a subject to which the pharmaceutical composition would be administered.

[0135] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical composition or formulation other than the active ingredient, which is non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0136] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings concerning the use of such therapeutic products.

[0137] As used herein, "treatment" (and grammatical variations such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed for prevention or during the course of clinical pathology. Desired effects of treatment include, but are not limited to, preventing the occurrence or recurrence of disease, alleviating symptoms, diminishing any direct or indirect pathological consequences of disease, preventing metastasis, reducing the rate of disease progression, ameliorating or alleviating disease symptoms, and alleviating or improving prognosis. In some embodiments, the molecules of the invention are used to delay the development of disease or to slow the progression of disease.

[0138] As used herein, the term "cancer" refers to a proliferative disease such as lymphoma, lymphocytic leukemia, lung cancer, non-small cell lung (NSCL) cancer, bronchoalveolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, bladder cancer, kidney cancer or ureter cancer, renal cell carcinoma, renal pelvis cancer, mesothelioma, hepatocellular carcinoma, bile duct cancer, central nervous system (CNS) tumors, spinal axis tumors, brain stem glioma, glioblastoma multiforme, astrocytoma, neurilemmoma, ependymoma, medulloblastoma, meningioma, squamous cell carcinoma, pituitary adenoma and Ewing's sarcoma, including refractory forms of any of the above cancers, or a combination of one or more of the above cancers.

[0139] As used herein, the term "chemotherapeutic agent" refers to a compound that can be used to treat cancer. In one aspect, the chemotherapeutic agent is an antimetabolite. In one aspect, the antimetabolite is selected from the group consisting of aminopterin, methotrexate, pemetrexed, raltitrexed, cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, thioguanine, capecitabine, cytarabine, fluorouracil, floxuridine and gemcitabine. In a specific aspect, the antimetabolite is capecitabine or gemcitabine. On the other hand, the antimetabolite is fluorouracil. In one aspect, the chemotherapeutic agent is an agent that affects microtubule formation. In one aspect, the agent that affects microtubule formation is selected from the group consisting of paclitaxel, docetaxel, vincristine, vinblastine, vindesine, vinorelbine, taxotere, etoposide and teniposide. On the other hand, the chemotherapeutic agent is an alkylating agent such as cyclophosphamide. In one aspect, the chemotherapeutic agent is a cytotoxic antibiotic, such as a topoisomerase II inhibitor. In one aspect, the topoisomerase II inhibitor is doxorubicin.

[0140] The term "agent for use in cancer immunotherapy" refers to any substance that affects the immune system, including monoclonal antibodies. The antigen binding molecules described herein can be considered as such agents. The agents for use in cancer immunotherapy can be used as anti-tumor agents for treating cancer. In one aspect, the agents include but are not limited to anti-CTLA4 antibodies (e.g., ipilimumab), anti-PD1 antibodies (e.g., nivolumab or pembrolizumab), PD-L1 antibodies (e.g., atezolizumab, avelumab or durvalumab), LAG3 antibodies (e.g., relalizumab), PD1-LAG3 bispecific antibodies and TIGIT antibodies (e.g., tirilimumab).

[0141] Antigen binding molecules containing interferon gamma (IFNG) variant polypeptides

[0142] The present invention provides a novel antigen binding molecule containing an interferon gamma (IFNG) variant polypeptide, which is capable of specifically binding to a tumor-associated antigen, particularly a fibroblast activation protein (FAP), and thus combining an antibody that specifically binds to FAP with a novel IFNG variant polypeptide homodimer. The antigen binding molecules described herein have particularly advantageous properties, such as manufacturability, stability, binding affinity, biological activity, targeting efficiency, reduced sink effect, excellent pharmacokinetic (PK) properties, reduced toxicity, extended therapeutic window, and thus potentially enhanced efficacy.

[0143] Exemplary Antigen Binding Molecules

[0144] In one aspect, disclosed herein is an antigen binding molecule characterized in that it comprises a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized by a C-terminal amino acid sequence KRKRP (SEQ ID NO: 1). It has been shown herein that the presence of the KRKR patch, i.e., the amino acid sequence of KRKR (SEQ ID NO: 78), is important for the activity of IFNG. Recently, it has been confirmed that the KRKR patch is associated with the binding of IFNG to the heparan sulfate portion of the extracellular matrix, and thereby prevents fatal systemic toxicity (J. Kemna et al., Nature Immunology 2023, 24, 414-422). In order to avoid proteolysis, the C-terminus of wild-type IFNG has been stabilized with a proline cap so that the sequence of the IFNG variant polypeptide terminates with the amino acid sequence KRKRP (SEQ ID NO: 1).

[0145] In addition, the antigen binding molecules include targeting moieties for tumor-associated antigens, particularly FAP. In addition, the antigen binding molecules described herein include Fc regions that include mutations that reduce effector functions. The use of Fc regions that include mutations that reduce or eliminate effector functions will prevent nonspecific agonism by cross-linking via Fc receptors, and prevent ADCC of cells expressing FAP. Antigen binding molecules as described herein have advantages over conventional IFNG because they selectively induce immune responses at target cells, which are typically in the tumor stroma (i.e., adjacent to the tumor).

[0146] In the presence of cells expressing FAP, the antigen binding molecules described herein can upregulate MHCI and PDL1 expression (Example 5). After MHCI expression is upregulated, the antigen binding molecules will increase the amount of CD8 T cells in tumor tissue (Example 5). In addition, treatment with the antigen binding molecules described herein results in an increase in CXCL9 (T cell attraction chemokine) levels after therapy, which is essential for the immune infiltration cascade.

[0147] Provided herein are antigen binding molecules comprising

[0148] (i) an antibody that specifically binds to a tumor-associated antigen, and

[0149] (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized by a C-terminal amino acid sequence KRKRP (SEQ ID NO: 1).

[0150] Thus, an antigen binding molecule is provided, which comprises (i) an antibody that specifically binds to a tumor-associated antigen and (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized in that it terminates at the C-terminus with the amino acid sequence KRKRP (SEQ ID NO: 1).

[0151] The IFNG variant polypeptide is truncated at the C-terminus and protected with proline at the C-terminus to prevent it from proteolysis.

[0152] In one aspect, the antibody that specifically binds to a tumor-associated antigen is an antibody that specifically binds to fibroblast activation protein (FAP). In one aspect, an antigen binding molecule is provided, wherein the antibody that specifically binds to FAP comprises: (a) a heavy chain variable region (V H FAP), the heavy chain variable region comprises: a heavy chain complementarity determining region (CDR-H1), which comprises the amino acid sequence of SEQ ID NO: 4; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 5; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 6; and a light chain variable region (V LFAP), the light chain variable region comprises: a light chain complementary determining region (iv) CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 7; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 8; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 9; or (b) a heavy chain variable region (V H FAP), the heavy chain variable region comprises: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 12; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 13; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 14; and a light chain variable region (V L FAP), the light chain variable region comprises: CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 15; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 16; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 17. In one aspect, an antigen binding molecule is provided, wherein the antibody that specifically binds to FAP comprises: a heavy chain variable region (V H FAP), which comprises the amino acid sequence of SEQ ID NO: 10; and a light chain variable region (V L FAP), which comprises the amino acid sequence of SEQ ID NO: 11; or the antibody comprises: a heavy chain variable region (V H FAP), which comprises the amino acid sequence of SEQ ID NO: 18; and a light chain variable region (V L FAP), which comprises the amino acid sequence of SEQ ID NO: 19. In a specific aspect, an antigen binding molecule is provided, wherein the antibody that specifically binds to FAP comprises: a heavy chain variable region (V H FAP), which comprises the amino acid sequence of SEQ ID NO: 10; and a light chain variable region (V L FAP), which comprises the amino acid sequence of SEQ ID NO:11.

[0153] In one aspect, the antigen binding molecules include Fc domains, particularly IgG1 Fc domains or IgG4 Fc domains. In one aspect, the Fc domains include one or more amino acid substitutions that reduce the binding affinity of antibodies to Fc receptors and / or effector functions. In one aspect, the Fc domains belong to human IgG1 subclasses, and they have amino acid mutations L234A, L235A and P329G (EU numbering according to Kabat EU indexes). On the other hand, the Fc domains are murine Fc domains, and include amino acid mutations D265A and P329G (EU numbering according to Kabat EU indexes).

[0154] In one aspect, the antigen binding molecule is protease activatable and comprises a protease recognition site and a masking portion. Thus, the antigen binding molecule comprises (i) an antibody that specifically binds to a tumor-associated antigen, (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized in that it terminates at the C-terminus with an amino acid sequence KRKRP (SEQ ID NO: 1), (iii) a protease recognition site and (iv) a masking portion.

[0155] Protease recognition site

[0156] In one aspect, the protease recognition site is a substrate for matriptase. In one aspect, the protease recognition site comprises or consists of the amino acid sequence PQARK (SEQ ID NO: 20) or HQARK (SEQ ID NO: 21). In a specific aspect, the protease recognition site comprises or consists of the amino acid sequence PQARK (SEQ ID NO: 20). In one aspect, the protease recognition site is part of a cleavable peptide linker that connects the masking moiety to the IFNG variant polypeptide. In one aspect, the cleavable peptide linker comprises the amino acid sequence of SEQ ID NO: 70 or SEQ ID NO: 71, and in a specific aspect, the cleavable peptide linker comprises the amino acid sequence of SEQ ID NO: 70.

[0157] In one aspect, an antigen binding molecule is provided wherein the masking moiety is fused at its N-terminus to the C-terminus of the IFNG variant polypeptide via a cleavable peptide linker (mask-released form). In one aspect, the IFNG variant polypeptide is fused at its N-terminus to the C-terminus of the antibody via a stable linker.

[0158] In another aspect, an antigen binding molecule is provided wherein the masking moiety is fused at its N-terminus to the C-terminus of the Fc domain via a stable linker and at its C-terminus to the N-terminus of the IFNG variant polypeptide via a cleavable peptide linker (cytokine releasing form).

[0159] Masking part

[0160] The protease-activatable antigen binding molecule comprises a masking moiety, in particular two masking moieties for the IFNG variant homodimer. In one aspect, the masking moiety is an antibody fragment that specifically binds to the IFNG variant polypeptide and is capable of masking it. In a specific aspect, the masking moiety is a scFv that specifically binds to the IFNG variant polypeptide.

[0161] In one aspect, the masking moiety that specifically binds to an IFNG variant polypeptide, in particular a scFv, comprises

[0162] (a) Heavy chain variable region (V HIFNG), the heavy chain variable region comprising: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 22; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 23; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 24; and a light chain variable region (V L IFNG), the light chain variable region comprising: a light chain complementary determining region (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 25; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 26; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 27; or

[0163] (b) Heavy chain variable region (V H IFNG), the heavy chain variable region comprising: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 30; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 31; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 32; and a light chain variable region (V L IFNG), the light chain variable region comprising: CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 33; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 34; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 35.

[0164] In one aspect, the masking moiety that specifically binds to an IFNG variant polypeptide, particularly an scFv, comprises: (a) a heavy chain variable region (V H IFNG), which comprises the amino acid sequence of SEQ ID NO: 28; and a light chain variable region (V L IFNG), which comprises the amino acid sequence of SEQ ID NO: 29; or (b) a heavy chain variable region (V H IFNG), which comprises the amino acid sequence of SEQ ID NO: 36; and a light chain variable region (V L IFNG), which comprises the amino acid sequence of SEQ ID NO: 37. In a specific aspect, the masking portion that specifically binds to the IFNG variant polypeptide, especially the scFv, comprises: (a) a heavy chain variable region (V H IFNG), which comprises the amino acid sequence of SEQ ID NO: 28; and a light chain variable region (V L IFNG), which comprises the amino acid sequence of SEQ ID NO:29.

[0165] In one aspect, the masking moiety that specifically binds to and masks an IFNG variant polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 38. In one aspect, the masking moiety that specifically binds to an IFNG variant polypeptide comprises the amino acid sequence of SEQ ID NO: 38.

[0166] In another aspect, the masking moiety that specifically binds to and masks an IFNG variant polypeptide comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 39. In one aspect, the masking moiety that specifically binds to an IFNG variant polypeptide comprises the amino acid sequence of SEQ ID NO: 39.

[0167] Masked release form and cytokine release form

[0168] In one aspect, an antigen binding molecule is provided in which the masking moiety is fused to the C-terminus of the IFNG variant polypeptide at its N-terminus via a cleavable peptide linker (mask-release form). In one aspect, the IFNG variant polypeptide is fused to the C-terminus of the antibody at its N-terminus via a stable linker. A schematic scheme of this form is shown in Figure 1D middle.

[0169] In a specific aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0170] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 40; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 40; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0171] In another specific aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0172] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 43; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 44. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 43; and two light chains comprising the amino acid sequence of SEQ ID NO: 44.

[0173] In another aspect, an antigen binding molecule is provided wherein the masking moiety is fused at its N-terminus to the C-terminus of the Fc domain via a stable linker and at its C-terminus to the N-terminus of the IFNG variant polypeptide via a cleavable peptide linker (cytokine release form). A schematic scheme of this form is shown in Figure 1E middle.

[0174] In a specific aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0175] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 42; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 42; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0176] In another specific aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0177] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 45; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 44. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 45; and two light chains comprising the amino acid sequence of SEQ ID NO: 44.

[0178] Forms comprising sterically masked IFNG variant polypeptides

[0179] Also provided herein are antigen binding molecules comprising

[0180] (i) an antibody that specifically binds to a tumor-associated antigen, and

[0181] (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized in that it terminates at the C-terminus with the amino acid sequence KRKRP (SEQ ID NO: 1), and wherein the IFNG variant polypeptide is inserted between the upper hinge region and the lower hinge region of an antibody.

[0182] These antigen binding molecules are characterized in that they comprise a sterically hidden, ie sterically masked, IFNG variant polypeptide.

[0183] In one aspect, an antigen binding molecule is provided, wherein the IFNG variant polypeptide is fused at its N-terminus via a first linker to the C-terminus of the VHCH1 chain of the Fab domain that specifically binds to a tumor-associated antigen, particularly FAP. In addition, the IFNG variant polypeptide is fused at its C-terminus via a second linker to the N-terminus of the lower hinge region of the Fc domain. A schematic scheme of this form is shown in Fig. 10A middle.

[0184] In one aspect, the first linker is a glycine-serine linker.In a specific aspect, the first linker has the amino acid sequence of SEQ ID NO:69.

[0185] In one aspect, the second linker is a glycine-serine linker or a cleavable linker.In a specific aspect, the second linker has an amino acid sequence selected from the group consisting of: SEQ ID NO:72, SEQ ID NO:73 or SEQ ID NO:75.

[0186] In one aspect, the lower hinge region has the amino acid sequence of SEQ ID NO: 76. In one aspect, the lower hinge region is shortened and has the amino acid sequence of SEQ ID NO: 77.

[0187] In one aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0188] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 119; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 119; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0189] In another aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0190] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 120; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 120; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0191] In another aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0192] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 121; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 121; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0193] In another aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0194] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 122; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 122; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0195] In another aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0196] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 123; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 124; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0197] Fc domain modifications that reduce Fc receptor binding and / or effector function

[0198] The antigen binding molecules of the present invention further include an Fc domain, which is composed of a first subunit and a second subunit and includes one or more amino acid substitutions that reduce the binding affinity of the antigen binding molecules to the Fc receptor and / or effector functions. Therefore, one or more amino acid modifications can be introduced into the Fc region of the antibody provided herein, thereby generating Fc region variants. Fc region variants may include a human Fc region sequence (e.g., human IgG1, IgG2, IgG3 or IgG4 Fc region), which includes amino acid modifications (e.g., substitutions) at one or more amino acid positions.

[0199] The Fc domain confers favorable pharmacokinetic properties to the bispecific antibodies of the present invention, including a long serum half-life and a favorable tissue-blood distribution ratio that contribute to good accumulation in the target tissue. However, at the same time, the bispecific antibodies of the present invention may be caused to undesirably target cells expressing Fc receptors, rather than preferred antigen-bearing cells. Therefore, in a specific embodiment, the Fc domain of the bispecific antibodies of the present invention exhibits reduced binding affinity to Fc receptors and / or reduced effector functions compared to a native IgG Fc domain, particularly an IgG1 Fc domain or an IgG4 Fc domain. More specifically, the Fc domain is an IgG1 Fc domain.

[0200] In one such aspect, the Fc domain (or the bispecific antigen binding molecule of the invention comprising the Fc domain) exhibits less than 50%, preferably less than 20%, more preferably less than 10% and most preferably less than 5% of the binding affinity for an Fc receptor compared to a native IgG1 Fc domain (or a bispecific antigen binding molecule of the invention comprising the Fc domain); and / or the Fc domain (or the bispecific antigen binding molecule of the invention comprising the Fc domain) exhibits less than 50%, preferably less than 20%, more preferably less than 10% and most preferably less than 5% of the effector function compared to a native IgG1 Fc domain (or a bispecific antigen binding molecule of the invention comprising the Fc domain). In one aspect, the Fc domain (or the bispecific antigen binding molecule of the invention comprising the Fc domain) does not significantly bind to an Fc receptor and / or induce effector function. In a specific aspect, the Fc receptor is an Fcγ receptor. In one aspect, the Fc receptor is a human Fc receptor. In one aspect, the Fc receptor is an activating Fc receptor. In a specific aspect, the Fc receptor is an activating human Fcγ receptor, more specifically human FcγRIIIa, FcγRI or FcγRIIa, most specifically human FcγRIIIa. In one aspect, the Fc receptor is an inhibitory Fc receptor. In a specific aspect, the Fc receptor is an inhibitory human Fcγ receptor, more specifically human FcγRIIB. In one aspect, the effector function is one or more of CDC, ADCC, ADCP and cytokine secretion. In a specific aspect, the effector function is ADCC. In one aspect, the Fc domain exhibits substantially similar binding affinity to the neonatal Fc receptor (FcRn) compared to the native IgG1 Fc domain. Substantially similar binding to FcRn is achieved when the Fc domain (or the bispecific antigen binding molecule of the invention comprising said Fc domain) exhibits greater than about 70%, specifically greater than about 80%, more specifically greater than about 90% of the binding affinity of a native IgG1 Fc domain (or a bispecific antigen binding molecule of the invention comprising a native IgG1 Fc domain) for FcRn.

[0201] In a particular aspect, the Fc domain is engineered to have a reduced binding affinity to Fc receptors and / or reduced effector functions compared to a non-engineered Fc domain. In a particular aspect, the Fc domain of the bispecific antigen binding molecule of the present invention comprises one or more amino acid mutations that reduce the binding affinity of the Fc domain to Fc receptors and / or effector functions. Typically, the same one or more amino acid mutations are present in each of the two subunits of the Fc domain. In one aspect, the amino acid mutation reduces the binding affinity of the Fc domain to Fc receptors. On the other hand, the amino acid mutation reduces the binding affinity of the Fc domain to Fc receptors by at least 2 times, at least 5 times, or at least 10 times. In one aspect, compared to the bispecific antibody of the present invention comprising a non-engineered Fc domain, the bispecific antigen binding molecule of the present invention comprising an engineered Fc domain exhibits less than 20%, specifically less than 10%, and more specifically less than 5% of the binding affinity to Fc receptors. In a particular aspect, the Fc receptor is an Fcγ receptor. In other aspects, the Fc receptor is a human Fc receptor. In one aspect, the Fc receptor is an inhibitory Fc receptor. In a specific aspect, the Fc receptor is an inhibitory human Fcγ receptor, more specifically human FcγRIIB. In some aspects, the Fc receptor is an activated Fc receptor. In a specific aspect, the Fc receptor is an activating human Fcγ receptor, more specifically human FcγRIIIa, FcγRI or FcγRIIa, most specifically human FcγRIIIa. Preferably, the binding to each of these receptors is reduced. In some aspects, the binding affinity to complementary components, especially the specific binding affinity to C1q, is also reduced. In one aspect, the binding affinity to the neonatal Fc receptor (FcRn) is not reduced. When the Fc domain (or the bispecific antigen binding molecule of the present invention comprising the Fc domain) exhibits a binding affinity of the non-engineered form of the Fc domain (or the bispecific antigen binding molecule of the present invention comprising the non-engineered form of the Fc domain) to FcRn greater than about 70%, substantially similar binding to FcRn is achieved, i.e., the retention of the binding affinity of the Fc domain to the receptor is achieved. The Fc domain or the bispecific antigen binding molecule of the present invention comprising the Fc domain may exhibit such affinity greater than about 80% or even greater than about 90%. In certain embodiments, the Fc domain of the bispecific antigen binding molecule of the present invention is engineered to have reduced effector function compared to the non-engineered Fc domain.Reduced effector function may include, but is not limited to, one or more of the following: reduced complement dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen uptake by antigen presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling-induced apoptosis, reduced dendritic cell maturation, or reduced T cell priming.

[0202] Antibodies with reduced effector function include those with substitutions of one or more of Fc region residues 238, 265, 269, 270, 297, 327, and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc mutant, in which residues 265 and 297 are substituted with alanine (U.S. Pat. No. 7,332,581). Certain antibody variants with improved or reduced binding to FcR are described. (e.g., U.S. Pat. No. 6,737,056; WO 2004 / 056312, and Shields, RL et al., J. Biol. Chem. 276 (2001) 6591-6604).

[0203] In one aspect of the invention, the Fc domain comprises amino acid substitutions at positions E233, L234, L235, N297, P331, and P329. In some aspects, the Fc domain comprises amino acid substitutions L234A and L235A ("LALA"). In one such embodiment, the Fc domain is an IgG1 Fc domain, particularly a human IgG1 Fc domain. In one aspect, the Fc domain comprises amino acid substitutions at position P329. In a more specific aspect, the amino acid substitutions are P329A or P329G, particularly P329G. In one embodiment, the Fc domain comprises amino acid substitutions at position P329 and comprises additional amino acid substitutions selected from the group consisting of E233P, L234A, L235A, L235E, N297A, N297D, or P331S. In a more preferred aspect, the Fc domain comprises amino acid mutations L234A, L235A and P329G ("P329GLALA"). The "P329GLALA" combination of amino acid substitutions almost completely eliminates the Fcγ receptor binding of human IgG1 Fc domains, as described in PCT patent application number WO 2012 / 130831 A1. The document also describes methods for preparing such mutant Fc domains and methods for determining their properties (such as Fc receptor binding or effector functions). Such antibodies are IgG1 with mutations L234A and L235A or with mutations L234A, L235A and P329G (according to Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition Public Health Service, National Institutes of Health, Bethesda, MD, EU index numbering of 1991).

[0204] In one aspect, the Fc domain is an IgG4 Fc domain. In a more specific embodiment, the Fc domain is an IgG4 Fc domain comprising an amino acid substitution at position S228 (Kabat numbering), specifically an IgG4 Fc domain of amino acid substitution S228P. In a more specific embodiment, the Fc domain is an IgG4 Fc domain comprising amino acid substitutions L235E and S228P and P329G. This amino acid substitution reduces the in vivo Fab arm exchange of IgG4 antibodies (see Stubenrauch et al., Drug Metabolism and Disposition 38, 84-91 (2010)).

[0205] Antibodies with extended half-life and improved binding to the neonatal Fc receptor (FcRn), responsible for the transfer of maternal IgG to the fetus (Guyer, RL et al., J. Immunol. 117 (1976) 587-593; and Kim, JK et al., J. Immunol. 24 (1994) 2429-2434) are described in US 2005 / 0014934. Those antibodies comprise an Fc region having one or more substitutions therein that improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of the following Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, ​​413, 424 or 434, such as substitutions at Fc region residue 434 (U.S. Pat. No. 7,371,826). See also Duncan, AR and Winter, G., Nature 322 (1988) 738-740; U.S. Pat. No. 5,648,260; U.S. Pat. No. 5,624,821; and WO 94 / 29351 for other examples of Fc region variants.

[0206] The binding to Fc receptors can be easily determined, for example, by ELISA or by surface plasmon resonance (SPR) using standard instruments (such as BIAcore instruments (GE Healthcare)), and Fc receptors such as can be obtained by recombinant expression. Suitable such binding assays are described herein. Alternatively, cell lines known to express specific Fc receptors (such as human NK cells expressing FcγIIIa receptors) can be used to evaluate the binding affinity of Fc domains or cell activation bispecific antigen binding molecules comprising Fc domains to Fc receptors. The effector functions of the bispecific antigen binding molecules comprising Fc domains of the Fc domain or the present invention can be measured by methods known in the art. Suitable assays for measuring ADCC are described herein. Other examples of in vitro assays for assessing ADCC activity of molecules of interest are described in U.S. Pat. No. 5,500,362; Hellstrom et al., Proc Natl Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499-1502 (1985); U.S. Pat. No. 5,821,337; Bruggemann et al., J Exp Med 166, 1351-1361 (1987). Alternatively, non-radioactive assays can be used (see, e.g., ACTI for flow cytometry). TMNonradioactive cytotoxicity assay (Cell Technology, Inc. Mountain View, CA); and CytoTox Non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively or additionally, ADCC activity of the molecule of interest may be assessed in vivo, for example, in an animal model such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656 (1998).

[0207] The following sections describe preferred aspects of antigen binding molecules described herein that include Fc domain modifications that reduce Fc receptor binding and / or effector function. In one aspect, an antigen binding molecule is provided that includes: (i) an antibody that specifically binds to a tumor-associated antigen and (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized by a C-terminal amino acid sequence KRKRP (SEQ ID NO: 1), and wherein the antigen binding molecule includes an IgG1 Fc domain or an IgG4 Fc domain, and wherein the Fc domain includes one or more amino acid substitutions that reduce the binding affinity of the antibody to an Fc receptor and / or effector function. In another aspect, an antigen binding molecule is provided, comprising: (i) an antibody that specifically binds to a tumor-associated antigen and (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized in that it terminates at the C-terminus with the amino acid sequence KRKRP (SEQ ID NO: 1), and wherein the Fc domain belongs to the human IgG1 subclass, having amino acid mutations L234A, L235A and P329G (EU numbering according to the Kabat EU index).

[0208] Exemplary IFNG variant polypeptides

[0209] In one aspect, an IFNG variant polypeptide is provided, characterized in that it terminates at the C-terminus with the amino acid sequence KRKRP (SEQ ID NO: 1). It has been shown herein that the presence of the KRKR patch, i.e. the amino acid sequence of KRKR (SEQ ID NO: 78), is important for the activity of IFNG. To avoid proteolysis, the C-terminus of wild-type IFNG has been stabilized with a proline cap, such that the sequence of the IFNG variant polypeptide terminates with the amino acid sequence KRKRP (SEQ ID NO: 1).

[0210] In one aspect, an IFNG variant polypeptide is provided comprising or consisting of the amino acid sequence of SEQ ID NO: 2. In another aspect, an IFNG variant polypeptide is provided comprising or consisting of the amino acid sequence of SEQ ID NO: 3.

[0211] Also provided herein is a mutation or insertion variant of an IFNG variant polypeptide characterized in that it terminates at the C-terminus with the amino acid sequence KRKRP (SEQ ID NO: 1).

[0212] In one aspect, provided herein is an IFNG variant polypeptide characterized in that it terminates at the C-terminus with the amino acid sequence KRKRP (SEQ ID NO: 1), wherein one or two amino acids in SEQ ID NO: 1 are replaced with an amino acid selected from the group consisting of serine (S), proline (P) and glutamic acid (E).

[00136] Accordingly, provided herein are IFNG variant polypeptides characterized in that they terminate at the C-terminus with an amino acid sequence selected from the group consisting of AKTGSRKRP (SEQ ID NO: 137), AKTGKSKRP (SEQ ID NO: 138), AKTGKRSRP (SEQ ID NO: 139), AKTGKRKSP (SEQ ID NO: 134), AKTGPRKRP (SEQ ID NO: 140), AKTGKPKRP (SEQ ID NO: 141), AKTGKRPRP (SEQ ID NO: 142), AKTGKRPPP (SEQ ID NO: 143), AKTGERKRP (SEQ ID NO: 144), AKTGKEKRP (SEQ ID NO: 145), AKTGKRERP (SEQ ID NO: 146), AKTGKRKEP (SEQ ID NO: 147), AKTGSRSRP (SEQ ID NO: 148), AKTGPRPRP (SEQ ID NO: 149), AKTGERERP (SEQ ID NO: 150), AKTGKSKSP (SEQ ID NO: 151). ID NO:151), AKTGKPKPP (SEQ ID NO:152), AKTGKEKEP (SEQ ID NO:153), AKTGSSKRP (SEQ ID NO:154), AKTGPPKRP (SEQ ID NO:155), AKTGEEKRP (SEQ ID NO:156), AKTGKRSSP (SEQ ID NO:157), AKTGKRPPP (SEQ ID NO:158) and AKTGKREEP (SEQ ID NO:159).

[0213] In a preferred aspect, the present invention provides an IFNG variant polypeptide characterized in that it terminates at the C-terminus with the amino acid sequence KRKRP (SEQ ID NO: 1), wherein one or two amino acids in SEQ ID NO: 1 are replaced with an amino acid selected from serine (S) or proline (P). This includes IFNG variant polypeptides characterized in that they terminate at the C-terminus with an amino acid sequence selected from the group consisting of AKTGSRKRP (SEQ ID NO: 137), AKTGKSKRP (SEQ ID NO: 138), AKTGKRSRP (SEQ ID NO: 139), AKTGKRKSP (SEQ ID NO: 134), AKTGPRKRP (SEQ ID NO: 140), AKTGKPKRP (SEQ ID NO: 141), AKTGKRPRP (SEQ ID NO: 142), AKTGKRPPP (SEQ ID NO: 143), AKTGSRSRP (SEQ ID NO: 148), AKTGPRPRP (SEQ ID NO: 149), AKTGKSKSP (SEQ ID NO: 151), AKTGKPKPP (SEQ ID NO: 152), AKTGSSKRP (SEQ ID NO: 154), AKTGPPKRP (SEQ ID NO: 155), AKTGKRSSP (SEQ ID NO: 157), and AKTGKRPPP (SEQ ID NO: 158). NO:158).

[0214] Also provided herein are antigen binding molecules comprising

[0215] (i) an antibody that specifically binds to a tumor-associated antigen, and

[0216] (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized in that it terminates at the C-terminus with the amino acid sequence KRKRP (SEQ ID NO: 1) and wherein one or two of the amino acids in SEQ ID NO: 1 are replaced with an amino acid selected from the group consisting of serine (S), proline (P) and glutamic acid (E).

[0217] In a specific aspect, an antigen binding molecule is provided, comprising

[0218] (i) an antibody that specifically binds to a tumor-associated antigen, and

[0219] (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized in that it terminates at the C-terminus with the amino acid sequence KRKRP (SEQ ID NO: 1), and wherein one or two of the amino acids in SEQ ID NO: 1 are replaced with an amino acid selected from serine (S) or proline (P).

[0220] In one aspect, an antigen binding molecule is provided, comprising

[0221] (i) an antibody that specifically binds to a tumor-associated antigen, and

[0222] (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized by a C-terminal amino acid sequence selected from the group consisting of AKTGSRKRP (SEQ ID NO: 137), AKTGKSKRP (SEQ ID NO: 138), AKTGKRSRP (SEQ ID NO: 139), AKTGKRKSP (SEQ ID NO: 134), AKTGPRKRP (SEQ ID NO: 140), AKTGKPKRP (SEQ ID NO: 141), AKTGKRPRP (SEQ ID NO: 142), AKTGKRPPP (SEQ ID NO: 143), AKTGSRSRP (SEQ ID NO: 148), AKTGPRPRP (SEQ ID NO: 149), AKTGKSKSP (SEQ ID NO: 151), AKTGKPKPP (SEQ ID NO: 152), AKTGSSKRP (SEQ ID NO: 154), AKTGPPKRP (SEQ ID NO: 155), AKTGKRSSP (SEQ ID NO: 156), AKTGKRSSP (SEQ ID NO: 157), AKTGKRS NO: 157) and AKTGKRPPP (SEQ ID NO: 158).

[0223] In one aspect, provided herein are antigen binding molecules containing IFNG variant polypeptides, wherein the antigen binding molecules comprise two heavy chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 91; and two light chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecules comprise two heavy chains comprising the amino acid sequence of SEQ ID NO: 91; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0224] In one aspect, provided herein are antigen binding molecules containing IFNG variant polypeptides, wherein the antigen binding molecules comprise two heavy chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 92; and two light chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecules comprise two heavy chains comprising the amino acid sequence of SEQ ID NO: 92; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0225] In one aspect, provided herein are antigen binding molecules containing IFNG variant polypeptides, wherein the antigen binding molecules comprise two heavy chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 93; and two light chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecules comprise two heavy chains comprising the amino acid sequence of SEQ ID NO: 93; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0226] In one aspect, provided herein are antigen binding molecules containing IFNG variant polypeptides, wherein the antigen binding molecules comprise two heavy chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 94; and two light chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecules comprise two heavy chains comprising the amino acid sequence of SEQ ID NO: 94; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0227] In one aspect, provided herein are antigen binding molecules containing IFNG variant polypeptides, wherein the antigen binding molecules comprise two heavy chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 95; and two light chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecules comprise two heavy chains comprising the amino acid sequence of SEQ ID NO: 95; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0228] In one aspect, provided herein are antigen binding molecules containing IFNG variant polypeptides, wherein the antigen binding molecules comprise two heavy chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 96; and two light chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecules comprise two heavy chains comprising the amino acid sequence of SEQ ID NO: 96; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0229] In one aspect, provided herein are antigen binding molecules containing IFNG variant polypeptides, wherein the antigen binding molecules comprise two heavy chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 97; and two light chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecules comprise two heavy chains comprising the amino acid sequence of SEQ ID NO: 97; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0230] In one aspect, provided herein are antigen binding molecules containing IFNG variant polypeptides, wherein the antigen binding molecules comprise two heavy chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 98; and two light chains comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecules comprise two heavy chains comprising the amino acid sequence of SEQ ID NO: 98; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0231] In one aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0232] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 103; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 103; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0233] In one aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0234] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 104; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 104; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0235] In one aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0236] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 106; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 106; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0237] In one aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0238] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 107; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 107; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0239] In one aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0240] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 109; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 109; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0241] In one aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0242] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 110; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 110; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0243] In one aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0244] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 112; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 112; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0245] In one aspect, provided herein is an antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0246] Two heavy chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 113; and two light chains comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In one aspect, the antigen binding molecule comprises two heavy chains comprising the amino acid sequence of SEQ ID NO: 113; and two light chains comprising the amino acid sequence of SEQ ID NO: 41.

[0247] Polynucleotide

[0248] Also provided herein are isolated polynucleotides encoding an antigen binding molecule or fragment thereof as described herein or isolated polynucleotides encoding an IFNG variant polypeptide as described herein.

[0249] The polynucleotide encoding the separation of antigen binding molecules disclosed herein can be expressed as a single polynucleotide encoding a complete antigen binding molecule, or as a plurality of (e.g., two or more) polynucleotides of co-expression. The polypeptide encoded by the co-expressed polynucleotide can be associated to form a functional antigen binding molecule via, for example, a disulfide bond or other means. For example, the light chain portion of an immunoglobulin can be encoded by a separate polynucleotide from the heavy chain portion of an immunoglobulin. When co-expressed, the heavy chain polypeptide will associate with the light chain polypeptide to form an immunoglobulin.

[0250] In some aspects, the isolated polynucleotide encodes a polypeptide contained in an antigen binding molecule as described herein. In one aspect, an isolated polynucleotide encoding an IFNG variant polypeptide is provided, wherein the IFNG variant polypeptide is characterized by a C-terminal amino acid sequence KRKRP (SEQ ID NO: 1)

[0251] In one aspect, isolated polynucleotides encoding antigen binding molecules are provided, the antigen binding molecules comprising (i) an antibody that specifically binds to a tumor-associated antigen and (ii) a homodimer of an IFNG variant polypeptide, wherein the IFNG variant polypeptide is characterized by a C-terminal amino acid sequence KRKRP (SEQ ID NO: 1). In one aspect, one or more isolated polynucleotides encoding antigen binding molecules are provided, the antigen binding molecules comprising (i) an antibody that specifically binds to a tumor-associated antigen and (ii) a homodimer of an IFNG variant polypeptide, wherein the IFNG variant polypeptide is characterized by a C-terminal amino acid sequence KRKRP (SEQ ID NO: 1), (iii) a protease recognition site, and (iv) a masking portion.

[0252] In certain embodiments, the polynucleotide or nucleic acid is DNA. In other embodiments, the polynucleotide of the invention is RNA, for example in the form of messenger RNA (mRNA). The RNA of the invention can be single-stranded or double-stranded.

[0253] Recombination methods

[0254] Antigen binding molecules as described herein can be obtained by, for example, recombinant production. For recombinant production, one or more polynucleotides encoding antigen binding molecules or polypeptide fragments thereof are provided. One or more polynucleotides encoding bispecific antigen binding molecules are separated and inserted into one or more vectors for further cloning and / or expression in host cells. Such polynucleotides can be easily separated and sequenced using conventional methods. In one aspect of the present invention, a vector is provided, preferably an expression vector, which contains one or more polynucleotides in the polynucleotides of the present invention. Methods well known to those skilled in the art can be used to construct expression vectors containing the coding sequence of antigen binding molecules (fragments) and appropriate transcription / translation control signals. These methods include in vitro recombinant DNA technology, synthetic technology, and in vivo recombination / genetic recombination. See, for example, the technology described in the following documents: Maniatis et al., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory, NY (1989); and Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Associates and Wiley Interscience, NY (1989). The expression vector can be a part of a plasmid, a virus, or can be a nucleic acid fragment. The expression vector includes an expression cassette, and the polynucleotide (i.e., coding region) encoding the antigen binding molecules or its polypeptide fragments is cloned into the expression cassette in an operably associated manner with a promoter and / or other transcription or translation control elements. As used herein, a "coding region" is a part of a nucleic acid, which is composed of codons translated into amino acids. Although "stop codons" (TAG, TGA or TAA) are not translated into amino acids, they (if present) can be considered as a part of the coding region, and any flanking sequences, such as promoters, ribosome binding sites, transcription terminators, introns, 5' and 3' untranslated regions, etc. are not a part of the coding region. Two or more coding regions may be present in a single polynucleotide construct (e.g., on a single vector), or in a separate polynucleotide construct (e.g., on a separate (different) vector). In addition, any vector may contain a single coding region, or may include two or more coding regions, such as a vector of the present invention may encode one or more polypeptides, which are separated into final proteins by proteolytic cleavage after translation or during translation. In addition, the vectors, polynucleotides or nucleic acids of the present invention may encode heterologous coding regions that may or may not be fused to polynucleotides encoding the antigen binding molecules disclosed herein or their polypeptide fragments, or variants or derivatives thereof. Heterologous coding regions include, but are not limited to, specialized elements or motifs, such as secretory signal peptides or heterologous functional domains.Operable association is when the coding region of a gene product (e.g., a polypeptide) is associated with one or more regulatory sequences in a certain manner so that the expression of the gene product is under the influence or control of the regulatory sequences. If the induction of promoter function leads to the transcription of mRNA encoding the desired gene product, and if the nature of the bond between the two DNA fragments does not interfere with the ability of the expression regulatory sequence to direct the expression of the gene product or the ability of the DNA template to be transcribed, then the two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are "operably associated". Therefore, if the promoter is able to affect the transcription of the nucleic acid, the promoter region will be operably associated with the nucleic acid encoding the polypeptide. The promoter can be a cell-specific promoter that directs the substantial transcription of the DNA only in a predetermined cell. In addition to the promoter, other transcription control elements, such as enhancers, operators, repressors, and transcription termination signals, can be operably associated with the polynucleotide to direct cell-specific transcription.

[0255] Suitable promoters and other transcription control regions are disclosed herein. A variety of transcription control regions are known to those skilled in the art. These include, but are not limited to, transcription control regions that function in vertebrate cells, such as, but not limited to, promoter and enhancer segments from cytomegalovirus (e.g., the immediate early promoter in conjunction with intron-A), simian virus 40 (e.g., the early promoter), and retroviruses (such as, for example, Rous sarcoma virus). Other transcription control regions include those derived from vertebrate genes (such as actin, heat shock protein, bovine growth hormone, and rabbit thymus). The expression cassette may also include other features, such as an origin of replication, and / or chromosomal integration elements, such as retroviral long terminal repeats (LTRs), or adeno-associated virus (AAV) inverted terminal repeats (ITRs).

[0256] The polynucleotides and nucleic acid coding regions of the present invention can be associated with additional coding regions encoding secretory peptides or signal peptides, which guide the secretion of polypeptides encoded by the polynucleotides as provided herein. For example, if the desired secretion antigen binding molecules or polypeptide fragments thereof, the DNA encoding the signal sequence can be placed upstream of the nucleic acid encoding the antigen binding molecules or polypeptide fragments thereof. According to the signal hypothesis, the protein secreted by mammalian cells has a signal peptide or secretory leader sequence, and once the protein chain growing across the rough endoplasmic reticulum has been started to be exported, the signal peptide or secretory leader sequence is cut from the mature protein. Those of ordinary skill in the art know that the polypeptides secreted by vertebrate cells usually have a signal peptide fused to the N-terminus of the polypeptide, and the signal peptide is cut from the translated polypeptide to produce the secretion or "mature" form of the polypeptide. In certain embodiments, a natural signal peptide (such as an immunoglobulin heavy chain or light chain signal peptide) is used, or a functional derivative of the sequence that retains the ability to guide the secretion of the polypeptide operably associated therewith. Alternatively, a heterologous mammalian signal peptide or a functional derivative thereof can be used. For example, the wild-type leader sequence can be replaced by the leader sequence of human tissue plasminogen activator (TPA) or mouse beta-glucuronidase.

[0257] DNA encoding a short protein sequence (eg, a histidine tag) that can be used to facilitate subsequent purification or to aid in labeling of fusion proteins can be included within or at the end of a polynucleotide encoding a bispecific antigen binding molecule of the invention or a polypeptide fragment thereof.

[0258] In a further aspect, a host cell comprising one or more polynucleotides of the present invention is provided. In some aspects, a host cell comprising one or more vectors is provided. Polynucleotides and vectors can be infiltrated individually or in combination into any features described herein for polynucleotides and vectors, respectively. In one aspect, the host cell comprises a vector (e.g., transformed or transfected with a vector), which comprises a polynucleotide encoding an antigen binding molecule (a part thereof) as described herein. Host cells suitable for replication and support of antigen binding molecule expression are well known in the art. Such cells can be appropriately transfected or transduced with specific expression vectors, and a large number of cells containing vectors can be grown for inoculating large-scale fermentation tanks to obtain sufficient amounts of antigen binding molecules for clinical applications. Suitable host cells include prokaryotic microorganisms, such as Escherichia coli, or various eukaryotic cells, such as Chinese hamster ovary cells (CHO), insect cells, etc. For example, polypeptides can be produced in bacteria, particularly when glycosylation is not required. Polypeptides can be separated from bacterial cell paste in a soluble fraction after expression, and can be further purified. In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are also suitable cloning or expression hosts for vectors encoding polypeptides, including fungi and yeast strains whose glycosylation pathways have been "humanized", resulting in the production of polypeptides with partially or fully human glycosylation patterns. See Gerngross, Nat Biotech 22, 1409-1414 (2004) and Li et al., Nat Biotech 24, 210-215 (2006).

[0259] Suitable host cells for expressing (glycosylated) polypeptides also come from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant cells and insect cells. Many baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfecting Spodoptera frugiperda cells. Plant cell cultures can also be used as hosts. See, for example, U.S. Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978 and 6,417,429 (describing PLANTIBODIES for producing antibodies in transgenic plants). TMTechniques). Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted to growth in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293T cells, as described, for example, in Graham et al., J Gen Virol 36, 59 (1977)), baby hamster kidney cells (BHK), mouse Sertoli cells (TM4 cells, as described, for example, in Mather, Biol Reprod 23, 243-251 (1980)), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK), Buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (Hep G2), mouse mammary tumor cells (MMT 060562), TRI cells (as described, for example, in Mather et al., Annals NY Acad Sci 383, 44-68 (1982)), MRC 5 cells, and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including dhfr-CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)); and myeloma cell lines, such as YO, NS0, P3X63 and Sp2 / 0. For a review of some mammalian host cell lines suitable for protein production, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo, Humana Press, Totowa, NJ), pp. 255-268 (2003). Host cells include cultured cells, such as mammalian cultured cells, yeast cells, insect cells, bacterial cells and plant cells, and also include cells contained in transgenic animals, transgenic plants or cultured plants or animal tissues. In one embodiment, the host cell is a eukaryotic cell, preferably a mammalian cell, such as a Chinese hamster ovary (CHO) cell, a human embryonic kidney (HEK) cell, or a lymphocyte (e.g., a Y0, NS0, Sp20 cell). Standard techniques for expressing foreign genes in these systems are known in the art. Cells expressing polypeptides comprising heavy or light chains of immunoglobulins can be engineered to also express another immunoglobulin chain so that the expressed product is an immunoglobulin with heavy and light chains.

[0260] In one aspect, a method for producing an antigen-binding molecule or a polypeptide fragment thereof as disclosed herein is provided, wherein the method comprises culturing a host cell comprising a polynucleotide encoding the antigen-binding molecule or a polypeptide fragment thereof under conditions suitable for expressing the antigen-binding molecule or a polypeptide fragment thereof, and recovering the antigen-binding molecule or a polypeptide fragment thereof of the present invention from the host cell (or host cell culture medium).

[0261] The antigen binding molecules prepared as described herein can be purified by techniques known in the art, such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, etc. The actual conditions for purifying a particular protein will depend in part on factors such as net charge, hydrophobicity, hydrophilicity, and will be apparent to those skilled in the art. For affinity chromatography purification, antibodies, ligands, receptors or antigens bound by antigen binding molecules can be used. For example, for affinity chromatography purification of the fusion protein of the present invention, a matrix with protein A or protein G can be used. Basically as described in the examples, sequential protein A or G affinity chromatography and size exclusion chromatography can be used to separate antigen binding molecules. The purity of antigen binding molecules or their fragments can be determined by any of a variety of well-known analytical methods, including gel electrophoresis, high pressure liquid chromatography, etc. For example, the antigen binding molecules expressed as described in the examples are shown to be complete and appropriately assembled, as shown by reduced and non-reduced SDS-PAGE.

[0262] Determination

[0263] The antigen binding molecules provided herein can be characterized by various assays known in the art to characterize their binding properties and / or biological activity. In particular, they are characterized by the assays described in more detail in the examples.

[0264] 1. Binding Assay

[0265] Can be for example by using the murine fibroblast cell line expressing human fibroblast activation protein (FAP) and flow cytometry (FACS) analysis to assess the antigen binding molecules provided herein and the IFNG variant polypeptides and the combination with the corresponding target expressing cells.The binding behavior of IFNG variants to IFNGR1 and IFNGR1 / 2 can be assessed by surface plasmon resonance (SPR) as described in the examples.

[0266] 2. Activity Assay

[0267] Test the biological activity of antigen binding molecules and IFNG variant polypeptides as described herein.Biological activity may include the efficacy and specificity of bispecific antigen binding molecules.The activity of IFNG variant polypeptides can be measured by HEKBlue IFNG reporter cell assay as described in the examples.In addition, the activity of IFNG variant polypeptides and antigen binding molecules can be measured by the upregulation of MHC-I and PD-L1 on the murine MC38-huCEA tumor cell line as described in the examples and the upregulation of chemoattractants (CXCL9).

[0268] Pharmaceutical compositions, formulations and routes of administration

[0269] In a further aspect, a pharmaceutical composition comprising any of the antigen binding molecules provided herein is provided, for example, for use in any of the following methods of treatment. In one aspect, the pharmaceutical composition comprises any of the antigen binding molecules provided herein and at least one pharmaceutical excipient. On the other hand, the pharmaceutical composition comprises any of the antigen binding molecules provided herein and at least one additional therapeutic agent, for example, as described below.

[0270] Pharmaceutical compositions as described herein include one or more antigen binding molecules dissolved or dispersed in a pharmaceutical carrier in a therapeutically effective amount. The phrase "pharmaceutically or pharmacologically acceptable" refers to molecular entities and compositions that are generally nontoxic to recipients at the dosage and concentration used, i.e., if appropriately applied to animals (such as humans), no adverse, allergic or other adverse reactions will be produced. The preparation of pharmaceutical compositions containing at least one antigen binding molecule as disclosed herein and optionally additional active ingredients will be known to those skilled in the art in view of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th edition, Mack Printing Company, 1990, and the document is incorporated herein by reference. In particular, the composition is a lyophilized preparation or an aqueous solution. As used herein, "pharmaceutical excipient" includes any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, salts, stabilizers and combinations thereof, as known to those of ordinary skill in the art.

[0271] Parenteral compositions include those designed for injection (e.g., subcutaneous, intradermal, intralesional, intravenous, intraarterial, intramuscular, intrathecal or intraperitoneal injection). For injection, the antigen binding molecules disclosed herein can be prepared in an aqueous solution, preferably in a physiologically compatible buffer (such as Hanks' solution, Ringer's solution or saline buffer). The solution may contain a formulation (formulatory agent), such as a suspending agent, a stabilizer and / or a dispersant. Alternatively, the antigen binding molecules can be in powder form for use with a suitable vehicle (e.g., sterile pyrogen-free water) to construct before use. As required, a sterile injectable solution is prepared by incorporating the antigen binding molecules of the present invention in a desired amount together with various other ingredients listed below into a suitable solvent. For example, sterility can be easily achieved by filtering with a sterile filtration membrane. Typically, dispersions are prepared by incorporating various sterilized active ingredients into a sterile vehicle containing a basic dispersion medium and / or other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, suspensions or emulsions, the preferred preparation method is vacuum drying or freeze drying techniques, which produce a powder of the active ingredient from a previously sterile filtered liquid medium plus any additional desired ingredients. If necessary, the liquid medium should be properly buffered, and sufficient saline or glucose should first be used to make the liquid diluent isotonic before injection. The composition must be stable under manufacturing and storage conditions and is preserved as a contamination agent against microorganisms such as bacteria and fungi. It should be understood that endotoxin contamination should be kept to a minimum, for example, at a safety level below 0.5 ng / mg protein. Suitable pharmaceutical excipients include, but are not limited to, buffers such as phosphates, citrates and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins such as Such as serum albumin, gelatin or immunoglobulin; hydrophilic polymers such as polyvinyl pyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates, including glucose, mannose or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., zinc protein complexes); and / or nonionic surfactants such as polyethylene glycol (PEG). Aqueous injection suspensions may contain compounds that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, dextran, etc.Optionally, the suspension may also contain a suitable stabilizer or an agent that increases the solubility of the compound to allow the preparation of a high concentration solution. In addition, the suspension of the active compound may be prepared as an appropriate oily injection suspension. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil; or synthetic fatty acid esters, such as ethyl oleate or triglycerides; or liposomes.

[0272] The active ingredient can be embedded in microcapsules (e.g., hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively) prepared, for example, by coacervation techniques or by interfacial polymerization; embedded in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules); or embedded in coarse emulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (18th edition, Mack Printing Company, 1990). Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing polypeptides in the form of molded articles such as films or microcapsules. In particular aspects, prolonged absorption of injectable compositions can be achieved by using agents that delay absorption (e.g., aluminum monostearate, gelatin, or combinations thereof) in the composition.

[0273] In addition to the compositions described previously, antigen binding molecules can also be formulated into long-acting preparations. Such long-acting preparations can be applied by implantation (e.g., subcutaneous or intramuscular implantation) or by intramuscular injection. Therefore, for example, antigen binding molecules can be formulated with suitable polymerization or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or with ion exchange resins, or formulated as slightly soluble derivatives, such as, for example, as slightly soluble salts.

[0274] Pharmaceutical compositions comprising antigen binding molecules as described herein can be produced by conventional mixing, dissolving, emulsifying, encapsulating, embedding or lyophilizing processes. Pharmaceutical compositions can be prepared in a conventional manner using one or more physiologically acceptable carriers, diluents, excipients or adjuvants, which help process the protein into a preparation that can be used pharmaceutically. Appropriate formulations depend on the selected route of administration.

[0275] Antigen binding molecules as disclosed herein can be formulated into compositions in the form of free acid or alkali, neutral or salt. Pharmaceutically acceptable salts are salts that substantially retain the biological activity of free acid or free alkali. These pharmaceutically acceptable salts include acid addition salts, such as acid addition salts formed with the free amino groups of proteinaceous compositions, or acid addition salts formed with inorganic acids (such as hydrochloric acid or phosphoric acid) or organic acids (such as acetic acid, oxalic acid, tartaric acid or mandelic acid). Salts formed with free carboxyl groups can also be derived from inorganic bases, such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide or ferric hydroxide; or organic bases, such as isopropylamine, trimethylamine, histidine or procaine. Compared with the corresponding free alkali form, pharmaceutically acceptable salts tend to be more soluble in aqueous and other protic solvents. The compositions herein may also contain more than one active ingredient that is necessary for the specific indications treated, preferably active ingredients with complementary activities that do not adversely affect each other. Such active ingredients are appropriately present in an amount effective for the intended purpose. Preparations for in vivo administration are generally sterile. For example, sterility can be readily accomplished by filtration through sterile filtration membranes.

[0276] Methods of treatment and compositions

[0277] Any of the antigen binding molecules provided herein can be used in therapeutic methods. In order to use in therapeutic methods, antigen binding molecules as described herein can be prepared, dosed and applied in a manner consistent with good medical practice. Factors to be considered in this case include the specific illness treated, the specific mammal treated, the clinical condition of the individual patient, the cause of the illness, the delivery site of the medicament, the method of administration, the time arrangement of administration, and other factors known to practitioners.

[0278] In one aspect, there is provided an antigen binding molecule or IFNG variant polypeptide as disclosed herein for use as a medicament.

[0279] In a further aspect, an antigen binding molecule or IFNG variant polypeptide as described herein is provided for use in upregulating CXCL9. In addition, an antigen binding molecule as described herein is provided for (i) treating cancer, (ii) delaying the progression of cancer, and (iii) prolonging the survival of patients suffering from cancer, particularly in the presence of cells expressing FAP. In a specific aspect, an antigen binding molecule or IFNG variant polypeptide as disclosed herein is provided for use in treating a disease, particularly for use in treating cancer.

[0280] In some aspects, antigen binding molecules or IFNG variant polypeptides as described herein are provided for use in a method of treating a disease in an individual in need thereof. In some aspects, antigen binding molecules or IFNG variant polypeptides are provided for use in a method for treating an individual with a disease, the method comprising administering a therapeutically effective amount of bispecific antigen binding molecules to an individual. In some aspects, the disease to be treated is cancer. The subject, patient or "individual" in need of treatment is typically a mammal, more particularly a person.

[0281] In a further aspect, the present invention provides the use of antigen binding molecules or IFNG variant polypeptides as described herein in the manufacture or preparation of a drug for treating a disease in an individual in need. In one aspect, the drug is used in a method for treating a disease, the method comprising administering a therapeutically effective amount of the drug to an individual with the disease. In some aspects, the disease to be treated is a proliferative disorder, particularly cancer. Examples of cancer include, but are not limited to, bladder cancer, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophageal cancer, colon cancer, colorectal cancer, rectal cancer, gastric cancer, prostate cancer, blood cancer, skin cancer, squamous cell carcinoma, bone cancer and renal cancer. Other examples of cancer include malignant tumors, lymphomas (e.g., Hodgkin's lymphoma and non-Hodgkin's lymphoma), blastomas, sarcomas and leukemias. Other cell proliferation disorders that can be treated with the bispecific antigen binding molecules or antibodies of the present invention include, but are not limited to, tumors located in the following parts: abdomen, bones, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal glands, parathyroid glands, pituitary glands, testicles, ovaries, thymus glands, thyroid glands), eyes, head and neck, nervous system (central nervous system and peripheral nervous system), lymphatic system, pelvis, skin, soft tissue, spleen, chest and urinary system. Precancerous conditions or lesions and cancer metastasis are also included. In certain embodiments, cancer is selected from the group consisting of the following items: renal cell carcinoma, skin cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, head and neck cancer. It is easy for those skilled in the art to recognize that in many cases, antigen binding molecules or IFNG variant polypeptides as described herein may not provide a cure, but may provide benefits. In some aspects, physiological changes with certain benefits are also considered to have therapeutic benefits. Therefore, in some aspects, the amount of antigen binding molecules or IFNG variant polypeptides providing physiological changes is considered to be an "effective amount" or a "therapeutically effective amount".

[0282] For the prevention or treatment of disease, the appropriate dosage of the antigen binding molecules described herein (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, route of administration, patient weight, specific molecule, severity and progression of the disease, whether the antigen binding molecules as described herein are administered for preventive or therapeutic purposes, previous or concurrent therapeutic interventions, the patient's clinical history and the response to the bispecific antigen binding molecules and the discretion of the attending physician. In any case, the practitioner responsible for administration will determine the concentration and appropriate dosage of the active ingredient in the composition for individual subjects. Various administration schedules are contemplated herein, including but not limited to single or multiple administrations, push administrations, and pulse infusions at various time points.

[0283] Antigen binding molecules or IFNG variant polypeptides as disclosed herein are suitable for being administered to patients at one time or in a series of treatments. Depending on the type and severity of the disease, about 1 μg / kg to 15 mg / kg (e.g., 0.1 mg / kg-10 mg / kg) of antigen binding molecules or IFNG variant polypeptides can be, for example, administered alone or by continuous infusion once or multiple times for the initial candidate dose administered to the patient. Depending on the above factors, a typical daily dose may range from about 1 μg / kg to 100 mg / kg or more. For repeated administration for several days or longer, depending on the condition, treatment will generally continue until the desired disease symptom suppression occurs. An exemplary dosage of an antigen binding molecule or IFNG variant polypeptide will range from about 0.005 mg / kg to about 10 mg / kg. In other examples, dosage can also include each administration of about 1 μg / kg body weight, about 5 μg / kg body weight, about 10 μg / kg body weight, about 50 μg / kg body weight, about 100 μg / kg body weight, about 200 μg / kg body weight, about 350 μg / kg body weight, about 500 μg / kg body weight, about 1 mg / kg body weight, about 5 mg / kg body weight, about 10 mg / kg body weight, about 50 mg / kg body weight, about 100 mg / kg body weight, about 200 mg / kg body weight, about 350 mg / kg body weight, about 500 mg / kg body weight to about 1000 mg / kg body weight or more, and any range derivable therein. In the example of a range derivable from the numbers listed herein, a range of about 0.1 mg / kg body weight to about 20 mg / kg body weight, about 5 μg / kg body weight to about 1 mg / kg body weight, etc. can be administered based on the above numbers. Therefore, one or more dosages of about 0.5mg / kg, 2.0mg / kg, 5.0mg / kg or 10mg / kg (or any combination thereof) can be administered to the patient. Such dosages can be administered intermittently, for example, weekly or every three weeks (for example, so that the patient receives about two to about twenty or, for example, about six dosages of fusion protein). In a particular aspect, the bispecific antigen binding molecule will be administered once every three weeks. An initial higher loading dose can be administered, followed by one or more lower doses. However, other dosing regimens may be useful. The progress of the therapy can be easily monitored by conventional techniques and determinations.

[0284] The antigen binding molecules or IFNG variant polypeptides described herein will generally be used in an amount effective to achieve the intended purpose. For the treatment or prevention of disease conditions, the antigen binding molecules or IFNG variant polypeptides or their pharmaceutical compositions are administered or applied in a therapeutically effective amount. The determination of a therapeutically effective amount is entirely within the capabilities of those skilled in the art, particularly in light of the detailed disclosure provided herein. For systemic administration, the therapeutically effective dose can initially be estimated based on in vitro assays such as cell culture assays. The dose can then be formulated in an animal model to achieve an IC as determined in cell culture. 50 Circulating concentration range. Such information can be used to more accurately determine useful doses for humans. The initial dose can also be estimated based on in vivo data (e.g., animal models) using techniques well known in the art. One of ordinary skill in the art can easily optimize administration to humans based on animal data.

[0285] Dosage and interval can be adjusted individually to provide plasma levels of antigen binding molecules or IFNG variant polypeptides disclosed herein sufficient to maintain therapeutic effect. The range of common patient doses administered by injection is about 0.1 to 50 mg / kg / day, typically about 0.1 to 1 mg / kg / day. Plasma levels effective for treatment can be achieved by administering multiple doses per day. The levels in plasma can be measured, for example, by HPLC. In the case of local administration or selective uptake, the effective local concentration of antigen binding molecules or IFNG variant polypeptides may be independent of plasma concentration. Those skilled in the art will be able to optimize the effective local dose for treatment without too much experimentation.

[0286] A therapeutically effective dose of an antigen binding molecule or IFNG variant polypeptide described herein will generally provide therapeutic benefit without causing substantial toxicity. The toxicity and therapeutic efficacy of the fusion protein can be determined by standard pharmaceutical procedures in cell culture or experimental animals. Cell culture assays and animal studies can be used to determine LD 50 (the dose that causes 50% of the population to die) and ED 50 (the dose that is therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD 50 / ED 50. Antigen binding molecules that exhibit a large therapeutic index are preferred. In one aspect, antigen binding molecules or IFNG variant polypeptides as disclosed herein exhibit a high therapeutic index. Data obtained from cell culture assays and animal studies can be used to formulate a series of doses suitable for humans. The dose is preferably within a circulating concentration range including an ED50 with little or no toxicity. The dose may vary within this range depending on a variety of factors, such as the dosage form used, the route of administration utilized, the subject's condition, etc. The exact formulation, route of administration, and dosage can be selected by an individual physician according to the patient's condition (see, e.g., Fingl et al., 1975, in: The Pharmacological Basis of Therapeutics, Chapter 1, page 1, the entire contents of which are incorporated herein by reference).

[0287] The attending physician of the patient treated with antigen binding molecules should know how and when to terminate, interrupt or adjust administration due to toxicity, organ dysfunction, etc. On the contrary, if the clinical response is insufficient (excluding toxicity), the attending physician will also know that treatment will be adjusted to a higher level. The size of the dosage used in the management of the target disease will change with the severity of the disease to be treated, route of administration, etc. For example, the severity of the disease can be assessed in part by standard prognostic assessment methods. In addition, dosage and possible dosage frequency will also change according to the age, body weight and response of individual patients.

[0288] Other medicines and treatments

[0289] Antigen binding molecules or IFNG variant polypeptides as disclosed herein can be administered in combination with one or more other agents in treatment. For example, antigen binding molecules or IFNG variant polypeptides can be co-administered with at least one additional therapeutic agent. The term "therapeutic agent" includes any agent that can be administered for treating the symptoms or diseases of individuals requiring such treatment. Such additional therapeutic agents may include any active ingredients suitable for the specific indications treated, preferably active ingredients with complementary activities that do not adversely affect each other. In certain embodiments, the additional therapeutic agent is another anticancer agent, such as a microtubule disruptor, an antimetabolite, a topoisomerase inhibitor, a DNA intercalator, an alkylating agent, a hormone therapy, a kinase inhibitor, a receptor antagonist, a tumor cell apoptosis activator, or an anti-angiogenic agent. In some aspects, the additional therapeutic agent is an immunomodulator, a cell growth inhibitor, a cell adhesion inhibitor, a cytotoxic agent or a cell inhibitor, an apoptosis activator, or an agent that increases the sensitivity of cells to apoptosis inducers.

[0290] Therefore, provided are antigen binding molecules or IFNG variant polypeptides as described herein or pharmaceutical compositions comprising the same for use in treating cancer, wherein the antigen binding molecules or IFNG variant polypeptides are administered in combination with chemotherapeutic agents, radiation and / or other agents for use in cancer immunotherapy.

[0291] Such other agents are appropriately present in combination in an amount effective for the intended purpose. The effective amount of such other agents depends on the amount of the bispecific antibody used, the type of illness or treatment, and other factors discussed above. The bispecific antigen binding molecules or antibodies of the present invention are generally used in the same dosage and route of administration as described herein, or about 1% to 99% of the dosage described herein, or in any dosage and determined to be a suitable route by experience / clinically. Such combination therapies described above encompass combined administration (wherein two or more therapeutic agents are included in the same composition or a separate composition), as well as separate administration, in which case the administration of the antigen binding molecules or IFNG variant polypeptides can occur before, simultaneously with, and / or after the administration of the additional therapeutic agent and / or adjuvant.

[0292] In a further aspect, there is provided an antigen binding molecule or IFNG variant polypeptide as previously described herein for use in the treatment of cancer, wherein the antigen binding molecule or IFNG variant polypeptide is administered in combination with another immunomodulator.

[0293] The term "immunomodulator" refers to any substance that affects the immune system, including monoclonal antibodies. The molecules described herein can be considered as immunomodulators. Immunomodulators can be used as anti-tumor agents for treating cancer. In one aspect, immunomodulators include but are not limited to anti-CTLA4 antibodies (e.g., ipilimumab), anti-PD1 antibodies (e.g., nivolumab or pembrolizumab), PD-L1 antibodies (e.g., atezolizumab, avelumab or durvalumab), LAG3 antibodies (relalizumab), PD1-LAG3 bispecific antibodies or TIGIT antibodies (tireliumab). In a further aspect, an antigen binding molecule or IFNG variant polypeptide as described herein is provided for use in treating cancer, wherein the antigen binding molecule or IFNG variant polypeptide is administered in combination with an agent that blocks the interaction of PD-L1 / PD-1. In one aspect, the agent that blocks the interaction of PD-L1 / PD-1 is an anti-PD-L1 antibody or an anti-PD1 antibody. More particularly, the agent that blocks the PD-L1 / PD-1 interaction is an antibody selected from the group consisting of atezolizumab, durvalumab, pembrolizumab and nivolumab. In a specific aspect, the agent that blocks the PD-L1 / PD-1 interaction is atezolizumab (MPDL3280A, RG7446). On the other hand, the agent that blocks the PD-L1 / PD-1 interaction is an anti-PD1 antibody, particularly an anti-PD1 antibody selected from pembrolizumab or nivolumab. On the other hand, the agent that blocks the PD-L1 / PD-1 interaction is an anti-PD1 / anti-LAG3 bispecific antibody. Such other agents are appropriately present in an effective amount combination for the intended purpose. The effective amount of such other agents depends on the amount of the antigen binding molecule used, the type of disease or treatment, and other factors discussed above. The antigen binding molecules or IFNG variant polypeptides as described herein before are generally used in the same dosages and administration routes as described herein, or about 1% to 99% of the dosages described herein, or in any dosage and by any route determined empirically / clinically to be appropriate.

[0294] Such combination therapies described above encompass combined administration, in which two or more therapeutic agents are contained in the same composition or in separate compositions, as well as separate administration, in which case administration of the bispecific antigen binding molecule may be carried out before, simultaneously with and / or after administration of the additional therapeutic agent and / or adjuvant.

[0295] Products

[0296] In another aspect of the present invention, a kind of article is provided, it contains the material that can be used for treating, preventing and / or diagnosing the above-mentioned illness.The article comprises a container and a label or package insert (package insert) on or associated with the container.Suitable containers include, for example, bottles, vials, syringes, intravenous (IV) solution bags, etc.The container can be formed by various materials such as glass or plastic.The container holds a composition, which is combined with another composition that is effective for treating, preventing and / or diagnosing the illness, and the container can have a sterile entrance (for example, the container can be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic needle).At least one active agent in the composition is an antigen binding molecule as described herein.

[0297] The label or package insert indicates that the composition is used to treat the selected condition. In addition, the article may include (a) a first container containing a composition, wherein the composition comprises an antigen binding molecule as described herein; and (b) a second container containing a composition, wherein the composition comprises a further cytotoxic agent or other therapeutic agent. The article in this embodiment of the invention may further include a package insert indicating that the compositions can be used to treat a specific condition.

[0298] Alternatively or additionally, the article may further comprise a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate buffered saline, Ringer's solution and dextrose solution. The article may further include other substances desired from a commercial and user perspective, including other buffers, diluents, filters, needles and syringes.

[0299] Table B (sequence):

[0300]

[0301]

[0302]

[0303]

[0304]

[0305]

[0306]

[0307]

[0308]

[0309]

[0310]

[0311]

[0312]

[0313]

[0314]

[0315]

[0316]

[0317]

[0318]

[0319]

[0320]

[0321]

[0322]

[0323]

[0324]

[0325]

[0326]

[0327]

[0328]

[0329]

[0330]

[0331]

[0332]

[0333]

[0334]

[0335]

[0336]

[0337]

[0338]

[0339]

[0340]

[0341]

[0342]

[0343]

[0344]

[0345]

[0346]

[0347]

[0348]

[0349]

[0350]

[0351]

[0352]

[0353]

[0354]

[0355]

[0356]

[0357]

[0358]

[0359]

[0360]

[0361]

[0362]

[0363]

[0364]

[0365]

[0366] The following paragraphs (paragraphs) are various aspects of the present invention:

[0367] 1. An antigen-binding molecule comprising

[0368] (i) an antibody that specifically binds to a tumor-associated antigen, and

[0369] (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized by a C-terminal amino acid sequence KRKRP (SEQ ID NO: 1).

[0370] 2. The antigen binding molecule according to paragraph 1, wherein the IFNG variant polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3.

[0371] 3. The antigen-binding molecule according to paragraph 1 or 2, wherein the antibody that specifically binds to a tumor-associated antigen is an antibody that specifically binds to fibroblast activation protein (FAP).

[0372] 4. The antigen binding molecule according to any one of paragraphs 1 to 3, wherein the antibody that specifically binds to FAP comprises

[0373] (a) Heavy chain variable region (V H FAP), the heavy chain variable region comprises: a heavy chain complementarity determining region (CDR-H1), which comprises the amino acid sequence of SEQ ID NO: 4; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 5; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 6; and a light chain variable region (V L FAP), the light chain variable region comprises: a light chain complementary determining region (iv) CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 7; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 8; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 9; or

[0374] (b) Heavy chain variable region (V H FAP), the heavy chain variable region comprises: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 12; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 13; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 14; and a light chain variable region (V L FAP), the light chain variable region comprises: CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 15; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 16; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 17.

[0375] 5. The antigen binding molecule according to any one of paragraphs 1 to 4, wherein the antibody that specifically binds to FAP comprises: a heavy chain variable region (V H FAP), which comprises the amino acid sequence of SEQ ID NO: 10; and a light chain variable region (V L FAP), which comprises the amino acid sequence of SEQ ID NO: 11; or the antibody comprises: a heavy chain variable region (V H FAP), which comprises the amino acid sequence of SEQ ID NO: 18; and a light chain variable region (V L FAP), which comprises the amino acid sequence of SEQ ID NO:19.

[0376] 6. An antigen binding molecule according to any one of paragraphs 1 to 5, wherein the antigen binding molecule comprises an IgG1 Fc domain or an IgG4 Fc domain, and wherein the Fc domain comprises one or more amino acid substitutions that reduce the binding affinity of the antibody to an Fc receptor and / or effector function.

[0377] 7. The antigen binding molecule according to any one of paragraphs 1 to 6, wherein the Fc domain is of human IgG1 subclass having amino acid mutations L234A, L235A and P329G (EU numbering according to Kabat EU index).

[0378] 8. An antigen binding molecule according to any one of paragraphs 1 to 5, wherein the antigen binding molecule is protease activatable and comprises a protease recognition site and a masking moiety.

[0379] 9. The antigen binding molecule according to paragraph 8, wherein the protease recognition site is a substrate for matriptase.

[0380] 10. An antigen binding molecule according to paragraph 8 or 9, wherein the protease recognition site comprises or consists of PQARK (SEQ ID NO: 20) or HQARK (SEQ ID NO: 21), in particular PQARK (SEQ ID NO: 20).

[0381] 11. An antigen binding molecule according to any one of paragraphs 8 to 10, wherein the protease recognition site is part of a cleavable peptide linker connecting the masking moiety to the IFNG variant polypeptide.

[0382] 12. The antigen binding molecule according to any one of paragraphs 8 to 11, wherein the masking moiety is fused at its N-terminus to the C-terminus of the IFNG variant polypeptide via the cleavable peptide linker.

[0383] 13. An antigen binding molecule according to any one of paragraphs 8 to 11, wherein the masking moiety is fused at its N-terminus to the C-terminus of the Fc domain via a stable linker and is fused at its C-terminus to the N-terminus of the IFNG variant polypeptide via the cleavable peptide linker.

[0384] 14. The antigen binding molecule according to any one of paragraphs 8 to 13, wherein the masking moiety is an antibody or antibody fragment that specifically binds to IFNG.

[0385] 15. The antigen binding molecule according to any one of paragraphs 8 to 14, wherein the masking moiety is a scFv that specifically binds to IFNG.

[0386] 16. An antigen binding molecule according to any one of paragraphs 8 to 15, wherein the scFv that specifically binds to IFNG comprises

[0387] (a) Heavy chain variable region (V H IFNG), the heavy chain variable region comprises: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 22; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 23; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 24; and a light chain variable region (V L IFNG), the light chain variable region comprises: a light chain complementary determining region (iv) CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 25; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 26; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 27; or

[0388] (b) Heavy chain variable region (V HIFNG), the heavy chain variable region comprising: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 30; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 31; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 32; and a light chain variable region (V L IFNG), the light chain variable region comprising: CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 33; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 34; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 35.

[0389] 17. The bispecific antigen binding molecule according to any one of paragraphs 1 to 16, wherein the scFv that specifically binds to IFNG comprises

[0390] (a) Heavy chain variable region (V H IFNG), which comprises the amino acid sequence of SEQ ID NO: 28; and a light chain variable region (V L IFNG), which comprises the amino acid sequence of SEQ ID NO: 29; or

[0391] (b) Heavy chain variable region (V H IFNG), which comprises the amino acid sequence of SEQ ID NO: 36; and a light chain variable region (V L IFNG), which comprises the amino acid sequence of SEQ ID NO:37.

[0392] 18. An antigen binding molecule containing an IFNG variant polypeptide, wherein the antigen binding molecule comprises

[0393] (i) two heavy chains comprising the amino acid sequence of SEQ ID NO: 40, and two light chains comprising the amino acid sequence of SEQ ID NO: 41; or

[0394] (ii) two heavy chains comprising the amino acid sequence of SEQ ID NO:42, and two light chains comprising the amino acid sequence of SEQ ID NO:41; or

[0395] (iii) two heavy chains comprising the amino acid sequence of SEQ ID NO: 43, and two light chains comprising the amino acid sequence of SEQ ID NO: 44; or

[0396] (iv) two heavy chains comprising the amino acid sequence of SEQ ID NO:45, and two light chains comprising the amino acid sequence of SEQ ID NO:44.

[0397] 19. An interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized by a C-terminal amino acid sequence KRKRP (SEQ ID NO: 1).

[0398] 20. The IFNG variant polypeptide according to paragraph 19, wherein the IFNG variant polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3.

[0399] 21. One or more isolated polynucleotides encoding an antigen binding molecule according to any one of paragraphs 1 to 18 or an IFNG variant polypeptide according to claim 19 or 20.

[0400] 22. An expression vector comprising one or more isolated polynucleotides according to paragraph 21.

[0401] 23. A prokaryotic or eukaryotic host cell comprising one or more isolated polynucleotides according to paragraph 21 or an expression vector according to paragraph 22.

[0402] 24. A method for producing an antigen binding molecule or an IFNG variant polypeptide, comprising the steps of: a) culturing the prokaryotic or eukaryotic host cell according to paragraph 23 under conditions suitable for expressing the antigen binding molecule or the IFNG variant polypeptide, and b) optionally recovering the antigen binding molecule or the IFNG variant polypeptide.

[0403] 25. A pharmaceutical composition comprising the antigen binding molecule according to any one of claims 1 to 18 or the IFNG variant polypeptide according to paragraph 19 or 20 and a pharmaceutically acceptable excipient.

[0404] 26. An antigen binding molecule according to any one of paragraphs 1 to 17 or an IFNG variant polypeptide according to paragraph 19 or 20 for use as a medicament.

[0405] 27. An antigen binding molecule according to any one of paragraphs 1 to 17 or an IFNG variant polypeptide according to paragraph 19 or 20 for use in treating cancer.

[0406] 28. An antigen binding molecule according to any one of paragraphs 1 to 17 or an IFNG variant polypeptide according to paragraph 19 or 20, for use in the treatment of cancer, wherein the antigen binding molecule or the IFNG variant polypeptide is used for administration in combination with a chemotherapeutic agent, radiation and / or other agents for use in cancer immunotherapy.

[0407] 29. Use of an antigen binding molecule according to any one of paragraphs 1 to 17 or an IFNG variant polypeptide according to paragraph 19 or 20 in the manufacture of a medicament for treating cancer.

[0408] 30. A method of treating a disease in an individual, comprising administering to the individual a therapeutically effective amount of an antigen binding molecule according to any one of paragraphs 1 to 17 or an IFNG variant polypeptide according to paragraph 19 or 20 in a pharmaceutically acceptable form.

[0409] 31. The method of paragraph 30, wherein the disease is cancer.

[0411] Examples

[0412] The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided herein.

[0413] Recombinant DNA technology and sequencing

[0414] Standard methods were used to manipulate DNA, as described in Sambrook et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biology reagents were used according to the manufacturer's instructions. General information on the nucleotide sequences of human immunoglobulin light and heavy chains is given in the following reference: Kabat, EA et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication No. 91-3242. The DNA sequence was determined by double-stranded sequencing.

[0415] Gene synthesis

[0416] The desired gene segment is generated by PCR using an appropriate template, or is synthesized by GenScript (China) from synthetic oligonucleotides and PCR products by automated gene synthesis. The gene segment flanked by a single restriction endonuclease cleavage site is cloned into a standard cloning / sequencing vector. Plasmid DNA is purified from the transformed bacteria, and the concentration is determined by ultraviolet spectroscopy. The DNA sequence of the subcloned gene fragment is confirmed by DNA sequencing. The gene segment with a suitable restriction site is designed to allow subcloning into a corresponding expression vector. All constructs are designed with a 5' end DNA sequence, which encodes a leader peptide that targets the protein secreted by eukaryotic cells.

[0417] Cell culture technology

[0418] Standard cell culture techniques as described in Current Protocols in Cell Biology (2000), Bonifacino, JS, Dasso, M., Harford, JB, Lippincott-Schwartz, J. and Yamada, KM (Eds.), John Wiley & Sons, Inc. were used.

[0419] Protein purification

[0420] Proteins were purified from filtered cell culture supernatants according to standard protocols. Briefly, Fc-containing proteins were purified from filtered cell culture supernatants using protein A affinity chromatography (equilibration buffer: 20 mM sodium citrate, 20 mM sodium phosphate, pH 7.5; elution buffer: 20 mM sodium citrate, pH 3.0). Elution was achieved at pH 3.0, followed by immediate pH neutralization of the sample. The elution was performed by centrifugation (Millipore ULTRA-15 (Art.Nr.: UFC903096)) protein concentration, and then the aggregated protein is separated from the monomeric protein by size exclusion chromatography (Superdex 200, GE Healthcare) in 20mM histidine, 140mM sodium chloride (pH 6.0). The monomeric compound fractions are combined, concentrated (if necessary) using, for example, a MILLIPOREAmicon Ultra (30MWCO) centrifugal concentrator, frozen and stored at -80°C. A portion of the sample is provided for subsequent protein analysis and analytical characterization by CE-SDS, size exclusion chromatography (SE-HPLC) and mass spectrometry (LC-MS).

[0421] Alternatively, gene synthesis, cloning, transfection and harvesting were outsourced to evitria AG (Schlieren, Switzerland). The corresponding cDNA was cloned into evitria's vector system using conventional (non-PCR-based) cloning techniques. The evitria vector plasmids were gene synthesized. Plasmid DNA was prepared under low-endotoxin conditions based on anion exchange chromatography. DNA concentration was determined by measuring the absorbance at a wavelength of 260 nm. The correctness of the sequence was verified by Sanger sequencing (two sequencing reactions were performed for each plasmid). Suspension-adjusted CHO K1 cells (originally received from ATCC and adapted to serum-free growth in evitria suspension culture) were used for production. Seeds were grown in eviGrow medium, a chemically defined, animal component-free, serum-free medium. Cells were transfected with eviFect, a proprietary transfection reagent customized by evitria, and after transfection cells were grown in eviMake2, a serum-free medium without animal components. The supernatant was collected by centrifugation and subsequent filtration (0.2 μm filter).

[0422] Alternatively, the compound of interest is prepared by WuXi Biologics using its proprietary vector system using conventional (non-PCR-based) cloning techniques and using suspension-adapted HEK293 cells. The expression of all genes is controlled by the human CMV promoter. For production, WuXi Biologics uses commercially available chemically defined culture media and cultures cells after transfection at 36.5°C and 6% carbon dioxide. The supernatant is harvested by centrifugation and subsequent filtration (0.2 μm filter), and the protein is purified from the harvested supernatant by standard methods.

[0423] The Fc-containing constructs in the supernatant were quantified by Protein A-HPLC on an Agilent HPLC system with a UV detector. The supernatant was injected on a POROS20A (Applied Biosystems). The elution peak area at 280 nm was integrated and converted to concentration by using a calibration curve using standards analyzed in the same run.

[0424] Proteins were purified from filtered cell culture supernatants according to standard protocols. Briefly, Fc-containing proteins were purified from cell culture supernatants by protein A-affinity chromatography. The pH of the sample was neutralized immediately after elution. The elution was performed by centrifugation (Millipore ULTRA-15 (Art.Nr.: UFC903096) was used to concentrate the protein and then analyzed by size exclusion chromatography ( Pure&HiLoad26 / 600Superdex 200; both from Cytiva) was used to separate aggregated proteins from monomeric proteins in 20 mM histidine, 140 mM sodium chloride (pH 6.0).

[0425] According to Pace et al., Protein Sci. 1995, 4 (11), 2411-2423, the concentration of purified protein was determined by measuring the absorbance at 280 nm using the mass extinction coefficient calculated based on the amino acid sequence (Little Lunatic, Unchained labs). The purity and molecular weight of the protein were analyzed by CE-SDS using LabChip GXII (PerkinElmer) in the presence and absence of a reducing agent. The aggregate content was determined by HPLC chromatography at 25 ° C using an analytical size exclusion column (TSKgel G3000SW XL).

[0426] Composition analysis of IgG-like proteins

[0427] According to Pace et al., Protein Science, 1995, 4 (11), 2411-1423, the concentration of purified protein is determined by measuring the absorbance at 280 nm using the mass extinction coefficient calculated based on the amino acid sequence. According to the manufacturer's protocol, in the presence or absence of rapidPNGase F, LabChip GXII or LabChip GX Touch (Perkin Elmer) (Perkin Elmer) are used to analyze the purity and molecular weight of protein by CE-SDS. The analytical size exclusion chromatography (TSKgel G3000 SW XL or UP-SW3000 column) balanced in running buffer (200mM KH2PO4, 250mM KCl pH6.2, 0.02% NaN3) is used at 25 ° C by SE-HPLC chromatography to determine the content of aggregates.

[0428] Mass determination by ESI-MS

[0429] To determine the intact / deglycosylated and deglycosylated / reduced masses of the purified compounds, samples were analyzed by mass spectrometry. For compounds with human Fc and conventional Fc glycosylation, 25 μg of protein was diluted to a volume of 40 μL with Milli-Q Type 1 ultrapure water. Then, 9 μL of 250 mM sodium phosphate (pH 7.5) and 1 μL of PNGase F PRIME were added. TM(N-ZymeScientifics, NZPP550, batch number NZ-2019-0123, 0.2g / L), and the mixture was incubated at 37°C overnight. For proteins with non-human Fc and / or compounds containing more than conventional N-glycosylation sites, 10 μg of protein was diluted to 8 μL using Milli-Q Type 1 ultrapure water and mixed with 2 μL of "non-reducing" buffer (Rapid PNGaseF non-reducing buffer, NEB#P0711S, batch number 10085473, 10 / 21) and incubated at 70°C for 5 minutes. Then, 1 μL Rapid PNGaseF was added and incubated at 50°C for 10 minutes. After deglycosylation, the sample was diluted to 20 μL using Milli-Q Type 1 ultrapure water. To reduce cysteine ​​bonds, 20 μL of human Fc protein was mixed with 20 μL of freshly prepared reducing agent (7 M guanidine, 0.4 M Tris pH 8.0, 0.5 M DTT). For samples digested by rapidPNGase F, 7 μL was mixed with 7 μL of reducing agent. For all types of samples, reduction and denaturation were performed at 70°C for 5 min. Reverse phase chromatography was performed on a divinylbenzene column (Agilent, PLRP-S The samples were desalted on a 2.1x 150mm, 8μm, 0.7mL / min, 75°C, 1μg on column) and mass spectra were recorded using a QTOF mass spectrometer (Agilent 6545XT AdvanceBio LC / Q-TOF). The mass spectrometer was calibrated before each sample sequence and a lock mass correction was applied to obtain high mass accuracy. For data analysis, a Roche MassAnalyzer was used to summarize the mass spectra of the chromatographic peaks and interpret the detected masses. The determined masses were then compared to the calculated theoretical masses.

[0430] Alternatively, LC-MS characterization was performed at NMI Technology Transfer (Reutlingen, Germany). In order to determine the intact mass, each sample 12.5 μg-25 μg was diluted with the "non-reducing" buffer contained in the rapidPNGase F enzyme kit (Rapid PNGaseF non-reducing, NEB#P0711S, batch number 10085472, 10 / 21) by 1:4 (v / v) dilution and denatured at 80 ° C for 2 minutes. Subsequently, 0.3 μL rapidPNGase F ("non-reducing") was added, and the compound was deglycosylated at 50 ° C for 10 minutes. Thereafter, the sample was diluted to a final volume of 31.25 μL-62.5 μL with double distilled water. To determine the quality of the reduced chain, 12.5 μg-25 μg of each sample was diluted 1 / 4 (v / v) with the "reduction" buffer contained in the rapidPNGase F enzyme kit (Rapid PNGaseF reduction, NEB # P0710S, batch number 10079163 07 / 21) and denatured at 80°C for 2 minutes. Subsequently, 0.3 μL rapidPNGase F ("reduction") was added and the compound was deglycosylated at 50°C for 10 minutes. Thereafter, the sample was diluted to a final volume of 31.25 μL-62.5 μL with double distilled water. The samples were desalted on a C4 column (AcquityBEH300 C4, 1 mm 50 mm, 1.7 μm Charge 133380461; 150 μL / min, 75 °C, 1.6 μg on the column) by reverse phase chromatography, and the mass spectra were recorded using a QTOF mass spectrometer (MAXIS, Bruker Daltonics). The mass spectrometer was calibrated before each sample sequence, and a lock mass correction was applied to obtain high mass accuracy. Data analysis was performed by summarizing the mass spectra of the chromatographic peaks and deconvoluting them using MaxEnt. Identity and integrity were checked by comparing the experimental mass with the theoretical mass.

[0431] Surface plasmon resonance

[0432] The binding behavior of IFNG variants to IFNGR1 and IFNGR1 / 2 was evaluated by surface plasmon resonance (SPR). On Biacore 8K device, HBS-EP was used as running buffer (0.01M HEPES pH 7.4, 0.15MNaCl, 3mM EDTA, 0.005% surfactant P20, Biacore, Freiburg / Germany) at 25 ° C to carry out SPR experiments. In order to determine the binding affinity of IFNG variants to IFNG receptors, biotinylated Fc (kih)-IFNG compounds (50nM) were captured in the flow cell of streptavidin (SA) sensor chip (contact time 80 seconds, flow rate 10uL / min). IFNG mutation series compounds were fixed with 25nM concentration, 80 seconds contact time and 10μL / min. Up to 450 resonance units (RU) were used for the fixed level. Subsequently, Fc(kih)-IFNGR1 monomer or Fc(kih)-IFNGR1 / 2 heterodimer was injected as a second analyte at decreasing concentrations (800 nM-3.13 nM) over 120 s at a flow rate of 30 μL / min, and dissociation was monitored for 500 s. Bulk refractive index differences were corrected by subtracting the response obtained in a reference flow cell, in which no protein was immobilized. Affinity constants were derived from rate constants by fitting to 1:1 Langmuir binding.

[0433] HEK Blue reporter assay

[0434] The HEK Blue IFNG reporter cell assay allows for specific measurement of IFNG activity. HEK blue detection medium is used to detect SEAP production over time. TM The detection medium is prepared by adding a bag of HEK-Blue TM Prepare the Detection by pouring the contents of the Detection into a 50 mL Falcon tube and dissolving the powder in 50 mL of endotoxin-free water. Homogenize the solution by vortexing or spinning. TM Detection Raise the temperature to 37°C within 20-60 minutes. Sterile filter the medium (put a 0.2 μm membrane into a sterile vial / bottle). HEK-Blue TMThe detection medium was kept at 37°C before use and stored at 2°C-8°C for up to 2 weeks. HEKblue cells were separated by vigorous pipetting to produce a homogenized cell suspension, and cell counts and viability were determined using a ViCell cell viability analyzer. The required amount of HEKblue cells was centrifuged and resuspended in HEKblue detection medium at 0.55 Mio / mL. According to the plate protocol, 180 μL of cells (corresponding to 100,000 cells) were distributed per well, and 20 μL of test compounds (diluted in PBS) were added to each well. The plate was incubated at 37°C in a CO2 incubator for 20 hours to 24 hours, and the SEAP levels over time were analyzed at 620nm-655nm using a spectrophotometer.

[0435] Activity assay

[0436] This assay is used in combination with or instead of the HEK blue reporter cell assay to assess the activity of IFNG compounds. In response to treatment with an anti-murine IFNG scFv masked FAP-IFNG compound containing a cleavable linker 2 (PQARK cleavage site) for two days, the induction of MHC-I and PD-L1 in the murine MC38-huCEA tumor cell line was assessed and compared with the activity of IFNG fused to unmasked IgG. Prior to treatment, the construct was incubated at 37 ° C for two hours with recombinant matriptase. When the PQARK linker was digested with Matriptase, the PQARK construct masked by the FAP-IFNG scFv induced MHC-I and PD-L1 in the tumor cell line. In contrast, the FAP-IFNG scFv masked construct that was not pre-incubated with recombinant matriptase did not induce MHC-I or PD-L1 upregulation.

[0437] MC38-huCEA cells are cultured in DMEM 10% FCS and harvested using cell dissociation buffer. Cells are washed in DMEM 10% FCS, resuspended in DMEM 10% FCS, and then Eve cell counter is used to assess cell viability and cell number. Cells are diluted to a concentration of 50,000 / mL in DMEM 10% FCS, and 100 μL of the cell suspension is inoculated into a 96F well plate treated with cell culture. Cells are incubated overnight at 37°C, 5% CO2 to ensure the adhesion of cells. The FAP-IFNG construct of the selected concentration is digested for two hours at 37°C with or without 163nM / 4.4ng recombinant matriptase (4735-SE, lot number RIK071951, 0.44mg / mL) in matriptase buffer (50mM Tris, 50mM NaCl, 0.01% Tween 20, pH 9.0). After incubation, the digested cytokine Fc fusion solution was diluted to a concentration of 30nM with DMEM 10% FCS, and 50μL of pre-seeded cells were added to each well in 100μL DMEM 10% FCS, so that the final maximum concentration was 10nM per well. The cytokine Fc fusion solution was serially diluted at a ratio of 1:10 until the final minimum concentration was 0.1pM per well. The cells were incubated in an incubator for 48 hours. After 48 hours, the cells were washed with PBS and then incubated with 50μL of trypsin EDTA for 10 minutes. The isolated cells were harvested in DMEM 10% FCS and transferred to a round-bottom 96-well plate. The cells were centrifuged (500g, 2min), the supernatant was discarded, and 150μL PBS was added to each well, followed by centrifugation (500g, 2min). The cells were resuspended in 50 μL staining mixture containing Zombie near-infrared fixable viability dye (Invitrogen, L10119). The cells were then washed with FACS buffer and 50 μL of antibody staining mixture containing anti-muH-2Kb / H-2D-PE (BioLegend, 114608) and anti-muCD274-APC (BioLegend, 124312) was added at 4°C for 20 min. Thereafter, the cells were washed with PBS and resuspended in 100 μL PFA and incubated at room temperature for 25 min. The cells were then washed with 100 μL FACS buffer, resuspended in 100 μL FCS buffer, and measured on a BD FACS Canto.

[0438] Example 1

[0439] 1.1 Engineering the C-terminus of IFNG to modulate homogeneity and activity

[0440] IFNG is a key immunomodulatory cytokine used to treat a variety of immune diseases. However, its clinical application as an anticancer drug is limited due to the distribution of IFNG receptor 1 (IFNGR1), which traps IFNG throughout the body and prevents its enrichment at tumor sites. Another challenge we observed is the inherent sensitivity of the IFNG C-terminus to proteases present in production cell lines, which results in a large number of partially cleaved byproducts with truncated C-terminal sequences, leading to heterogeneity of the final product ( Figure 1A To increase the homogeneity and stability of the compounds, we applied sequence engineering to the IFNG C-terminus and identified IFNG variants with differentiated byproduct profiles and selective functional behaviors ( Figure 1B ). We initially designed a series of IFNG C-terminal deletion variants to identify the shortest C-terminal sequence of IFNG that maintained functional activity in signaling assays (Table 1A). Several C-terminal variants of IFNG have been described, and the importance of the KRKR residues in the C-terminus of IFNG has been emphasized (Figure 1). Deletion of the KRKR sequence (SEQ ID NO: 78) renders IFNG inactive in downstream signaling ( et al., Journal of Biotechnology 1988, 7(3), 199-216). However, shortened IFNG variants were shown to have similar activity to wild-type IFNG (Slodowski et al., Eur. J. Biochem. 1991, 202. 1133-1140). Therefore, we combined systematic shortening of the KRKR patch with proline or serine-proline capping to maximize C-terminal stability and sequence homogeneity, similar to the approach described for the C-terminus of IgG (van den Bremer et al., mAbs 2015, 7: 4, 672-680). The desired candidate should show a minimal number of byproducts and comparable signaling activity to wild-type IFNG.

[0441] Table 1A: C-terminal heavy chain sequences of IFNG fused compounds in the deletion series. The IFNG variants were linked to the C-terminus of IgG using a 15 amino acid linker with the sequence GGGGSGGGGSGGGGS (SEQ ID NO: 66).

[0442]

[0443] The second series was based on P1AF3574 from the deletion series, and we introduced additional point mutations in the KRKR sequence with the goal of further increasing proteolytic stability (Tables 1B and Figure 1BIn the systematic sequence variation method, we replaced one or two positions in the KRKR sequence with serine, proline or glutamic acid. Serine was selected as a neutral amino acid, proline was introduced to sterically interfere with the proteolytic recognition sequence, and glutamic acid was introduced to partially reverse the charge of the KRKR sequence (SEQ ID NO: 78).

[0444] Table 1B: C-terminal heavy chain sequences of IFNG-fused compounds in the deletion series. Positions refer to the KRKR sequence (SEQ ID NO: 78). The IFNG variants were linked to the C-terminus of the IgG using a 15 amino acid linker with the sequence GGGGSGGGGSGGGGS (SEQ ID NO: 66).

[0445]

[0446]

[0447] 1.2 Production and purification of IgG-fused IFNG deletion and mutation variants

[0448] All IFNG deletion and mutation series variants were produced, purified, and the effects of the engineered changes on byproduct profiles and signaling activity were characterized (Example 2). IFNG sequence variants were fused to the heavy chain of an IgG antibody specific for fibroblast activation protein (FAP) (i.e., anti-FAP clone 4B9) (disclosed in WO 2012 / 020006 A2) and the C-terminus of an Fc domain containing a P329G LALA mutation via a glycine-serine linker (Schlothauer et al., Protein Eng Des Sel. 2016, 29(10), 457-466) ( Figure 1A). The compounds were expressed using evitria's transient CHO expression system. The compounds of the deletion series (Table 1A) reached a median titer of 118 mg / L, and the compounds of the mutation series (Table 1B) were expressed at 45.5 mg / L (median titer). Tables 2A and 2B list the individual titer values ​​obtained for each compound. Next, the compound was captured via MabSelectSure HP and eluted to pH 3.0 with a pH gradient. The fractions were neutralized and analyzed for composition by CE-SDS, and their HMW content was analyzed by SE-HPLC. The fractions with the highest monomer content were combined and further purified by SEC. The SEC fractions with the highest monomer content were combined as the final batch. It was determined by SE-HPLC that the median monomer content of the compounds of the deletion series was 88.9%, and the compounds of the mutation series were purified to a median 99.8% homogeneity. LC-MS characterization confirmed the sequence identity of the two series. Detailed LC-MS mass profiles of the compounds are provided in Table 3 of Example 2. The expression titer and monomer content of each compound are listed in Tables 2A and 2B.

[0449] Table 2A: Mass profile of purified compounds of the deletion series. Production titers were determined by Protein A SE-HPLC and monomer content was assessed by SE-HPLC. LC-MS confirmed the correct compound identity and detailed side product profiles are listed in Table 3.

[0450]

[0451] Table 2B: Mass profile of purified compounds of the mutant series. Production titers were determined by Protein A SE-HPLC and monomer content was assessed by SE-HPLC. LC-MS confirmed the correct compound identity and detailed side product profiles are listed in Table 3.

[0452]

[0453]

[0454] Example 2

[0455] 2.1 Identification of C-terminal variants of IFNG with improved mass profiles

[0456] To maximize the sequence integrity of the C-terminus of IFNG, we identified IFNG sequences with favorable heavy chain byproduct profiles. Therefore, we combined proline or serine-proline capping with systematic shortening of the KRKR sequence ( Figure 1B, Table 1A). All compounds were expressed, purified, and the final batches were analyzed by LC-MS to identify and quantify heavy chain byproducts (Table 3). Compounds containing wild-type human IFNG contained 7% intact heavy chain and varying numbers of 8 truncated heavy chain byproducts. Published IFNG variants (including in P1AF3570 and P1AF3571) also exhibited heavy chain sequence heterogeneity due to proteolysis that produced 3 and 4 byproducts, respectively. The number of byproducts correlated with the length of the IFNG C-terminal sequence: shortening of the C-terminus reduced the number of truncated heavy chains, and compounds without the KRKR sequence were 100% correct. C-terminal proline capping produced fewer heavy chain byproducts than the serine-proline capped equivalent (Table 3).

[0457] Table 3: Byproduct profiles of IFNG benchmark molecules (P1AF3570, P1AF3571) and deletion series molecules with different C-terminal sequences. The bold sequence of each compound corresponds to the C-terminal full-length sequence, and the observed truncated products are listed subsequently. The relative amount (%) of each byproduct is estimated using the mass peak intensity.

[0458]

[0459]

[0460] 2.2 Signaling activity of IFNG deletion variants

[0461] The ability of the benchmark compound and other compounds of the deletion series to induce IFNG signaling was further characterized using the HEKblue assay. Functional activity correlated with the length of the C-terminal sequence: compounds containing only the entire KRKR sequence retained activity levels comparable to wild-type IFNG (Figure 2 and Table 4), while systematic shortening of the KRKR sequence progressively reduced functional activity.

[0462] Table 4: Signaling activity relative to wild-type IgG-IFNG determined in the HEKblue assay (area under the curve)

[0463]

[0464]

[0465] Combined with the quality data (Table 3), it was observed that the proline capped IFNG variant terminating in KRKRP (P1AF3574) had the best profile, i.e., the highest activity with the least amount of by-products. This compound contained 95% correct heavy chain, 5% truncated by-products, and showed 84% activity compared to wild-type IFNG. Therefore, this sequence was selected as the basis for further stability engineering in the mutation series (Example 2.4).

[0466] 2.3 IFNG-KRKRP and wild-type IFNG show comparable binding behavior to the IFNG receptor

[0467] IFNG is a constitutive homodimer that initiates the formation of a signal complex with the IFNG receptor, thereby activating the JAK / STAT signal transduction pathway. The signal transduction complex is composed of a symmetrical arrangement of two IFNGR1 / 2 heterodimers, wherein the IFNG homodimer is located in the center. Each IFNG monomer interacts with an IFNGR1 / 2 heterodimer, thereby contacting two receptor subunits. It is suggested that the assembly of the signal transduction complex is triggered by the initial interaction of IFNG with IFNGR1, which produces the binding surface of IFNGR2 (Mendoza et al., Nature 2019, 567 (7746), 56-60). Although the assembly of the signal transduction complex is mainly driven by the structured domain of IFNG, the unstructured C-terminus of IFNG may also promote active signal transduction by interacting with sites closer to the cell membrane in IFNGR1 / 2. However, the exact binding mode is unknown and has not been resolved in the available crystal structure.

[0468] In order to further evaluate the similar properties of wild-type IFNG and our engineered compounds with C-terminal KRKRP (SEQ ID NO: 1), we determined the binding affinity of IFNG variants to IFNG receptors by SPR. Therefore, wild-type IFNG (P1AG2651) and IFNG KRKRP (P1AG1550) are produced and purified as C-terminal Fc (kih)-fusion proteins and fixed in flow cells. The knob and mortise (kih) mutation is a specific mutation in the Fc domain (mutation S354C and T366W of EU numbering in the "knob" chain and mutation Y349C, T366S, L368A and Y410V of EU numbering in the "mortise" chain), which allows the enhanced heterodimerization of two different heavy chains (Merchant et al., Nature Biotechnology 1998, 16 (7), 677-681). As a secondary analyte, IFNGR1 monomer (P1AF7104) or IFNGR1 / 2 heterodimer (P1AF8126) was passed through the flow cell at various concentrations, and the dissociation constant (KD) was calculated based on the observed association and dissociation behavior. Fc(kih)-IFNG KRKRP was expressed with an apparent KD of 154 nM. D Binds to IFNGR1, which binds to K D The wild-type Fc(kih)-IFNG with a K of 177 nM was in a similar range. A higher apparent binding affinity was observed for the IFNGR1 / 2 heterodimer: Fc(kih)-IFNG-KRKRP (P1AG1550) with a K of 54.4 nMD Binding, wild-type Fc(kih)-IFNG(P1AF2651) with a K of 73.8 nM D Combine.

[0469] 2.4 Mutations in the IFNG KRKR sequence differentially affect IFNG receptor binding and signaling

[0470] After identifying the minimum C-terminal sequence length, we introduced additional point mutations in the KRKR sequence to further improve stability to proteases. All compounds in the mutant series were expressed and purified as IgG fusion proteins (see Example 1). Analysis of the mass profiles by LC-MS confirmed the beneficial effect of the C-terminal proline cap, as no proteolytic byproducts were detected in compounds in this mutant series.

[0471] It was determined by SPR that mutations in the KRKR sequence have an effect on receptor binding. In order to measure binding affinity, compounds of the mutant series were fixed in a flow cell. As a second analyte, Fc(kih)-IFNGR1 monomer or Fc(kih)-IFNGR1 / R2 heterodimer passed through the flow cell, and the binding affinity (KD) was calculated based on the observed association and dissociation constants. Compared with compounds with C-terminal KRKRP, single-point mutations have reduced the apparent binding affinity to the receptor. Double-point mutations have an additional negative effect on receptor binding. The binding behavior of the mutant series of compounds to IFNGR1 and IFNGR1 / 2 is summarized in Table 5.

[0472] Table 5: Apparent binding affinity of the mutant series of compounds to Fc(kih)-IFNGR1 monomer and Fc(kih)-IFNGR1 / 2 heterodimer

[0473]

[0474]

[0475] The impaired function of the mutant series variants was even more evident in the reporter cell assay (Figure 3). Functional characterization showed that single serine or proline mutations were well tolerated regardless of their position in the KRKR sequence. In contrast, single glutamate mutations rendered the compound inactive, as did all double mutations, regardless of the amino acid exchanged.

[0476] 2.5 Mutations in the IFNG KRKR sequence prevent proteolysis by Matriptase

[0477] To assess the effect of mutations on the proteolytic stability of the KRKR motif, all compounds in the mutant series were treated with matriptase (custom purified according to a protocol published by Cepter Biopartners) at a molar ratio of 1:3500 enzyme to substrate at 37°C for 1 hour. Subsequently, the release of the main proteolytic byproduct (IgG-IFNG cut between IFNG-K / RKRP) was detected and quantified by LC-MS in a deglycosylated reducing state. Point mutations at positions 1 or 2 had a positive effect on proteolytic stability, with no proteolysis observed under the selected conditions, while for the reference molecule, 35% cleavage of the K / RKR motif was detected (Table 6). Mutations of serine, proline or glutamic acid at positions 3 or 4 interfered with proteolysis less efficiently, with 2%-11% of proteolytic products detected. Double mutations comprising positions 1 or 2 also effectively prevented proteolysis, while double mutations at positions 3 and 4 were permissive. However, given the lower functional activity of the mutant series of compounds in the absence of target binding, IFNG KRKRP remained the preferred sequence and was used to generate masked IFNG compounds (Example 3).

[0478] Table 6: Mutations at positions 1 and 2 in the KRKR sequence motif improve the proteolytic stability of the KRKR patch. Compounds were incubated with matriptase and the proteolytic profile was analyzed and quantified by LC-MS. Position reference KRKR sequence (SEQ ID NO: X)

[0479] Mutation type Extent of K / RKR proteolysis after 1 hour IFNG-KRKRP 35% (reference molecule) S / P / E in position 1 0% / 0% / 0% S / P / E in position 2 2% / 0% / 0% S / P / E in position 3 6% / 9% / 3% S / P / E in position 4 5% / 11% / 2% SS / PP / EE in positions 1 and 2 0% / 0% / 0% SS / PP / EE in positions 3 and 4 4% / 1% / 0% SS / PP / EE in positions 1 and 3 0% / 0% / 0% SS / PP / EE in positions 2 and 4 0% / 0% / 0%

[0480] Example 3

[0481] 3.1 Design of tumor-targeted masked IFNG compounds

[0482] To develop IFNG with greater therapeutic potential, we designed tumor-targeted IFNG compounds in which an IFNG-specific masking domain prevented IFNG from binding to IFNGR1. We hypothesized that effective masking would counteract the associated sink effect and allow the compound to be enriched at the tumor site, ultimately triggering the desired downstream effects. The masking domain was based on an IFNG-specific scFv domain and was introduced at the C-terminus (mask-released form) or N-terminus (cytokine-released form) of IFNG-KRKRP. Figure 1C ). The masked compound is designed to be activated in the tumor microenvironment by proteolysis of the cleavable linker that connects IFNG and its masking.

[0483] To generate a masked release form, IFNG-KRKRP was fused via a glycine-serine linker (Linker 1, GGGGSGGGGSGGGGSGGGGSGGGGSGGGG, SEQ ID NO: 69) to a targeting antibody (i.e., anti-FAP clone 4B9), which is an IgG antibody specific for fibroblast activation protein (FAP) (disclosed in WO 2012 / 020006 A2) and the C-terminus of an Fc domain containing a P329GLALA mutation (Schlothauer et al., Protein Eng Des Sel. 2016, 29(10), 457-466). Anti-human IFNG scFv masking (based on US 6,329,511B1) is fused to the C-terminus of IFNG-KRKRP via a second glycine-serine linker (linker 2, GGGGSGGGGSGGGGSGGGGSGGGGSGGGG, SEQ ID NO: 69). In order to produce a cytokine release form, the scFv masking is fused to the C-terminus of the targeting IgG antibody via a glycine-serine linker (linker 1), and IFNG-KRKRP is connected to the C-terminus via a second glycine-serine linker (linker 2). In order to enable proteolytic activation of masked compounds in the tumor microenvironment, a matriptase cleavage site (PQAR / K, SEQ ID NO: 20) is introduced in two forms of linker 2. The cleavable linker has the amino acid sequence GGGGSGGGGSGGGPQARKGGGGGGSGGGGG (linker 2', PQARK linker, SEQ ID NO: 70). Proteolytic cleavage of linker 2' in the mask-released form yields IgG-fused, unmasked IFNG, whereas proteolytic cleavage of linker 2' in the cytokine-released form yields free IFNG-KRKRP homodimers.

[0484] Table 7A: Identifiers and forms of tumor-targeting masked IFNG compounds

[0485]

[0486] 3.2 Production and purification of masked release and cytokine-released forms

[0487] The masked forms with cleavable linker sequences (P1AG7568, P1AG7571) and non-cleavable linker sequences (P1AG7567, P1AG7570) were expressed and purified using the transient expression system of WuXi Biologics. The unmasked positive control compound (P1AG1310) was expressed and purified internally at evitria AG. All compounds were captured via MabSelectSure HP and eluted to pH 3.0 with a pH gradient. The fractions were neutralized and analyzed for their composition by CE-SDS, and their HMW content was analyzed by SE-HPLC. The eluted fractions with the highest monomer content were combined and further purified by SEC. The SEC fractions with the highest monomer content were combined as the final batch (Table 7B). Depending on the form, different expression titers and quality profiles were achieved: the highest production titer (152 mg / L) of the unmasked compound was observed. The masked form was expressed at a lower level (6.9 mg / L-54.6 mg / L). LC-MS confirmed the correct chain composition and no proteolytic byproducts were detected.

[0488] Table 7B: Mass profile of purified masked compounds and control molecules. Production titers were determined by Protein A SE-HPLC, monomer content was assessed by SE-HPLC and CE-SDS. LC-MS confirmed the correct compound identity.

[0489]

[0490] Example 4

[0491] 4.1 Generation of a masked murine IFNG form as a murine alternative

[0492] To assess the therapeutic potential of the masked form in vivo, we turned to a murine alternative model (Example 5). The masking domain was based on a scFv domain specific for murine IFNG, and the mask was introduced at the C-terminus (masked release form) or N-terminus (cytokine release form) of murine IFNG-KRKRP (Figure 1, Figure 4A As for the human counterpart, the masked murine compound was designed to be activated in the tumor microenvironment by proteolysis of the cleavable linker that attached IFNG and its masking.

[0493] The design of the surrogate molecule is similar to the human masked compound: To produce the masked release form (P1AG3766), murine IFNG-KRKRP was fused to the C-terminus of the murine IgG1 heavy chain of a targeting IgG antibody specific for fibroblast activation protein (FAP) (i.e., anti-FAP clone 28H1) via a glycine-serine-linker (linker 1, GGGGSGGGGSGGGGSGGGGSGGGGSGGGG, SEQ ID NO: 69) (disclosed in WO 2012 / 020006 A2). In addition, a DAPG mutation was introduced in the constant region of the heavy chain to eliminate binding to mouse Fcγ receptors, according to the methods described in, for example, Baudino et al. J. Immunol. (2008), 181, 6664-6669 or WO 2016 / 030350A1. The anti-murine IFNG scFv mask is fused to the C-terminus of murine IFNG-KRKRP via a second glycine-serine linker (Linker 2, GGGGSGGGGSGGGGSGGGGSGGGGSGGGG, SEQ ID NO: 69). To produce a cytokine release form (P1AG3755), the scFv mask is fused to the C-terminus of the targeting IgG via a glycine-serine linker (Linker 1), and the murine IFNG-KRKRP is connected to the C-terminus via a second glycine-serine linker (Linker 2). In order to enable proteolytic activation in the tumor microenvironment, a matriptase cleavage site (PQAR / K) is introduced in two forms of Linker 2 (Linker 2'). The cleavable linker has the amino acid sequence GGGGSGGGGSGGGPQARKGGGGGGSGGGGG (Linker 2', PQARK Linker, SEQ ID NO: 70). Proteolysis of linker 2' in the mask-released form yielded IgG-fused, unmasked murine IFNG-KRKRP, whereas proteolysis of linker 2' in the cytokine-released form yielded free murine IFNG-KRKRP homodimers. As a positive control, murine IFNG-KRKRP was also expressed as a C-terminal IgG fusion without a masking domain (P1AF9672).

[0494] Table 8A: Identifiers and forms of tumor-targeted masked murine IFNG compounds

[0495]

[0496] 4.2 Production and purification of rodent substitutes

[0497] The mouse replacement compound was expressed using evitria's transient CHO expression system. A complete protease inhibitor cocktail (Roche) was added at a concentration of 0.5x immediately after harvest, and the compound was captured using MabSelectSure HP and eluted to pH 3.0 with a pH gradient. The fractions were neutralized and analyzed for composition by CE-SDS, and their HMW content was analyzed by SE-HPLC. The fractions with the highest monomer content were combined and further purified by SEC. After each SEC purification, the respective peak fractions were analyzed by SE-HPLC and CE-SDS. The SEC fractions with the highest monomer content were combined as the final batch. SE-HPLC showed that the monomer content of the two forms (P1AG3766 and P1AG3755) and the unmasked control (P1AF9672) was >95%, and CE-SDS and LC-MS confirmed the correct chain composition (Table 8B). For the cytokine releasing form (P1AG3755), LC-MS showed that in 10% of the compounds, one of the two cleavable linkers had been cleaved at the expected cleavage site (PQAR / K, SEQ ID NO: 20).

[0498] Table 8B: Quality profile of purified murine surrogate compounds. Production titer determined by Protein A SE-HPLC, monomer content assessed by SE-HPLC and CE-SDS. LC-MS confirmed correct compound identity.

[0499]

[0500] 4.3 Functional characterization of rodent alternatives

[0501] To assess the in vitro activity of FAP-anti-murine IFNG compounds masked by FAP-targeted scFvs containing cleavable linkers, MC38-huCEA cells were treated in vitro with the aforementioned surrogate molecules. Anti-murine IFNG scFv-masked FAP-muIFNG compounds were incubated at 37°C for 2 hours in the absence or presence of 163nM recombinant murine matriptase. After a 48-hour culture period, flow cytometry was used to quantify MHC-I and PD-L1 expression on MC38-huCEA cells. Treatment with unmasked FAP-muIFNG compounds was used as a positive control, demonstrating that MHC-I and PD-L1 expression on MC38-huCEA cells was induced upon treatment ( Figure 4A and 4B ).

[0502] Anti-murine IFNG scFv-masked FAP-muIFNG molecules without pretreatment with recombinant murine matriptase did not result in enhanced MHC-I or PD-L1 levels ( Figure 4Aand 4B Preincubation of anti-murine IFNG scFv-masked FAP-muIFNG with Matriptase partially restored activity, as evidenced by increased MHC-I and PD-L1 expression on MC38-huCEA cells ( Figure 4A and 4B ).

[0503] Example 5

[0504] 5.1 In vivo characterization of murine surrogate molecules

[0505] For in vivo experiments, a single intravenous dose of 1.25 mg / kg or 10 mg / kg of P1AG3755 was administered to C57Bl / 6 mice expressing human CEA bearing KPC-4662huCEA tumors (excluding tumor models with low CD8 T cell infiltration) that were injected subcutaneously as a cell suspension 21 days before the start of treatment ( Figure 5 ).

[0506] KPC 4662 cells were obtained from the University of Pennsylvania and engineered in-house to express human CEA. Cells were cultured in DMEM + 10% FBS + 500 μg / ml hygromycin, counted and 300,000 cells were subcutaneously injected into the flank of mice in a 1:1 mixture with RPMI and Matrigel in a total volume of 100 μL. Tumor growth was measured at least twice a week using a caliper and tumor volume was calculated as follows: Tumor volume = (W 2 / 2)x L (W: width, L: length).

[0507] After 21 days of initial tumor growth in mice, when the tumor size reached approximately 225 mm 3 At 14:1, mice were randomly divided into three groups and treated three times per week with different doses of P1AG3755 or histidine buffer (vehicle). All mice were injected intravenously with 200 μL of the appropriate solution. In order to obtain the appropriate amount of compound per 200 μL, the stock solution was diluted with histidine buffer (20 mM histidine, 140 mM NaCl, pH 6.0). At least five mice were killed on the 3rd and 7th days after the therapy injection (day 7 = termination). Tumors and blood from these mice were removed for downstream analysis.

[0508] 5.2 In vitro readings

[0509] Half of the tumor dedicated for flow cytometry analysis was weighed and digested with Liberase and DNase. Single cell suspensions were then stained with DAPI, Podoplanin PE-Cy7, E-cadherin BV421, CD45AF700, TCRb PE-Cy5, and CD8a BV711 and analyzed on a BD Fortessa flow cytometer. Plots and statistical tests were performed in GraphPad PRISM 8.

[0510] For histological analysis by immunofluorescence (3DIP), half of the tumor was fixed in a BD Cytofix solution diluted in PBS at 1:4 for about 20 hours. After washing and transferring to PBS, the tumor was embedded in 4% low gelling temperature agarose. Tumor sections (70 μm thick) were cut from these blocks using a Leica VT1200s Vibratome equipped with a common razor blade. The sections were then permeabilized (TBS+0.3% Triton-X) and blocked for two hours using BSA and mouse serum (each 1%), then stained overnight (about 15 hours) at room temperature using the following antibodies: CD8aBV421, E-cadherin CF488, MHCIPE. Image acquisition was completed on a Leica SP8 inverted confocal microscope.

[0511] For cytokine analysis, serum samples of 5 mice in each group were collected (once again on the 3rd and 7th day after therapy injection) and stored at -20°C until needed for determination. On the same date, a piece of tumor from 5 mice in each group was collected in liquid nitrogen and stored at -80°C until further use. 5 μL serum (1 / 10 dilution) and 40 μg of protein from tumor lysate were used for determination. Tumor lysate was obtained using Bio-plex cell lysis kit (171304012, BioRad) and Precellys evolution homogenizer lysis device (Bertin instruments). Tumor lysate was centrifuged, and the supernatant was retained and subsequently stored at -80°C. Protein levels were determined using Pierce BCA protein assay kit (Thermo Fisher Scientific) and ELISA reader (PerkinElmer, EnVision 2104 multi-label reader). Tumor lysate was diluted accordingly with sample diluent from the kit to obtain a final amount of 40ug protein per sample. The assay was performed using the ProcartaPlex Simplex kit (reference number EPX010-26061-901, Thermo Fisher) on a LuminexFlexmap 3D instrument following the manufacturer's protocol.

[0512] Statistical analysis

[0513] For flow cytometry and cytokine analysis, one-way Anova tests were run with multiple comparisons of treatment groups versus vehicle groups and Dunnet correction for multiple testing. Plots and statistical tests were done in GraphPad PRISM 8.

[0514] 5.3 Observation

[0515] Proximal biomarkers of IFNG signaling are upregulation of MHCI and PDL1 expression. Figure 5 ), we can easily observe MHCI and PDL1 upregulation by flow cytometry in the high-dose group of cancer cells and fibroblasts 3 days after therapy administration (Figure 6). Increased MHCI expression can also be observed 7 days after therapy administration, while PDL1 levels at 7 days after therapy administration were not statistically significantly different from the vehicle group.

[0516] Next, we observed by immunofluorescence microscopy that increased MHCI expression in tumor tissues was very heterogeneous and that the presence of CD8 T cells was associated with MHCI-positive areas in tumor tissues ( Figure 7 ).

[0517] Although there were no statistically significant differences in the presence of overall CD8 T cells between treatment and vehicle groups by flow cytometry, we again showed by imaging that there were increased amounts of CD8 T cells present in MHCI-expressing regions of tumors, particularly early after treatment ( Figure 8 Since in this tumor, CD8 T cells were also present at the tumor margin in both the baseline and vehicle groups, non-local quantification by flow cytometry could not reveal statistically significant differences between the treatment groups and vehicle.

[0518] Finally, we could observe that treatment with the murine surrogate resulted in an increase in the levels of CXCL9 (T cell attracting chemokine) in the serum of mice 7 days after therapy administration ( Fig. 9 ), showing that not only cancer cells are altered and the tumor immune environment is changed, but also the cytokine environment is affected by tumor-targeted IFNG.

[0519] Example 6

[0520] 6.1 Design of Spatial Masked IFNG

[0521] In view of the species specificity of IFNG, species-specific masking domains are also needed to prevent receptor binding outside the tumor microenvironment. Therefore, we explored species-independent masking and designed a series of spatially masked targeted IFNG compounds. Based on the available crystal structure of the IFNG signaling complex (Mendoza et al., Nature 2019, 567 (7746), 56-60), we assume that in the assembled complex, the C-terminus of IFNG is close to the membrane positioning, and therefore, the fusion of the large domain with the C-terminus may interfere with IFNGR1 binding. In order to produce targeted, masked molecules, we insert the IFNG domain between the upper hinge region and the lower hinge region of IgG1. At the N-terminus and C-terminus, IFNG is connected using a glycine-serine linker. In addition, we explored several hinge variants.

[0522] Table 9A: Identifiers and formats of tumor-targeted masked murine IFNG compounds

[0523]

[0524] The amino acid sequences of the different linkers are as follows: Linker 1 is GGGGSGGGGSGGGGSGGGGSGGGGSGGGGG (SEQ ID NO: 69), Linker 2 is GGGGSGGG (SEQ ID NO: 72), Linker 3 is LEVLFQGP (SEQ ID NO: 73), Linker 4 is GGGGSGGGGSGGGGSGGGGSGLEVLFQGPGGGGGSGGGGG (SEQ ID NO: 74) and Linker 5 is QARK (SEQ ID NO: 75). The amino acid sequence of Hinge 1 is TCPPCP (SEQ ID NO: 76) and Hinge 2 is PCP (SEQ ID NO: 77).

[0525] 6.2 Production and purification of sterically masked IFNG

[0526] The sterically masked compounds were expressed using evitria's transient CHO expression system, captured via MabSelectSure HP and eluted with a pH gradient to pH 3.0. The fractions were neutralized and analyzed for composition by CE-SDS, and for HMW content by SE-HPLC. The fractions with the highest monomer content were combined and further purified by SEC. In some cases, a second SEC step and a third SEC step were required to remove all HMW impurities. After each SEC purification, the respective peak fractions were analyzed by SE-HPLC and CE-SDS. The fractions with the highest monomer content were combined as the final batch. The median monomer content of all compounds was >98% (SE-HPLC, 100% by CE-SDS), and sequence identity was confirmed by LC-MS. The detailed quality attributes are summarized in Table 9B.

[0527] Table 9B: Mass profile of purified sterically masked compounds. Production titer determined by Protein A SE-HPLC, monomer content assessed by SE-HPLC and CE-SDS. LC-MS confirmed the correct compound identity.

[0528]

[0529] 6.3 Blocking efficiency of spatially masked IFNG

[0530] To assess the in vitro blocking efficiency of spatially masked IFNG, HEK Blue IFNG reporter cells were stimulated with unmasked IFNG (used as a positive control) (P1AG8697) and spatially masked IFNG molecules (P1AG8692) for 20-24 hours, respectively. SEAP reporter activity in response to IFNG was measured at 620nm-655nm using a spectrophotometer. The results obtained showed that spatially masked IFNG had reduced IFNG activity ( Fig. 10B ).

[0531] Although the present invention has been previously described in considerable detail by way of illustration and example for purposes of clarity of understanding, these descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated by reference in their entirety.

Claims

1. An antigen-binding molecule comprising (i) an antibody that specifically binds to a tumor-associated antigen, and (ii) a homodimer of an interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized in that it ends at the C-terminus with the amino acid sequence KRKRP (SEQ ID NO: 1).

2. The antigen binding molecule according to claim 1, wherein the IFNG variant polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO:

3. 3 . The antigen-binding molecule according to claim 1 , wherein the antibody that specifically binds to a tumor-associated antigen is an antibody that specifically binds to fibroblast activation protein (FAP).

4. The antigen-binding molecule according to any one of claims 1 to 3, wherein the antibody that specifically binds to FAP comprises (a) Heavy chain variable region (V H FAP), the heavy chain variable region comprises: a heavy chain complementarity determining region (CDR-H1), which comprises the amino acid sequence of SEQ ID NO: 4; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 5; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 6; and a light chain variable region (V L FAP), the light chain variable region comprises: a light chain complementary determining region (iv) CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 7; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 8; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 9; or (b) Heavy chain variable region (V H FAP), the heavy chain variable region comprises: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 12; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 13; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 14; and a light chain variable region (V L FAP), the light chain variable region comprises: CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 15; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 16; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO:

17.

5. The antigen binding molecule according to any one of claims 1 to 4, wherein the antibody that specifically binds to FAP comprises: a heavy chain variable region (V H FAP), which comprises SEQ ID NO:10 amino acid sequence; and light chain variable region (V L FAP), which comprises SEQ ID NO:11 amino acid sequence; or the antibody comprises: a heavy chain variable region (V H FAP), which comprises the amino acid sequence of SEQ ID NO: 18; and a light chain variable region (V L FAP), which comprises the amino acid sequence of SEQ ID NO:

19.

6. An antigen binding molecule according to any one of claims 1 to 5, wherein the antigen binding molecule comprises an IgG1 Fc domain or an IgG4 Fc domain, and wherein the Fc domain comprises one or more amino acid substitutions that reduce the binding affinity of the antibody to an Fc receptor and / or the effector function.

7. The antigen binding molecule according to any one of claims 1 to 6, wherein the Fc domain is of human IgG1 subclass, having amino acid mutations L234A, L235A and P329G (EU numbering according to Kabat EU index).

8. The antigen binding molecule according to any one of claims 1 to 7, wherein the first IFNG variant polypeptide is fused at its N-terminus to the C-terminus of the first heavy chain via a first linker, and the second IFNG variant polypeptide is fused at its N-terminus to the C-terminus of the second heavy chain via a second linker. 9 . The antigen binding molecule according to claim 8 , wherein the first linker and the second linker are peptide linkers.

10. The antigen binding molecule according to any one of claims 1 to 9, wherein the antigen binding molecule is protease activatable and comprises a protease recognition site and a masking moiety. The antigen binding molecule according to claim 10 , wherein the protease recognition site is a substrate for matriptase.

12. The antigen binding molecule according to claim 10 or 11, wherein the protease recognition site comprises PQARK (SEQ ID NO: 20) or HQARK (SEQ ID NO: 21), in particular PQARK (SEQ ID NO: 20), or consists thereof.

13. The antigen binding molecule according to any one of claims 10 to 12, wherein the protease recognition site is part of a cleavable peptide linker connecting the masking moiety to the IFNG variant polypeptide.

14. The antigen binding molecule according to any one of claims 10 to 13, wherein the masking moiety is fused at its N-terminus to the C-terminus of the IFNG variant polypeptide via the cleavable peptide linker.

15. The antigen binding molecule according to any one of claims 10 to 14, wherein the masking moiety is fused at its N-terminus to the C-terminus of the Fc domain via a stable linker, and is fused at its C-terminus to the N-terminus of the IFNG variant polypeptide via the cleavable peptide linker.

16. The antigen binding molecule according to any one of claims 10 to 15, wherein the masking moiety is an antibody or antibody fragment that specifically binds to IFNG.

17. The antigen binding molecule according to any one of claims 10 to 16, wherein the masking moiety is a scFv that specifically binds to IFNG.

18. The antigen binding molecule according to any one of claims 10 to 17, wherein the scFv that specifically binds to IFNG comprises (a) Heavy chain variable region (V H IFNG), the heavy chain variable region comprises: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 22; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 23; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 24; and a light chain variable region (V L IFNG), the light chain variable region comprises: a light chain complementary determining region (iv) CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 25; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 26; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 27; or (b) Heavy chain variable region (V H IFNG), the heavy chain variable region comprises: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 30; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 31; and CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 32; and a light chain variable region (V L IFNG), the light chain variable region comprising: CDR-L1 comprising the amino acid sequence of SEQ ID NO:33; CDR-L2 comprising the amino acid sequence of SEQ ID NO:34; and CDR-L3 comprising the amino acid sequence of SEQ ID NO:

35.

19. The bispecific antigen binding molecule according to any one of claims 10 to 18, wherein the scFv that specifically binds to IFNG comprises (a) Heavy chain variable region (V H IFNG), which comprises the amino acid sequence of SEQ ID NO: 28; and the light chain variable region (V L IFNG), which comprises the amino acid sequence of SEQ ID NO: 29; or (b) Heavy chain variable region (V H IFNG), which comprises the amino acid sequence of SEQ ID NO: 36; and the light chain variable region (V L IFNG), which comprises the amino acid sequence of SEQ ID NO:

37.

20. The antigen binding molecule according to any one of claims 1 to 19, wherein the antigen binding molecule comprises (i) two heavy chains comprising the amino acid sequence of SEQ ID NO: 40, and two light chains comprising the amino acid sequence of SEQ ID NO: 41; or (ii) two heavy chains comprising the amino acid sequence of SEQ ID NO:42, and two light chains comprising the amino acid sequence of SEQ ID NO:41; or (iii) two heavy chains comprising the amino acid sequence of SEQ ID NO: 43, and two light chains comprising the amino acid sequence of SEQ ID NO: 44; or (iv) two heavy chains comprising the amino acid sequence of SEQ ID NO:45, and two light chains comprising the amino acid sequence of SEQ ID NO:

44.

21. An interferon gamma (IFNG) variant polypeptide, wherein the IFNG variant polypeptide is characterized in that it ends with a C-terminal amino acid sequence KRKRP (SEQ ID NO: 1).

22. The IFNG variant polypeptide according to claim 21, wherein the IFNG variant polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO:

3.

23. One or more isolated polynucleotides encoding an antigen binding molecule according to any one of claims 1 to 20 or an IFNG variant polypeptide according to claim 21 or 22.

24. An expression vector comprising one or more isolated polynucleotides according to claim 23.

25. A prokaryotic or eukaryotic host cell comprising one or more isolated polynucleotides according to claim 23 or an expression vector according to claim 24.

26. A method for producing an antigen binding molecule or an IFNG variant polypeptide, the method comprising the following steps: a) culturing the prokaryotic or eukaryotic host cell according to claim 25 under conditions suitable for expressing the antigen binding molecule or IFNG variant polypeptide, and b) optionally recovering the antigen binding molecule or IFNG variant polypeptide.

27. A pharmaceutical composition comprising the antigen binding molecule according to any one of claims 1 to 20 or the IFNG variant polypeptide according to claim 21 or 22 and a pharmaceutically acceptable excipient.

28. An antigen binding molecule according to any one of claims 1 to 20 or an IFNG variant polypeptide according to claim 21 or 22 for use as a medicament.

29. An antigen binding molecule according to any one of claims 1 to 20 or an IFNG variant polypeptide according to claim 21 or 22 for use in the treatment of cancer.

30. An antigen binding molecule according to any one of claims 1 to 20 or an IFNG variant polypeptide according to claim 21 or 22, for use in the treatment of cancer, wherein the antigen binding molecule or the IFNG variant polypeptide is used for administration in combination with a chemotherapeutic agent, radiation and / or other agents for use in cancer immunotherapy.

31. Use of an antigen binding molecule according to any one of claims 1 to 20 or an IFNG variant polypeptide according to claim 21 or 22 in the manufacture of a medicament for treating cancer.

32. A method of treating a disease in an individual, the method comprising administering to the individual a therapeutically effective amount of an antigen binding molecule according to any one of claims 1 to 20 or an IFNG variant polypeptide according to claim 21 or 22 in a pharmaceutically acceptable form.

33. The method of claim 32, wherein the disease is cancer.